



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/02, 1/14, 1/18, 1/68	A1	(11) International Publication Number: WO 99/25865 (43) International Publication Date: 27 May 1999 (27.05.99)																		
(21) International Application Number: PCT/US98/24646 (22) International Filing Date: 18 November 1998 (18.11.98) (30) Priority Data: <table border="0"> <tr> <td>60/066,129</td> <td>19 November 1997 (19.11.97)</td> <td>US</td> </tr> <tr> <td>60/066,308</td> <td>21 November 1997 (21.11.97)</td> <td>US</td> </tr> <tr> <td>60/066,462</td> <td>24 November 1997 (24.11.97)</td> <td>US</td> </tr> <tr> <td>60/078,610</td> <td>19 March 1998 (19.03.98)</td> <td>US</td> </tr> <tr> <td>60/094,523</td> <td>29 July 1998 (29.07.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>10 November 1998 (10.11.98)</td> <td>US</td> </tr> </table> (71) Applicant: MICROBIA, INC. [US/US]; 840 Memorial Drive, Cambridge, MA 02139 (US).		60/066,129	19 November 1997 (19.11.97)	US	60/066,308	21 November 1997 (21.11.97)	US	60/066,462	24 November 1997 (24.11.97)	US	60/078,610	19 March 1998 (19.03.98)	US	60/094,523	29 July 1998 (29.07.98)	US	Not furnished	10 November 1998 (10.11.98)	US	(72) Inventors: RUPP, Steffan; 7 Marney Street, Cambridge, MA 02141 (US). ROBERTSON, Laura; 6 Fulkerson Street, Cambridge, MA 02141 (US). SUMMERS, Eric, F.; 75 Parkton Road #2, Jamaica Plain, MA 02130 (US). HECHT, Peter; 17 Duffield Road, Newton, MA 02166 (US). ROBERTS, Radclyffe; 85 Linwood Circle, Princeton, NJ 08540 (US). MADHANI, Hiren; 82 Brook Street #1, Brookline, MA 02146 (US). STYLES, Cora, Ann; 56 Milton Street, Arlington, MA 02174 (US). LO, Hsiu-Jung; 137 Jerry Road, Brookline, MA 02146 (US). SHERMAN, Amir; Apartment #10, 2 Joy Street, Boston, MA 02108 (US). CALI, Brian, M.; 21 Hoew Street, Somerville, MA 02145 (US). FINK, Gerald, R.; 40 Aston Road, Chestnut Hill, MA 02167 (US). (74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
60/066,129	19 November 1997 (19.11.97)	US																		
60/066,308	21 November 1997 (21.11.97)	US																		
60/066,462	24 November 1997 (24.11.97)	US																		
60/078,610	19 March 1998 (19.03.98)	US																		
60/094,523	29 July 1998 (29.07.98)	US																		
Not furnished	10 November 1998 (10.11.98)	US																		
(54) Title: REGULATION OF FUNGAL GENE EXPRESSION (57) Abstract Disclosed herein are methods for regulating fungal gene expression, and reagents for carrying out those methods.																				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

REGULATION OF FUNGAL GENE EXPRESSION

Background of the Invention

5 The present invention relates to methods of identifying and isolating genes which are involved in the regulation of fungal gene expression. The invention also relates to methods useful for identifying fungal virulence factors. It further relates to a method of identifying agents which increase or decrease the expression or activity of a gene that regulates or is required for fungal pathogenesis. The invention also relates
10 to the use of such agents as fungicides or fungistats.

 Fungi are a large and diverse group of organisms with enormous importance to humans. Pathogenic fungi are a significant cause of human disease, particularly in the rapidly increasing proportion of the population whose immune system has been compromised by disease, chemotherapy, or immunosuppressive
15 drugs. A wide variety of plant-pathogenic fungi (e.g., blights, rusts, molds, smuts, mildews) cause huge food crop loss and damage to ornamental plants. Plant diseases are caused by a myriad of invasive fungal pathogens falling into many genera, for example: soft rot (e.g., Rhizopus), leaf curl (e.g., Taphrina), powdery mildew (e.g., Sphaerotheca), leaf spots (e.g., Fulvia), blight (e.g., Alternaria), blast (e.g.,
20 Magnaporthe), black rot (e.g., Guignardia), scab (e.g., Venturia), wilts (e.g., Fusarium), rusts (e.g., Puccinia), smuts (e.g., Ustilago), and cankers (e.g., Rhizoctonia). In addition, fungal species are the commercial source of a great many medicinally useful products, such as antibiotics (e.g., beta-lactam antibiotics such as penicillin, cephalosporin, and their derivatives), anti-hypercholesterolemic agents
25 (e.g., lovastatin and compactin), immunosuppressives (e.g., cyclosporin), and antifungal drugs (e.g., pneumocandin and echinocandin). All of these drugs are fungal secondary metabolites, small secreted molecules that fungi utilize against competitors in their microbial environment. Finally, fungi also produce commercially important enzymes (e.g., cellulases, proteases, and lipases) as well as other products

-2-

(e.g., citric acid, gibberellic acid, natural pigments, and flavorings).

The specifics by which fungi invade their growth substrate are not understood in detail. However, two important themes regarding the fungal invasion process have emerged in recent years. First, important human fungal pathogens, such as *Candida sp.*, *Aspergillus sp.*, *Mucor sp.*, *Rhizopus sp.*, *Fusarium sp.*, *Penicillium marneffei*, *Microsporium sp.* and *Trichophyton sp.* invade through host tissues as filamentous hyphae. The virulence of *Candida (C.) albicans* has been shown to be dependent upon invasion of host tissues; mutations in any of several genes required for invasive growth substantially reduce virulence in a mouse model of systemic infection. Pathogenesis of the plant fungal pathogen *Ustilago (U.) maydis* also requires invasion. Second, there is a correlation between genes that regulate agar invasion in *Saccharomyces (S.) cerevisiae* and genes that control invasion in pathogenic yeast. As *S. cerevisiae* is amenable to genetic studies, it can be utilized to molecularly dissect the genetics of fungal invasion.

Homologs of certain *S. cerevisiae* genes required for invasion also regulate the production of secondary metabolites and secreted catabolic enzymes in other fungi. For example, activating mutations in *Aspergillus* homologs of the *S. cerevisiae INV* genes cause increased production of the secondary metabolite penicillin and a secreted alkaline phosphatase (Orejas et al., Genes Dev. 1995, 9:1622).

Summary of the Invention

In one aspect, the invention features a method for determining whether a candidate compound decreases the expression of a gene operably linked to a fungal invasin gene promoter. The method generally includes the steps of (a) providing a fungus expressing the gene operably linked to a fungal invasin gene promoter; (b) contacting the fungus with the candidate compound; and (c) detecting or measuring expression of the gene following contact of the fungus with the candidate compound. In preferred embodiments, the fungus is a wild-type strain (e.g., *Saccharomyces*

-3-

cerevisiae, *Candida albicans*, or *Aspergillus nidulans*); a mutant strain; or a transgenic fungus. In other preferred embodiments, the gene used in the method of the invention is a fungal invasin gene. Exemplary fungal invasin genes include, without limitation, *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*,
5 *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *FLO11*, *IRA1*, *MCM1*, *MGA1*,
MUC1, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*,
SWI4, *TPK2*, *TPK3*, *RIM1*, or *YPR1*.

In still other preferred embodiments, the gene used in the method of the invention is a reporter gene. Exemplary reporter genes useful in the methods of the
10 invention include, without limitation, chloramphenicol transacetylase (CAT), green fluorescent protein (GFP), β -galactosidase (*lacZ*), luciferase, *URA3*, or *HIS3*.

In preferred embodiments, the fungal invasin gene promoter utilized in the methods of the invention is derived from the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter. In other preferred embodiments, the fungal invasin gene promoter
15 includes a promoter sequence derived from an *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*,
INV7, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *RIM1*, *INV14*, *INV15*, *BEM2*,
CDC25, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*,
SRB11, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene promoter.
Preferably, the fungal invasin gene promoter is a fragment or a deletion of the fungal
20 invasin gene promoter (e.g., a fragment of the *FLO11* gene promoter); and, if desired, the fragment is fused to a basal promoter (e.g., a basal promoter from a *PGK1*, *ADH1*,
GAL1-10, *tet-R*, *MET25*, *CYC1* or *CUP1* gene).

Typically, the expression of the gene (e.g., the endogenous *FLO11* or a recombinant reporter gene expressed under the control of the *FLO11* gene promoter
25 or fragment thereof) is measured by assaying the RNA or protein levels or both of the expressed gene. For example, the polypeptide expressed by the fungal invasin gene or by the reporter gene produces a detectable signal under conditions such that the compound causes a measurable signal to be produced. Quantitatively determining the amount of signal produced requires comparing the amount of signal produced to the

-4-

amount of signal detected in the absence of any compound being tested or upon contacting the cell with any other compound as is described herein. The comparison permits the identification of the compound as one which causes a change in the detectable signal produced by the expressed gene (e.g., at the RNA or protein level) and thus identifies a compound that is capable of inhibiting fungal invasion. A decrease in the expression of the fungal invasin gene is generally accompanied by an inhibition of fungal invasion or an inhibition of the developmental switch from yeast form to pseudohyphal growth or both.

In related aspects, the invention also features a method for determining whether a candidate compound increases the expression of a gene operably linked to a fungal invasin gene promoter. The method generally includes the steps of (a) providing a fungus expressing the gene operably linked to a fungal invasin gene promoter; (b) contacting the fungus with the candidate compound; and (c) detecting or measuring expression of the gene following contact of the fungus with the candidate compound. In preferred embodiments, the method further includes determining whether the candidate compound increases the production of a secondary metabolite in the fungus.

In another aspect, the invention features a method for determining whether a candidate compound inhibits fungal invasion. The method generally includes the steps of (a) contacting a fungus with a candidate compound under conditions suitable for invasion and (b) measuring or detecting invasion by the fungus following contact with the candidate compound. In preferred embodiments, the fungus is *Candida albicans* or *Saccharomyces cerevisiae*.

In another aspect, the invention features a method for determining whether a candidate compound promotes fungal invasion. The method generally includes the steps of (a) contacting a fungus with a candidate compound under conditions suitable for invasion and (b) measuring or detecting invasion by the fungus following contact with the candidate compound. In preferred embodiments, the fungus is *Candida albicans*, *Saccharomyces cerevisiae*, or *Aspergillus nidulans*.

-5-

In still another aspect, the invention features a method for identifying a fungal invasion-promoting gene. The method generally includes the steps of (a) expressing in a fungus (i) a first gene operably linked to a fungal invasin gene promoter and (ii) a second candidate gene or a fragment thereof and (b) monitoring the expression of the first gene, wherein an increase in the expression of the first gene identifies the second candidate gene as a fungal invasion-promoting gene. In preferred embodiments, the fungus is a wild-type strain (e.g., *Saccharomyces cerevisiae*, *Aspergillus nidulans*, *Penicillium chrysogenum*, or *Acremonium chrysogenum*); is a mutant strain; or is a transgenic fungus.

Preferably, the first gene includes a fungal invasin gene (e.g., *FLO11* or *MUC1*). In yet other preferred embodiments, the first gene includes a fungal invasin gene derived from *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *RIM1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene; or the first gene includes a reporter gene (e.g., *lacZ*, *URA3*, or *HIS3*).

In preferred embodiments, the fungal invasin gene promoter is derived from the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter. In other preferred embodiments, the fungal invasin gene promoter is derived from the *AFL1*, *DHH1*, *INV1*, *RIM1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene promoter; or is a fragment or a deletion of the above-mentioned fungal invasin gene promoters. Preferably, the fragment of a fungal invasin gene promoter is fused to a basal promoter (e.g., a basal promoter of a *PGK1*, *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1*, or *CUP1* gene).

Preferably, the expression of the gene utilized in the method of the invention is measured by assaying the protein level of the expressed first gene or by assaying the RNA level of the expressed first gene.

-6-

In related aspects, the invention also features a method for identifying a fungal invasion-inhibiting gene. The method generally includes the steps of (a) expressing in a fungus (i) a first gene operably linked to a fungal invasin gene promoter and (ii) a second candidate gene or fragment thereof and (b) monitoring the
5 expression of the first gene, wherein a decrease in the expression of the first gene identifies the second candidate gene as a fungal invasion-inhibiting gene.

In yet another aspect, the invention features a method for increasing production of a secondary metabolite in a fungal cell; the method generally includes the step of contacting the fungal cell with a fungal invasion-promoting compound and
10 culturing the cells under conditions which promote the increased synthesis of a secondary metabolite.

In another aspect, the invention features a method for increasing production of a secondary metabolite in a fungal cell. The method generally includes the step of decreasing the expression of a fungal invasion-inhibiting gene. In
15 preferred embodiments, the decreased expression of the fungal invasion-inhibiting gene (e.g., *HOG1*, *BEM2*, *RIM15*, *SFL1*, *IRA1*, *SSD1*, *SRB11*, *SWI4*, or *TPK3*) results from an inactivation of the fungal invasion-inhibiting gene. In other preferred embodiments, the increased production of a secondary metabolite results from the expression of a mutated fungal invasion-inhibiting gene.

20 In still another aspect, the invention features a method for increasing production of a fungal secondary metabolite. The method generally includes the step of increasing the expression of a fungal invasion-promoting gene. In preferred embodiments, the fungal invasion-promoting gene is *AFL1*, *DHH1*, *INV7*, *INV8*, *STE21*, *PET9*, *MEP2*, *INV1*, *INV5*, *INV6*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*,
25 *INV14*, *INV15*, *CDC25*, *MCM1*, *MGA1*, *PHD2*, *PHO23*, *PTC1*, *RIM1*, *STP22*, *TPK2*, or *YPR1*. In other preferred embodiments, the increased expression of the fungal invasion-promoting gene is achieved by constitutively expressing the fungal invasion-promoting gene or by overexpressing such a gene. In yet other preferred embodiments, the fungal invasion-promoting gene is mutated.

-7-

In another aspect, the invention features a method for increasing production of a fungal secondary metabolite. The method generally includes the step of expressing a gene or fragment thereof that encodes an activated form of a invasion-promoting polypeptide. In preferred embodiments, the activated form of the invasion-promoting polypeptide includes a fusion between the invasion-promoting polypeptide and a second polypeptide that further enhances the activity of the invasion-promoting polypeptide. In other preferred embodiments, the gene has a mutation.

In another aspect, the invention features a method for increasing production of a secondary metabolite in a fungal cell. The method generally includes the step of decreasing the activity of a fungal invasion-inhibiting polypeptide. In preferred embodiments, the fungal invasion-inhibiting polypeptide has a mutation (e.g., a dominant-inactive polypeptide). In other preferred embodiments, the fungal invasion-inhibiting polypeptide is Hog1, Bem2, Rim15, Ira1, Sfl1, Ssd1, Srb11, Swi4, or Tpk3.

In another aspect, the invention features a method for increasing production of a fungal secondary metabolite. The method generally includes the steps of increasing the activity of a fungal invasion-promoting polypeptide. In preferred embodiments, the fungal invasion-promoting polypeptide has a mutation (e.g., a dominant-active polypeptide). In other preferred embodiments, the fungal invasion-promoting polypeptide is Afl1, Dhh1, Inv1, Inv5, Inv6, Inv9, Inv10, Inv11, Inv12, Inv13, Inv14, Rim1, Inv15, Cdc25, Inv7, Mcm1, Mga1, Phd2, Pho23, Ptc1, Inv8, Ste2, Pet9, Mep2, Stp22, Tpk2, or Ypr1.

In another aspect, the invention features a method of isolating a fungal invasin gene. The method generally involves the steps of (a) providing a fungus expressing a gene operably linked to a fungal invasin gene promoter; (b) mutagenizing the fungus; (c) measuring expression of the gene, wherein an increase or decrease in the expression of said gene identifies a mutation in said invasin gene; and (d) using said mutation as a marker for isolating said invasin gene. In preferred embodiments, the fungus is a wild-type strain (e.g., *Saccharomyces cerevisiae*) or is a

-8-

mutant strain. In preferred embodiments, the gene utilized in the method includes a fungal invasin gene (e.g., *FLO11*, *MUC1*, *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *RIM1*, *PTC1*, *RIM15*, *SFL1*, *SRB11*,
5 *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1*). In other preferred embodiments, the gene includes a reporter gene (e.g., *lacZ*, *URA3*, or *HIS3*). In still other preferred, the fungal invasin gene promoter is from *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter; or is from the *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *RIM1*,
10 *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene promoter. In other preferred embodiments, the fungal invasin promoter is a fragment or deletion of the above-mentioned fungal invasin gene promoters. Preferably, the fragment of a fungal invasin gene promoter is fused to a basal promoter (e.g., a basal promoter of a *PGK1*,
15 *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1* or *CUP1* gene).

In another aspect, the invention features a method of using a cell (e.g., a fungal cell) for identifying a gene which regulates the expression from a *Candida albicans* gene promoter. The method generally includes the steps of (a) providing a cell expressing a reporter gene operably linked to a *Candida albicans* gene promoter;
20 (b) expressing a candidate gene in the cell; and (c) detecting or measuring the expression of the reporter gene. In preferred embodiments, the fungal cell is *Saccharomyces cerevisiae*.

In another aspect, the invention features a method for preparing a transgenic fungal cell having increased secondary metabolite production. The method
25 generally includes the steps of (a) introducing a transgene (e.g., a transgene encoding an invasin gene such *AFL1*, *DHH1*, *INV7*, *INV8*, *STE21*, *PET9*, *MEP2*, *INV1*, *INV5*, *INV6*, *INV9*, *INV10*, *INV11*, *RIM1*, *INV12*, *INV13*, *INV14*, *INV15*, *CDC25*, *MCM1*, *MGA1*, *PHD2*, *PHO23*, *PTC1*, *STP22*, *TPK2*, *YPR1* or a fragment thereof, which is positioned for expression in a fungal cell) and (b) selecting a cell that expresses the

-9-

transgene. In preferred embodiments, the transgene has a mutation (e.g., a dominant-active mutation or a dominant-inactive mutation).

In another aspect, the invention features a method for increasing a secondary metabolite in a fungus. The method generally includes the steps of (a) 5 culturing the fungus in culture with conditions allowing for secondary metabolite production; (b) adding to the culture a fungal invasion-promoting compound; and (c) isolating the metabolite from the culture. In preferred embodiments, the fungus has a mutation. In other preferred embodiments, the fungus is a wild-type strain.

In still another aspect, the invention features a transgenic fungus (e.g., a 10 filamentous fungus) which includes a mutation in an invasin gene that inhibits its activity. Preferably, the invention features a transgenic filamentous fungus having a mutation in a *HOG1*, *SWI4*, *BEM2*, *SRB11*, *SSD1*, *TPK3*, *SFL1*, or an *IRA1* gene or any combination thereof. Preferably, such mutations inhibit the activity of the expressed protein (e.g., Hog1, Swi4, Bem2, Srb11, Ssd1, Tpk3, Sfl1, or Ira1 or any 15 combination thereof). In other preferred embodiments, the transgenic fungus has increase secondary metabolite production (e.g., increased production of antibiotics).

In another aspect, the invention features a substantially pure Inv9 polypeptide. Preferably, the Inv9 polypeptide is at least 55% identical to the amino acid sequence of Fig. 6B (SEQ ID NO: 6). In preferred embodiments, the Inv9 20 polypeptide is from a fungus (e.g., a yeast such as *Saccharomyces*). In other preferred embodiments, the Inv9 has invasion promoting activities.

In a related aspect, the invention features an isolated nucleic acid (e.g., DNA) encoding an Inv9 polypeptide. Preferably, such an isolated nucleic acid sequence includes the *INV9* gene of Fig. 6A (SEQ ID NO: 5) and complements an 25 *INV9* mutation in *Saccharomyces cerevisiae*.

In another aspect, the invention features a substantially pure Rim1 polypeptide. Preferably, the Rim1 polypeptide is at least 75% identical to the amino acid sequence of Fig. 5A (SEQ ID NO: 4) in the zinc-finger domain, and at least 25% identical throughout the entire length of the polypeptide amino acid sequence. In

-10-

preferred embodiments, the Rim1 polypeptide is from a fungus (e.g., a yeast such as *Saccharomyces*). In other preferred embodiments, the Rim1 polypeptide has invasion promoting activities.

In a related aspect, the invention features an isolated nucleic acid (e.g.,
5 DNA) encoding a Rim1 polypeptide. Preferably, such an isolated nucleic includes the *RIM1* gene of Fig. 5A (SEQ ID NO: 3) and complements a *RIM1* mutation in *Saccharomyces cerevisiae*, as is described herein.

In related aspects, the invention further features a cell or a vector (for
example, a fungal expression vector), each of which includes an isolated nucleic acid
10 molecule of the invention. In preferred embodiments, the cell is a fungal cell (for
example, *S. cerevisiae*). In yet another preferred embodiment, the isolated nucleic
acid molecule of the invention is operably linked to a promoter that mediates
expression of a polypeptide encoded by the nucleic acid molecule. The invention
further features a cell (for example, a fungal cell) which contains the vector of the
15 invention.

In still another aspect, the invention features a transgenic fungus including
any of the above nucleic acid molecules of the invention, wherein the nucleic acid
molecule is expressed in the transgenic fungus.

In related aspects, the invention also features a method of producing an
20 Inv9 or Rim1 polypeptide. The method involves: (a) providing a cell transformed
with a nucleic acid molecule of the invention positioned for expression in the cell; (b)
culturing the transformed cell under conditions for expressing the nucleic acid
molecule; and (c) recovering the Inv9 or Rim1 polypeptide. The invention further
features a recombinant Inv9 or Rim1 polypeptide produced by such expression of an
25 isolated nucleic acid molecule of the invention, and a substantially pure antibody that
specifically recognizes and binds to each of these polypeptides or a portion thereof.

By "fungal invasion" is meant a process by which a fungus penetrates,
digs, adheres to, or attaches to a substrate. Invasion of a substrate by a fungus may be

-11-

measured according to standard methods as described herein.

By "fungal invasin" gene is meant a gene encoding a polypeptide capable of promoting or inhibiting the invasion by a fungus into a substrate. This response may occur at the transcriptional level or it may be enzymatic or structural in nature.

- 5 Fungal invasin genes may be identified and isolated from any fungal species, using any of the sequences disclosed herein in combination with conventional methods known in the art.

By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation).

- 10 By a "reporter gene" is meant a gene whose expression may be assayed; such genes include, without limitation, genes encoding β -galactosidase, β -glucuronidase, β -glucosidase, and invertase, amino acid biosynthetic genes, e.g., the yeast *LEU2*, *HIS3*, *LYS2*, *TRP1* genes, nucleic acid biosynthetic genes, e.g., the yeast *URA3* and *ADE2* genes, the mammalian chloramphenicol transacetylase (CAT) gene,
15 or any surface antigen gene for which specific antibodies are available. A reporter gene may encode a protein detectable by luminescence or fluorescence, such as green fluorescent protein (GFP). Reporter genes may encode also any protein that provides a phenotypic marker, for example, a protein that is necessary for cell growth or viability, or a toxic protein leading to cell death, or the reporter gene may encode a
20 protein detectable by a color assay leading to the presence or absence of color. Alternatively, a reporter gene may encode a suppressor tRNA, the expression of which produces a phenotype that can be assayed. A reporter gene according to the invention includes elements (e.g., all promoter elements) necessary for reporter gene function.

- 25 By "substantially identical" is meant a polypeptide or nucleic acid exhibiting at least 25%, preferably 50%, more preferably 80%, and most preferably 90%, or even 95% identity to a reference amino acid sequence (for example, the amino acid sequence shown in Fig. 5A (SEQ ID NO: 4) or nucleic acid sequence (for example, the nucleic acid sequences shown in Fig. 5A; SEQ ID NO: 3). For

-12-

polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids or greater. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60
5 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides or greater.

Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison,
10 WI 53705, BLAST, BEAUTY, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine,
15 threonine; lysine, arginine; and phenylalanine, tyrosine.

By a "substantially pure polypeptide" is meant a polypeptide (for example, an invasin polypeptide such as the Inv9 or Rim1 polypeptide) that has been separated from components which naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and
20 naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, an invasin polypeptide. A substantially pure invasin polypeptide may be obtained, for example, by extraction from a natural source (for example, a fungal cell); by expression of a recombinant nucleic acid encoding an
25 invasin polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

By "derived from" is meant isolated from or having the sequence of a naturally-occurring sequence (e.g., a cDNA, genomic DNA, synthetic, or combination

-13-

thereof).

By "isolated DNA" is meant DNA that is free of the genes which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant
5 DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional
10 polypeptide sequence.

By "transgenic fungal cell" is meant a fungal cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) an invasin polypeptide.

By "positioned for expression" is meant that the DNA molecule is
15 positioned adjacent to a DNA sequence which directs transcription and translation of the sequence (i.e., facilitates the production of, for example, an invasin polypeptide, a recombinant protein, or an RNA molecule).

By "promoter sequence" is meant any minimal sequence sufficient to direct transcription. Included in the invention are promoter elements that are
20 sufficient to render promoter-dependent gene expression controllable for gene expression, or elements that are inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene or engineered into a transgene construct.

By "operably linked" is meant that a gene and a regulatory sequence(s) are
25 connected in such a way as to permit gene expression when the appropriate molecules (for example, transcriptional activator proteins) are bound to the regulatory sequence(s).

By "candidate gene" is meant any piece of DNA which is inserted by artifice into a cell and expressed in that cell. A candidate gene may include a gene

-14-

which is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism.

By "transgene" is meant any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome of the organism which develops from that
5 cell. Such a transgene may include a gene which is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism.

By "transgenic" is meant any cell which includes a DNA sequence which is inserted by artifice into a cell and becomes part of the genome of the organism
10 which develops from that cell. As used herein, the transgenic organisms are generally transgenic fungal cells. A transgenic fungal cell according to the invention may contain one or more invasin genes.

By "increasing production of a secondary metabolite" is meant a greater level of production of a secondary metabolite in a transgenic fungus of the invention
15 than the level of production relative to a control fungus (for example, a non-transgenic fungus). In preferred embodiments, the level of secondary metabolite production in a transgenic fungus of the invention is at least 10% greater (and preferably more than 30% or 50%) than the level in a control fungus. The level of secondary metabolite production is measured using conventional methods.

20 By "detectably-labelled" is meant any direct or indirect means for marking and identifying the presence of a molecule, for example, an oligonucleotide probe or primer, a gene or fragment thereof, or a cDNA molecule or a fragment thereof. Methods for detectably-labelling a molecule are well known in the art and include, without limitation, radioactive labelling (for example, with an isotope such as ³²P or
25 ³⁵S) and nonradioactive labelling (for example, chemiluminescent labelling, for example, fluorescein labelling).

By "purified antibody" is meant antibody which is at least 60%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably

-15-

90%, and most preferably at least 99%, by weight, antibody, for example, an acquired resistance polypeptide-specific antibody. A purified invasin antibody (e.g., Inv9 or Rim1) may be obtained, for example, by affinity chromatography using a recombinantly-produced acquired resistance polypeptide and standard techniques.

5 By "specifically binds" is meant an antibody which recognizes and binds an invasin polypeptide but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes an invasin polypeptide such as Inv9 or Rim1.

10 By a "mutation" is meant an alteration in sequence, either by site-directed or random mutagenesis. A mutated form of a protein encompasses point mutations as well as insertions, deletions, or rearrangements. A mutant is an organism containing a mutation

The invention provides long awaited advantages over a wide variety of standard screening methods used for distinguishing and evaluating the efficacy of a compound in regulation of gene expression in fungal pathogens. For example, the
15 methods allow for the identification, by genetic selection in a high throughput format, of peptides and compounds that specifically activate or inhibit fungal invasion. These methods also allow the mode of action for such agents to be rapidly delineated. Moreover, these methods are amenable to an iterative compound modification and
20 retesting process to allow for the evolution of more effective compounds from initial hits and leads.

Compounds which inhibit fungal invasion will likely also prevent fungal virulence. These compounds may have therapeutic value in treating plant or animal fungal diseases. Compounds which promote fungal invasion may be useful in
25 increasing yields of commercially important fungal secondary metabolites.

The invention also provides an approach to isolating novel fungal genes important for pathogenesis. These novel genes and the proteins they encode comprise additional targets for compounds.

In addition, the invention provides a means to increase the yield of

-16-

commercially important secondary metabolites by genetic manipulation of the fungal organism itself. This facilitates the large scale production of fungal products which to date has not been possible. In addition, it allows for the facile identification of "potentiators," (i.e., compounds and peptides) that can activate secondary metabolite production when contacting, or expressed in, fungi. The ability to increase fungal secondary metabolite production has at least two important applications. First, increasing production of secondary metabolites will facilitate identification of new antimicrobial compounds in fungi that otherwise make undetectable levels of these compounds in the laboratory. Second, it will allow increased production of existing secondary metabolites which are useful clinically or for research.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Detailed Description

The drawings will first be described.

15 Drawings

Figure 1 is a western blot showing the effect of mutations in the *INV* pathway and *STE* pathway on Inv8 proteolytic processing.

Figure 2A is a series of photographs showing haploid invasion phenotypes for wild-type strains and strains with mutations in *TPK* genes.

Figure 2B is a series of photographs showing pseudohyphal phenotypes for wild-type strains and strains with mutations in *TPK* genes.

Figure 3 is a photograph showing the results of a yeast two-hybrid analysis showing preferential affinity of Tpk2 for Mga1 and Sfl1. Gene products tested are shown on the vertical and horizontal axes. Yeast growth indicates an interaction between the products of the genes shown on the respective axes.

Figure 4A is a photograph of an epistasis analysis showing that *FLO11* acts downstream of both *SFL1* and *TPK2* during haploid invasive growth.

-17-

Figure 4B is a photograph of an epistasis analysis showing that *FLO11* acts downstream of both *SFL1* and *TPK2* during pseudohyphal growth.

Figure 5A shows the DNA sequence of the *Candida RIM1* gene (SEQ ID NO: 3) and the predicted encoded protein (SEQ ID NO: 4).

5 Figure 5B is a schematic illustration describing the complementation of the *S. cerevisiae inv8* phenotype with *Candida RIM1*.

Figure 6A shows the DNA sequence of *S. cerevisiae INV9* (SEQ ID NO: 5).

10 Figure 6B shows the predicted amino acid sequence of *S. cerevisiae Inv9* (SEQ ID NO: 6).

Figure 7 is a series of photographs of phenotypic analysis of the serum response of *Candida rim1/rim1* mutants.

Figure 8 is a series of photographs showing that processing of *Inv8* is required for its nuclear accumulation.

15 Figure 9 is a photograph of a northern blot showing the steady-state levels of *FLO11* mRNA in a variety of invasion-defective (*flo8*, *stel2*, *phd1*, *phd2*, *afl1*, *ras2*, *tpk2*, *tec1*, *flo11*, and *inv6*) and hyper-invasive mutants (*ira1*). The blot was probed with probes for *FLO11* and *ACT1*.

20 Figure 10 is a schematic illustration of genes and pathways that regulate invasion. Pointed arrows denote activation, flat-ended arrows indicate repression.

Figure 11 is a schematic illustration showing the relative positions of the *FLO11* promoter fragments used to generate reporter constructs.

25 Figure 12 shows the results of a gradient plate assay, demonstrating that an agar invasion screen could be employed as a system for identifying antifungal compounds.

We have discovered a series of interconnected signal transduction cascades which regulate fungal invasion and pseudohyphal growth. From *S. cerevisiae*, we identified new roles for previously characterized genes invasion and pseudohyphal

-18-

growth (*AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, *YPR1*). Genetic and biochemical analysis has allowed us to place these genes, and
5 other genes known to regulate invasion, into a series of parallel signal transduction cascades. Table 1, below, lists the genes of which we have identified that regulate invasion and/or pseudohyphal growth in *S. cerevisiae*. These genes are cross-referenced with the corresponding sequence name as designated by the Saccharomyces Genome Database. Sequences of these genes and their putative
10 transcriptional regulatory elements are also found at the Saccharomyces Genome Database (<http://genome-www.stanford.edu/Saccharomyces/>).

-19-

TABLE I

	<u>Gene Name</u>	<u>Sequence Name</u>	<u>Gene Name</u>	<u>Sequence Name</u>
	INV1/VPS36	YLR417w	PHD1	YKL043w
	INV3/DFG16	YOR030w	ELM1	YKL048c
5	INV5	YOR275c	FLO11	YIR019c
	INV6	YMR164c	SSD1	YDR293c
	INV7	YDL233w	IRA1	YBR140c
	INV8	YHL027w	CDC25	YLR310c
	INV9	YGL046w + YGL045w	RAS2	YNL098c
10	INV10	YMR063w	BCY1	YIL033c
	INV11	YNL294c	TPK3	YKL166c
	INV12/SNF8	YPL002c	MGA1	YGR249w
	INV13	YJR102c	SFL1	YOR140w
	INV14	YMR154c	BEM2	YER155c
15	INV15/VPS28	YPL065w	CDC55	YGL190c
	INV16	not cloned	NPR1	YNL183c
	STP22/	YCL008c	MEP2	YNL142w
	MCM1	YMR043w	SHR3	YDL212w
	FLO8	YER108c	URE2	YNL229c
20	WH13	YNL197c	GLN3	YER040w
	SRV2	YNL138w	CDC42	YLR229c
	CYR1	YJL005w	CDC24	YAL041w
	AFL1	YEL007w	STSE11	YLR362w
	PTC	YDL006w	STE7	YDL159w
25	STE20	YHL007c	KSS1	YGR040w
	TPK2	YPL203w	STE12	YHR084w
	YPR1	YDR368w	TEC1	YBR083w
	PH023	YNL097c	STE21	YDR335w
	DHH1	YDL160c	SIR4	YDR227w
30	PHD2	YOL116w	PET9	YBL030c
	GRR1	YJR090c	SWI4	YER111c
	RIM15	YFL033c	SRB11	YNL025c
	HOG1	YLR113w		

-20-

We have constructed a "wiring diagram" of these signal transduction cascades and shown directly that many of these genes regulate fungal invasion, at least in part, through the regulation of a single gene, *FLO11*. The identification of the convergence of signals onto a single target has facilitated improved screening methods designed to evaluate and identify therapeutic agents useful for inhibiting fungal pathogenesis in either animal or plant hosts. Furthermore, our discovery provides the basis for screening methods useful for identifying a variety of new fungal virulence factors. Identification of such virulence factors further facilitates the development of targeted reagents for use as anti-pathogens. In addition, the improved screening methods provide the basis for identifying factor that increase production of important fungal secondary metabolites.

The following experimental examples are intended to illustrate, not limit, the scope of the claimed invention.

Screens to Isolate Genes Involved in Pseudohyphal Growth and Invasion

Below we describe experimental evidence that a series of signal transduction cascades operates in cooperation to regulate pseudohyphal growth and haploid digging in solid medium in *S. cerevisiae*.

On solid media containing high glucose and low nitrogen, diploid cells of *S. cerevisiae* form pseudohyphae, which consist of chains of elongated cells that form invasive filaments (Gimeno et al., Cell 1992, 68:1077-1090). On rich medium, haploid cells, but not diploid cells, manifest invasive growth, referred to as "digging" (Roberts and Fink, Genes Dev. 1994, 8:2974-85). The nutritional signals that eventuate in both pseudohyphal growth and haploid invasive growth involve several pathways. To isolate *S. cerevisiae* genes involved in these behaviors, we have performed a series of screens for mutants defective in either pseudohyphal growth or haploid invasion. These screens are described below.

-21-

Screen 1. Identification of Mutants that Eliminate Invasion During Pseudohyphal Growth.

Mutagenesis of yeast and screens were conducted as described in Mösch and Fink, (Genetics 1997, 145:671-684). Briefly, a direct visual screen for
5 transposon-induced mutants unable to invade the agar when grown on low nitrogen SLAD agar was conducted in a MATa/ α haploid strain capable of pseudohyphal growth. Secondary screening identified a subset of mutants that make long cells and, thus, are capable of all aspects of pseudohyphal growth other than invasion.

Screen 2. Identification of Digging-Defective Mutants.

10 *S. cerevisiae* mutants defective for haploid invasive growth were identified using a plate washing assay described in (Roberts and Fink, *supra*). Transposon-mutagenized haploids, constructed as described in Mösch and Fink (Genetics 1997, 145:671-84 and Burns et al., Genes Dev. 1994 8:1087-105), were
15 plated on YPD to allow formation of well-isolated single colonies. After 3-5 days growth at 30°C, plates were replica-plated and the surface of the master plate was washed with a stream of water. Colonies of invasion-defective mutants wash completely (or nearly so) from the agar, whereas many cells of a wild-type strain remained in the agar after washing. Mutant strains were subsequently picked from the replicas of colonies that exhibited an invasion-defective phenotype.

20 Screen 3. Identification of Hyperinvasive Mutants.

Transposon-mutagenized haploids were plated to YPD and grown as described in Screen 2 above. Colonies with a surface morphology that appeared more "rough" than wild-type colonies were picked-- a rough colony surface is indicative of hyperinvasion. Secondary testing subsequently identified mutants in which more
25 cells remained in the agar after washing as compared to wild-type controls. Such mutants were retained as hyper-invasive mutants.

-22-

Screen 4. Identification of Mutations Specifically Affecting The *INV* Pathway.

This screen relied upon our observation that, unlike mutations affecting other characterized genes required for pseudohyphal growth, *inv* mutants were more resistant than wild-type strains to the whitening agent calcoflour. In addition, as is true for all invasion-defective mutants, *inv* haploids exhibited a colony surface morphology that appears more smooth than wild-type colonies when grown on YPD agar. A collection of transposon-induced calcoflour-resistant mutants exhibiting a smooth colony morphology when grown on YPD agar were also identified.

For all mutations induced by transposon insertion, genomic DNA flanking the transposon insertion site was isolated and sequenced by conventional methods. Nucleotide sequence of flanking DNA was then compared to the genomic sequence of *S. cerevisiae* to identify the affected gene.

Screen 5. Identification of High-Copy Suppressors of an Invasion-Defective Mutant.

A library of plasmids containing yeast genomic DNA was transformed into an invasion-defective (*Inv*-) diploid *whi3* strain. These library plasmids contained an origin of replication that promotes maintenance in high-copy number (the 2 μ origin). Transformants were plated on selective media (SC-URA), plates were incubated for 1-2 days, and then a plate washing assay was performed. High-copy plasmids that suppress the *Inv*- phenotype promoted a transient period of invasive growth into synthetic media. This growth was identified as small pits of colonies that remained in the agar after the plate washing assay. Several genes were identified as high-copy suppressors of the *Inv*- phenotype of *whi3* mutants, including *MCM1* and *PHD2*. Subsequent analysis of *phd2*-deleted and *mcm1* partial loss-of-function mutants demonstrated that these genes regulate invasion and *FLO11* expression.

From the above screens, we have identified 60 genes which regulate pseudohyphal growth or haploid invasion in *S. cerevisiae*. These genes, referred to as

-23-

invasins, have been further categorized into at least six signal transduction cascades. Based on the resulting phenotype following mutation or overexpression, these genes can be further classified as "fungal invasion-promoting" or "fungal invasion-inhibiting." For example, a *S. cerevisiae* strain containing a complete deletion of
5 *AFL1* does not form filaments or invade under conditions in which a wild-type strain does, and no invasion is observed under conditions that normally induced invasion during pseudohyphal growth or haploid digging. An example of a signal transduction cascade is described below.

Twelve *S. cerevisiae* genes which comprise this signal transduction
10 pathway required for agar invasion have been identified, cloned, and characterized. *INV8*, encoding a transcription factor whose activity is regulated by proteolysis, is the most downstream member of the pathway. The other twelve members (*INV1*, *INV3*, *INV5*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *INV16*, and *STP22*) are all required for proteolytic regulation of Inv8. As shown in Figure 1, mutations in these
15 genes, but not mutations in any other invasin genes thus far examined, block Inv8 processing. One of the *INV* members, Inv14, is a cytoplasmic cysteine protease of the calpain family. It was surprising that this signal transduction pathway was conserved in fungi and served, in other fungi, to regulate the production of secondary metabolites and secreted enzymes that are able to degrade extracellular substrates.
20 Homologs of the *S. cerevisiae* genes have been found, for example, in *A. nidulans*, where a similar set of genes regulate transcription of a number of secreted catabolizing enzymes in response to extracellular pH; in *Yarrowia lipolytica*, as the transcriptional regulator of an abundant, secreted alkaline protease; and in *Penicillium* (*P.*) *chrysogenum* and *A. niger*, where it has a role similar to that found in *A. nidulans*.
25 In *A. nidulans* and in *P. chrysogenum*, the pathway directly regulates the production of penicillin (penicillin production is regulated by the activated form of the transcription factor).

Other additional members of these signal transduction cascades are identified through a variety of standard techniques. First, enhancers and suppressors

-24-

of phenotypes of mutant strains are isolated using standard techniques known to those skilled in the art (Ausubel, *supra*). Second, proteins which interact with pathway members are isolated using yeast two-hybrid methods (Fields and Song, Nature 1989, 340:245-246; Chien et al., Proc. Natl. Acad. Sci. USA 1991, 88:9578-9582; Brent and
5 Finley, Annu. Rev. Genet. 1997, 31:663-704). In one example, proteins which specifically interact with an A kinase catalytic subunit Tpk2, and not with related proteins Tpk1 and Tpk3 were identified and shown to be important for pseudohyphal development. Diploid *tpk2* strains grown on SLAD (low nitrogen medium) were completely defective for pseudohyphal development, whereas *tpk3* diploid strains
10 were greatly enhanced for filamentation (Figure 2B). Similarly, haploid *tpk2* mutants were defective for invasive growth and *tpk3* mutants were hyperinvasive (Figure 2A). *tpk1* mutants were indistinguishable from wild-type strains as both haploids and diploids. The accentuated filamentation and invasion phenotypes of *tpk3* mutants required a functional Tpk2 as *tpk2 tpk3* mutants had the same phenotype as *tpk2*
15 single mutants. As Tpk2 appeared to be uniquely required for pseudohyphal growth, we used a two-hybrid screen to identify proteins that interact specifically with Tpk2. The intact open reading frame of *TPK2* was fused to coding sequence for the Gal4 DNA binding domain and used to screen a library of yeast genomic fragments fused to coding sequence for the Gal4 transcriptional activation domain. Activation of the
20 *GAL4-ADE2* reporter, leading to adenine-independent growth of an *ade-* strain, was taken as preliminary evidence for an interaction between the Gal4 DNA binding domain:Tpk2 fusion and the Tpk2 interacting protein fused to the Gal4 activation domain. Positive clones were then retested in the two-hybrid assay with Tpk1, Tpk2, Tpk3, or Dph1 fused to the Gal4 DNA binding domain. *DPH1*, a gene required for
25 diphthamide biosynthesis, was used to control for interactions that were not specific to the PKA isoforms.

Two classes of proteins interacted with Tpk2 in the two-hybrid assay: the first class was indiscriminate and interacted with Tpk1, Tpk2, and Tpk3; the second class was selective and interacted preferentially with Tpk2 (Figure 3). One of the

-25-

proteins that interacted with all three catalytic subunits is Bcy1, the negative regulatory subunit of PKA, which had previously been shown to bind Tpk1, Tpk2, and Tpk3. The second class consisted of Sfl1 and Mga1, putative transcription factors belonging to a group of five yeast proteins (Mga1, Sfl1, Hsf1, Skn7, and Hms2) containing a helix-turn-helix DNA binding motif. All but Skn7 contain at least one consensus PKA phosphorylation site ([R/K][R/K]X[S/T]): Sfl1 has five, Mga1 has two, Hsf1 has four, and Hms2 has one.

We deleted the open reading frame of both *MGA1* and *SFL1*. *sfl1* mutants had a dramatic phenotype: *sfl1* haploid strains were extremely flocculent and hyperinvasive, whereas diploids homozygous for a deletion of *sfl1* were greatly enhanced for filamentation (Figure 4A-B). We constructed an *sfl1 tpk2* double mutant to see if the *tpk2* pseudohyphal defect was blocked by loss of function of Sfl1. *sfl1 tpk2* double mutants had the same phenotype as *sfl1* single mutants, suggesting Sfl1 acts downstream of Tpk2 (Figure 4A-B). We could not detect a dramatic defect in pseudohyphal formation in *mga1* null mutants.

Similar two-hybrid screens can also be used to identify additional members of any of the signal transduction cascades described herein. Candidate genes are then analyzed using a variety of techniques known to those skilled in the art, such as construction of mutant strains or overexpression.

Identification of transcriptional targets of genes in the fungal signal transduction pathways, such as Inv8 or Sfl1, are used to identify gene products which are directly responsible for extracellular substrate degradation or invasion. For example, identification of Inv8 transcriptional targets is useful to identify gene products directly responsible for agar invasion. Identification of such target genes provides excellent reporters of the *INV* pathway, which will make it possible to demonstrate the relative activities of the unprocessed versus the proteolyzed Inv8 protein and to define the mechanisms by which Inv8 activates and represses target genes. Alternatively, identification of homologs, such as by screening for complementation of the phenotype in *S. cerevisiae*, in other fungi can be carried out to

-26-

identify fungal gene products which regulate production of secondary metabolites, such as antibiotics, anti-hypercholesterolemic agents, immunosuppressives, or antifungal drugs.

Based on the work described herein, it is possible to discover and develop novel antifungal therapeutic drugs; identify and commercialize new fungal secondary metabolites; improve yields of presently available fungal products; and develop technologies and products to address unmet fungal challenges. It is likely that the signal transduction machinery is conserved among fungi. Thus, based on the discoveries described herein, each of these signal transduction cascades represents a target for antifungal drugs and/or regulation of secondary metabolites. Strains of *S. cerevisiae* carrying mutant alleles of any of the genes can be used to screen for fungal homologs, including those from important pathogenic fungi and commercially important fungi, such as *Aspergillus sp.*, *Penicillium sp.*, *Acremonium chrysogenum*, *Yarrowia lipolytica* and *Phaffia rhodozyma*, which are capable of complementing or rescuing the mutant phenotype. These strains can be genetically modified such that the rescued organisms are capable of increased growth or survival, such that these organisms can be isolated using selection based screens described herein. Selection-based screens allow for high-throughput, and thus provide a more rapid approach to gene isolation than those currently used. Moreover, screens for genes which complement mutant phenotypes allows for isolation of genes which share functional properties but which do not contain high degrees of similarity at the nucleotide or amino acid level.

Isolation of Invasin Homologs

Any fungal cell can serve as the nucleic acid source for the molecular cloning of an invasin homolog. Isolation of an invasin homolog (e.g., *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1*) involves

-27-

the isolation of those DNA sequences which encode a polypeptide exhibiting properties or activities associated with promotion or inhibition of fungal invasion. Based on the sequences of the invasin genes and polypeptides described herein, the isolation of additional invasin homolog regulatory and coding sequences from a variety of fungi (e.g., *Candida*, *Aspergillus*, *Penicillium*, *Mucor*, *Monascus*, *Trichoderma*, *Fusarium*, *Tolypocladium*, *Acremonium*, *Cryptococcus*, *Ustilago*, *Magneporthe*, *Acremonium*, *Yarrowia*, and *Phaffia*) is made possible using standard strategies and techniques that are well known in the art.

In one particular example, any of the invasin sequences described herein may be used, together with conventional screening methods of nucleic acid hybridization screening. Such hybridization techniques and screening procedures are well known to those skilled in the art and are described, for example, in Benton and Davis, *Science* 1977, 196:180; Grunstein and Hogness, *Proc. Natl. Acad. Sci., USA* 1975, 72:3961; Ausubel et al. et al., 1997, *Current Protocols in Molecular Biology*, Wiley Interscience, New York; Berger and Kimmel, *Guide to Molecular Cloning Techniques*, 1987, Academic Press, New York; and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York. In one particular example, all or part of the *Candida albicans RIM1* cDNA (described herein) may be used as a probe to screen a recombinant fungus DNA library (e.g., a recombinant expression library prepared from *Aspergillus nidulans*) for homologs having sequence identity to the *Candida albicans RIM1* gene. Hybridizing sequences are detected by plaque or colony hybridization according to the methods described below.

Alternatively, using all or a portion of the amino acid sequence of the Rim1 polypeptide, one may readily design Rim1-specific oligonucleotide probes, including Rim1 degenerate oligonucleotide probes (i.e., a mixture of all possible coding sequences for a given amino acid sequence). These oligonucleotides may be based upon the sequence of either DNA strand and any appropriate portion of the Rim1 sequence. General methods for designing and preparing such probes are

-28-

provided, for example, in Ausubel et al. (*supra*), and Berger and Kimmel (*supra*). These oligonucleotides are useful for *RIM1* homolog isolation, either through their use as probes capable of hybridizing to *RIM1* complementary sequences or as primers for various amplification techniques, for example, polymerase chain reaction (PCR) cloning strategies. If desired, a combination of different oligonucleotide probes may be used for the screening of a recombinant DNA library. The oligonucleotides may be detectably-labeled using methods known in the art and used to probe filter replicas from a recombinant DNA library. Recombinant DNA libraries are prepared according to methods well known in the art, for example, as described in Ausubel et al. (*supra*), or they may be obtained from commercial sources.

In one particular example of this approach, homolog *RIM1* sequences having greater than 75% identity are detected or isolated using high stringency conditions. High stringency conditions may include hybridization at about 42°C and about 50% formamide, 0.1 mg/mL sheared salmon sperm DNA, 1% SDS, 2X SSC, 10% Dextran sulfate, a first wash at about 65°C, about 2X SSC, and 1% SDS, followed by a second wash at about 65°C and about 0.1X SSC. Alternatively, high stringency conditions may include hybridization at about 42°C and about 50% formamide, 0.1 mg/mL sheared salmon sperm DNA, 0.5% SDS, 5X SSPE, 1X Denhardt's, followed by two washes at room temperature and 2X SSC, 0.1% SDS, and two washes at between 55-60°C and 0.2X SSC, 0.1% SDS.

In another approach, low stringency hybridization conditions for detecting *RIM1* homologs having about 25% or greater sequence identity to the *Candida albicans RIM1* gene described herein include, for example, hybridization at about 42°C and 0.1 mg/mL sheared salmon sperm DNA, 1% SDS, 2X SSC, and 10% Dextran sulfate (in the absence of formamide), and a wash at about 37°C and 6X SSC, about 1% SDS. Alternatively, the low stringency hybridization may be carried out at about 42°C and 40% formamide, 0.1 mg/mL sheared salmon sperm DNA, 0.5% SDS, 5X SSPE, 1X Denhardt's, followed by two washes at room temperature and 2X SSC, 0.1% SDS and two washes at room temperature and 0.5X SSC, 0.1%

-29-

SDS. These stringency conditions are exemplary; other appropriate conditions may be determined by those skilled in the art.

If desired, RNA gel blot analysis of total or poly(A+) RNAs isolated from any fungus (e.g., those fungi described herein) may be used to determine the presence or absence of a *RIM1* transcript using conventional methods. As an example, a northern blot of *Aspergillus nidulans* RNA is prepared according to standard methods and probed with a *RIM1* gene fragment in a hybridization solution containing 50% formamide, 5X SSC, 2.5X Denhardt's solution, and 300 µg/mL salmon sperm DNA at 37°C. Following overnight hybridization, the blot was washed two times for ten minutes each in a solution containing 1X SSC, 0.2% SDS at 37°C. An autoradiogram of the blot is used to demonstrate the presence an *RIM1*-hybridizing RNA in the fungal RNA sample. A hybridizing band is taken as an indication that this fungus expresses a *C. albicans* *RIM1* homolog. Isolation of this hybridizing transcript is performed using standard cDNA cloning techniques. Other fungal invasions may be evaluated and cloned in a similar fashion.

As discussed above, invasin oligonucleotides (e.g., oligonucleotides prepared from the *Candida albicans* *RIM1* gene) may also be used as primers in amplification cloning strategies, for example, using PCR. PCR methods are well known in the art and are described, for example, in *PCR Technology*, Erlich, ed., Stockton Press, London, 1989; *PCR Protocols: A Guide to Methods and Applications*, Innis et al., eds., Academic Press, Inc., New York, 1990; and Ausubel et al. (*supra*). Primers are optionally designed to allow cloning of the amplified product into a suitable vector, for example, by including appropriate restriction sites at the 5' and 3' ends of the amplified fragment (as described herein). If desired, *RIM1* sequences may be isolated using the PCR "RACE" technique, or Rapid Amplification of cDNA Ends (see, e.g., Innis et al. (*supra*)). By this method, oligonucleotide primers based on an *Candida albicans* *RIM1* sequence are oriented in the 3' and 5' directions and are used to generate overlapping PCR fragments. These overlapping 3'- and 5'-end RACE products are combined to produce an intact full-length cDNA. This method is

-30-

described in Innis et al. (*supra*); and Frohman et al., *Proc. Natl. Acad. Sci. USA* 85:8998, 1988. Exemplary oligonucleotide primers useful for amplifying *RIM1* homolog sequences include, without limitation:

- 5 A. GAATTAACCCTCACTAAAGGGAAARMGNGAYCAYATHA
 C (SEQ ID NO: 1); and
- B. GTAATACGACTCACTATAGGGTGYTTYTTNARRTCYTG
 (SEQ ID NO: 2).

For each of the above sequences, N is A, T, G or C.

10 Alternatively, any fungal cDNA or cDNA expression library may be
screened by functional complementation of an invasin mutant (for example, the *RIM1*
and *AFL1* mutants described herein) according to standard methods described herein.

15 Confirmation of a sequence's relatedness to an invasin polypeptide may be
accomplished by a variety of conventional methods including, but not limited to,
functional complementation assays and sequence comparison of the homolog and its
expressed product. In addition, the activity of the gene product may be evaluated
according to any of the techniques described herein, for example, the functional or
immunological properties of its encoded product.

20 Once an invasin homolog is identified, it is cloned according to standard
methods and used for the construction of fungal expression vectors according to
standard methods.

Interacting Polypeptides

25 The isolation of invasin protein sequences also facilitates the identification
of polypeptides which interact with the invasin proteins. Such polypeptide-encoding
sequences are isolated by any standard two hybrid system (see, for example, Fields et
al., *Nature* 1989, 340:245-246; Yang et al., *Science* 1992, 257:680-682; Zervos et al.,
Cell 1993, 72:223-232). For example, all or a part of the Tpk2 sequence may be
fused to a DNA binding domain (such as the GAL4 or LexA DNA binding domain).
After establishing that this fusion protein does not itself activate expression of a

-31-

reporter gene (for example, a *lacZ* or *LEU2* reporter gene) bearing appropriate DNA binding sites, this fusion protein is used as an interaction target. Candidate interacting proteins fused to an activation domain (for example, an acidic activation domain) are then co-expressed with the Tpk2 fusion in host cells, and interacting proteins are identified by their ability to contact the Tpk2 sequence and stimulate reporter gene expression. Tpk2-interacting proteins identified using this screening method provide good candidates for proteins that are involved in the acquired resistance signal transduction pathway. An example of this method is described herein (*infra*).

Isolating Fungal Homologs which Complement *S. cerevisiae* Mutations

One use of the *S. cerevisiae* mutant strains is to screen for homologs in other fungi which can complement the *S. cerevisiae* mutations. Here we provide evidence for the efficacy of such an approach. We have identified the *C. albicans* homolog of *INV8* (referred to as *RIM1* (Figure 5A; SEQ ID NO: 3)). When the full length *RIM1* was expressed from a plasmid in *S. cerevisiae inv8* strains, the cells still showed an *inv8* phenotype. However, the homologs of *RIM1* (*S. cerevisiae INV8*, *Y. lipolytica RIM101*, and *A. nidulans pacC*) require proteolytic processing for activation. It is likely that the *S. cerevisiae* protease could not cleave *C. albicans* Rim1 (Figure 5A; SEQ ID NO: 4). In support of this, a *RIM1* gene truncated just prior to the protease cleavage site, was found to complement the *inv8* phenotype in *S. cerevisiae* (Figure 5B.) This makes it likely that a Rim1 protease exists in *C. albicans*, and this protease would be considered to be a homolog of *INV14*. Based on our discovery of the correlation between *S. cerevisiae* invasion and secondary metabolite production by other fungi, it is likely that many if not all of the *S. cerevisiae INV* genes will have homologs in diverse fungi. Indeed, *INV5*, *INV9* and *INV14* are predicted to encode proteins with high amino acid similarity to the products of the *A. nidulans* genes *pala*, *palF*, and *palB*, respectively. We found that the published sequence for the genomic region near *INV9* contains several errors. The correct DNA sequence of *INV9* (SEQ ID NO: 5) and the sequence of the predicted polypeptide

-32-

(SEQ ID NO: 6) is shown in Figure 6A-B. *INV5/palA*, *INV9/palF*, and *INV14/palB* are required to activate Inv8/PacC in their respective organisms. Thus, these genes are structurally and functionally conserved genes. In addition, homologs of *INV9*, *INV11*, and *INV13* appear on the list of partially sequenced *C. albicans* genes (http://alces.med.umn.edu). An *INV11* homolog in the fungus *Kluyveromyces lactis* has also been partially sequenced (GENBANK locus: KLAJ9848), as have homologs of *INV1* (GENBANK locus: SPBC3B9), *INV13* (GENBANK locus: SPBC4B4) and *INV15* (GENBANK locus: SPAC1B3) in the fungus *Schizosaccharomyces pombe*. An *STP22* homolog has been identified in the fungus *Saccharomyces carlsbergensis* (GENBANK locus: SCZ86109). Of the 12 cloned genes in the *INV* pathway, six (*INV5*, *INV8*, and *INV12-15*) have obvious structural homologs outside the fungal kingdom. The existence of *INV* homologs in a wide variety of fungi, including the pathogenic fungus, *C. albicans*, and one that produces the important secondary metabolite penicillin, *A. nidulans*, underscores the potential utility of manipulating these genes and/or their activities to affect both pathogenesis and secondary metabolite production in diverse fungi. Additional homologs can be isolated by expressing genes from fungal cDNA or genomic libraries in *S. cerevisiae* mutant strains and selecting for those transformants in which the mutant phenotype is complemented or enhanced.

20 Mutating Genes in Other Fungi to Determine Their Roles in Invasion

Following isolation of any specific homolog of a *S. cerevisiae* gene involved in invasion from any fungal species, we can determine the role of that gene in pathogenesis or invasion by that fungus. Any such gene that activates or increases invasion is also likely to activate or increase virulence. Deletion or inactivation of the function of these genes would likely reduce the virulence of that fungal strain. The following gene deletion example utilizes the *C. albicans RIM1* gene from the previous section.

We tested whether the *C. albicans RIM1* gene was required for invasive

-33-

hyphal growth in *C. albicans*. A homozygous *rim1/rim1* deletion was created. The *C. albicans rim1/rim1* mutant does not form invasive hyphae in the presence of serum on agar at 37°C, while nonmutant *C. albicans* does (Figure 7). The virulence of the mutated strains can be determined using a variety of animal models. One model of systemic infection is described as an example. To test the relative virulence (infectivity) of a mutant strain of *Candida* compared to a normal "wild-type" strain, mutant and normal *Candida* cells are injected into the tail veins of separate healthy mice. The mice are then observed for a period of two weeks to one month. The relative numbers of mice killed by the mutant versus normal *Candida* provides an index of virulence (see Lo et al., Cell 1997, 90: 939-949). Furthermore, any fungal gene that inhibits or decreases invasion is also likely to inhibit or decrease secondary metabolite production. Deleting or disrupting the function of any such gene is likely to increase secondary metabolite production. Genetic engineering methods, including transformation and homologous recombination techniques, are practiced in many fungi (Punt and van den Hondel, Methods Enzymol. 1992, 216:447-457; Timberlake and Marshall, Science, 1989, 244:1313-1317; Fincham, Microbiol Rev. 1989, 53:148-170). Gene deletion techniques are currently practiced in many fungi, including, but not limited to, *Candida albicans* (Fonzi and Irwin, Genetics 1993, 134: 717-728), *Ustilago maydis* (Fotheringham and Hollman, Mol. Cell Biol. 1989, 9:4052-4055; Bolker et al., Mol. Gen. Genet. 1995, 248:547-552), *Yarrowia lipolytica* (Neuveglise et al., Gene 1998, 213:37-46; Chen et al., Appl. Microbiol. Biotechnol. 1997, 48:232-235; Cordero et al., Appl. Microbiol. Biotechnol. 1996, 46:143-148), *Acremonium chrysogenum* (Skatrud et al., Curr. Genet. 1987, 12:337-348; Walz and Kuck, Curr. Genet. 1993, 24:421-427), *Magnaporthe grisea* (Sweigard et al., Mol. Gen. Genet. 1992, 232:183-190); Kershaw et al., EMBO J. 1998, 17:3838-3849), *Histoplasma capsulatum* (Woods et al., J. Bacteriol. 1998, 180:5135-5143) and *Aspergillus sp.* (Miller et al., Mol. Cell Biol. 1985, 5:1714-1721; de Ruiter-Jacobs et al., Curr. Genet. 1989, 16:159-163; Gouka et al., Curr. Genet. 1995, 27:536-540; van den Hombergh et al., Mol. Gen. Genet. 1996, 251:542-550; D'Enfert, Curr. Genet. 1996, 30:76-82;

-34-

Weidner et al., Curr. Genet. 1998, 33:378-385).

This gene deletion technique allows for the selection of fungal homologs which give the strongest phenotypes, as well as those which are invasion specific. Some of the gene disruptions will likely produce nonpathogenic fungi. These genes
5 and the encoded proteins are excellent candidates to target with compounds. Other disruptions will likely produce hyperinvasive fungi. The mutation of these genes in fungi such as *Aspergillus sp.*, *Penicillium sp.*, *Acremonium chrysogenum*, *Yarrowia lipolytica*, and *Phaffia rhodozyma* should lead to increased production of secondary metabolites of commercial value, such as beta-lactam antibiotics and their derivatives,
10 or anti-hypercholesterolemic agents such as the statins.

A System to Increase Production of Secondary Metabolites

Fungi secrete secondary metabolites in order to produce an environment favorable for their survival. These metabolites have also been shown to have a great number of commercial uses. We have discovered a correlation between secondary
15 metabolite production and the regulation of invasion. The *A. nidulans pacC* gene, involved in regulation of the penicillin production, has a homolog in both *S. cerevisiae* and *C. albicans* which has a role in invasion. The *A. nidulans* genes *pala*, *palD*, and *palF*, involved in regulation of penicillin production, also have homologs in *S. cerevisiae* that are required for invasion. In addition, as described above, we have
20 identified the homolog of *pacC* in *C. albicans* (*RIM1*) and showed that it is also necessary for invasion. Similarly, many of the nutritional conditions that induce substrate invasion by *S. cerevisiae* also lead to increased penicillin production in *A. nidulans*. For example, growth in the presence of limiting amounts of ammonia is important both for pseudohyphal growth in *S. cerevisiae* and production of penicillin
25 in *A. nidulans* (see Gimeno et al., *supra*, and Brakhage, A. A., Micro. Mol. Biol. Rev. 1998, 62: 547-585). Many of the genes we have shown to regulate invasion, as well as expression from the *FLO11* promoter (*infra*), will also regulate production of secondary metabolites in fungi such as *Aspergillus sp.*, *Penicillium sp.*, *Acremonium*

-35-

chrysogenum, *Yarrowia lipolytica* and *Phaffia rhodozyma*. This knowledge can be used to produce fungal strains which produce greater amounts of these secondary metabolites, many of which are of great commercial value.

One example of how genetic manipulation can increase secondary metabolite production utilizes the fungal invasion-inhibiting gene, *HOG1*. We have shown that *HOG1* is a negative regulator of haploid invasion and pseudohyphal growth in *S. cerevisiae*. Mutating or deleting *HOG1* in *S. cerevisiae* produces a transgenic strain which invades its substrate in conditions in which a wild-type strain does not. Decreasing the activity of the Hog1 protein in fungal species such as *Aspergillus sp.*, *Penicillium sp.*, *Acremonium chrysogenum*, *Yarrowia lipolytica* and *Phaffia rhodozyma*, results in an increased production of secondary metabolites through a de-repression of the signal transduction pathway. There are a variety of ways to decrease protein activity. One method is to delete the entire *HOG1* gene or a portion thereof, using homologous recombination techniques known to be applicable in fungi as described herein. Similarly, mutagenesis of genes could also lead to decreased protein activity. Another method would be to apply a gene or compound which, directly or indirectly, inhibits the expression of *HOG1* or the activity of Hog1. These genes and compounds can be isolated using screening techniques described herein. The methods described for *HOG1* are equally applicable to any fungal anti-invasion gene, including, but not limited to, *GRR1*, *IRA1*, *BEM2*, *TPK3*, *SFL1*, *SSD1*, *RIM15*, *CDC55*, *SWI4*, and *ELM1*.

A second mechanism to increase production is to increase the activity of a fungal invasion-promoting gene, such as homologs of *INV8* or any other fungal invasion-promoting gene. One method is to express such a gene from a constitutively active promoter. Expression systems, such as those which drive expression of genes from promoter sequence from either the *Aspergillus nidulans* *gpdA* gene, the *Acremonium chrysogenum* *ipnS* gene, or the *Penicillium chrysogenum* *phoA* gene, are well-known to those skilled in the art (Skatrud et al., Curr. Genet. 1987, 12:337-348; Kolar et al., Gene 1988, 62:127-134; de Ruiter-Jacobs et al., Curr. Genet. 1989,

-36-

16:159-163; Smith et al., Gene 1988, 114:211-216; Graessle et al., Appl. Environ. Microbiol. 1997, 63:753-756).

Another method to increase activity of a fungal invasion-promoting gene is to genetically alter the fungal invasion gene, either through the introduction of an activating mutation or by creating fusions to other genes that result in increased activity. The fusion proteins are preferably constitutively active. A third method is to mutate the fungal invasion gene such that the activity of the encoded protein is increased. For example, *S. cerevisiae* Inv8 and its homolog, PacC, require proteolytic cleavage for transcriptional activating properties. We have shown that this cleavage is required for the nuclear localization of Inv8. Inability to truncate Inv8 results in its accumulation in the cytoplasm (Figure 8). These data suggest that activation of Inv8 and its homologs is likely to be a consequence of allowing the protein to gain access to its target genes in the nucleus. Thus, truncation of Inv8 or PacC caused by the introduction of a stop codon upstream of the coding sequence for the protease cleavage site would create a constitutively active transcription factor. Another method is to apply a compound which, directly or indirectly, increases the expression of *INV8* or the activity of Inv8. These compounds can be isolated using screening techniques described herein. *S. cerevisiae* *INV8* is homologous to *Y. lipolytica* *RIM101*, and *pacC* from *A. nidulans*, *A. niger*, and *P. chrysogenum*. *pacC* is known to directly regulate penicillin production; penicillin production is regulated by the activated form of the transcription factor. Thus, increased PacC activity using any of the described methods will lead to increased penicillin production.

The *FLO11* Promoter is a Reporter of Fungal Invasion

The cell surface protein Flo11 has been reported to be required for invasive and filamentous growth (Lambrechts et al., 1996; Liu et al., 1996; Lo and Dranganis, 1996; Lo and Dranganis, 1998; Flo11 is referred to as Muc1 in *S. cerevisiae* var. *diastaticus*). The *FLO* genes encode proteins required for cell-cell adhesion (Teunissen and Steensma, 1995). The MAP kinase pathway, involving four

-37-

protein kinases (Ste20, Ste11, Ste7, and Kss1), regulates the activity of the transcription factor Ste12/Tec1. One of the genes regulated by this signal transduction cascade is *FLO11*.

5 We have discovered that *FLO11* is a downstream target for other signal transduction pathways that regulate filamentous growth in diploids and invasion in haploids. While it was known that one pathway which regulated these phenotypes also regulated *FLO11* expression, it was surprising that *FLO11* appeared to be under such complex regulation by several signal transduction pathways. These findings are outlined below.

10 An example of another signal transduction cascade which regulates *FLO11* expression is the cAMP/PKA pathway. The evidence which implicated *FLO11* as a target of the cAMP pathway follows. Since both the MAPK pathway and the cAMP/PKA pathway are activated for filamentation by the same activator, Ras2, analysis of the distinct role of cAMP on filamentous growth requires the ability to
15 activate the PKA branch independently of Ras. To achieve this goal, we constructed a strain (*ras1 ras2 pde2*) lacking both *RAS* genes (*RAS1* and *RAS2*) and the high-affinity cAMP phosphodiesterase, *PDE2*. Since Ras1 and Ras2 are required for the activation of adenylate cyclase, Cyr1 and *PDE2* encodes the phosphodiesterase required for cAMP hydrolysis, a *ras1 ras2 pde2* strain is impaired in the synthesis and
20 breakdown of cAMP. Such a strain should be dependent upon exogenous cAMP for induction of the A kinase and, as no Ras-induced signal can be transmitted to the MAPK cascade, the effects of cAMP on filamentation should be independent of the Ras/MAPK signal.

25 The *ras1 ras2 pde2* strain (SR957) requires cAMP for growth on YPD (yeast extract, peptone, dextrose), but grows without cAMP on SC (synthetic complete), SLAD (synthetic low ammonia dextrose), and YNB (yeast nitrogen base), media where it displays hyper-accumulation of glycogen, indicative of low cAMP levels. We presume that the ability of this triple mutant to grow without added cAMP, as has been observed by others (Nikawa et al., 1987), results from basal

-38-

cyclase activity that is sufficient to provide internal cAMP. In support of this notion, we observed that growth of our *ras1 ras2 pde2* strain depended upon a functional cyclase (*CYR1*) gene.

A diploid *ras1 ras2 pde2* (SR959) strain grows on SLAD medium without
5 cAMP but does not form pseudohyphae. However, on SLAD medium containing
cAMP, the strain is extremely filamentous. Moreover, the addition of cAMP leads
not only to induction of filamentation, but also to invasion of the substrate. In the
presence of cAMP, the *ras1 ras2 pde2* strain (SR959) is invasive on all media tested
(YPD, SC, SLAD). Since invasive growth is usually observed with haploid strains on
10 YPD, both the cell type signal and the nutritional signal can be bypassed by high
cAMP levels in the cell.

To determine whether cAMP induces filamentation by activating the
MAPK pathway, we measured the expression of the Kss1 MAPK pathway-specific
reporter *FG::Ty1-lacZ* (Mosch et al., *supra*) in *ras1 ras2 pde2* strains grown on
15 SLAD plates containing concentrations of cAMP that induce filamentation. The level
of expression of the *FG::Ty1-lacZ* reporter in the *ras1 ras2 pde2* strain (SR959) was
not altered by these cAMP levels. Moreover, cAMP induced filamentation in a *ste12*
ras1 ras2 pde2 deletion strain (SR1088), indicating that the cAMP/PKA pathway acts
in parallel with the MAPK pathway.

20 We demonstrated the induction of *FLO11* mRNA by cAMP in the *ras1*
ras2 pde2 strain, but not in a wild-type background. The *FLO11* transcript was
undetectable when the triple mutant strain is grown without cAMP and strongly
induced in the presence of 2mM cAMP. Expression of *FLO1*, which encodes Flo1,
another cell surface protein required for flocculation and 26% identical to Flo11, is
25 only induced 1.4 fold under identical conditions. This result shows that the strong
induction of *FLO11* is not a general feature of all flocculation genes. The
correspondence between cAMP induction of *FLO11* and the morphological changes
observed when the cells are grown in the presence of cAMP is further supported by
the phenotype of the *FLO11* deletion; in the *flo11 ras1 ras2 pde2* strain (SR1121),

-39-

cAMP fails to induce either invasion or filamentation. These data suggest that *FLO11* is a key target of a cAMP-dependent signaling pathway, one that is required for the induction of invasive and filamentous growth.

5 The enhanced *FLO11* transcription in the presence of cAMP is correlated with a change in cellular morphology. Cells grown in liquid SC with 2mM cAMP show pseudohyphal-like chains of cells, whereas the majority of cells grown in liquid SC without cAMP are either single cells or cells with a single bud. The effect of cAMP on cell-cell attachment is much more pronounced than the effect of the cyclic nucleotide on cell elongation.

10 The use of the *FLO11* promoter as a reporter of invasion and filamentous growth appears to be universal. As shown in Figure 9, the *FLO11* promoter is an excellent reporter for invasion and pseudohyphal growth. For mutants that reduce invasion or pseudohyphal growth, there was a direct correlation between *FLO11* expression and invasion/pseudohyphal growth for *af11*, *stel2*, *tec1*, *flo8*, *inv8*, *ras2*,
15 *tpk2*, *phd1*, *phd2*, *inv6*, *inv7*, *whi3*, *dhh1*, *mep2*, *ptc1*, *mcm1*, *inv1*, *inv13*, and *inv14*. In addition, *hog1*, *grr1*, *ira1*, *tpk3*, and *sfl1* mutants, which exhibited increased invasion/pseudohyphal growth, also displayed increased *FLO11* expression. For example, *FLO11* is transcriptionally regulated by both Tpk2 and Sfl1. *tpk2* mutants showed a 10-fold reduction in *FLO11* expression, whereas *tpk3* mutants had a
20 threefold elevation. The levels of *FLO11* mRNA were also reduced 10-fold in *tpk2* *tpk3* double mutants. *FLO11* mRNA levels were also increased threefold in an *sfl1* mutant and were similarly increased in an *sfl1* *tpk2* double mutant. The levels of *FLO11* mRNA in the *sfl1* *tpk3* double mutant exceeded that of either single mutant.

25 Not only is *FLO11* an excellent reporter of pseudohyphal growth and invasion, it is also central to invasion and pseudohyphal growth. *sfl1 flo11* haploid mutant strains were defective for invasive growth on rich medium, and *sfl1 flo11* homozygous diploid mutants were defective for pseudohyphal development. Thus, *flo11* loss of function blocked the hyperinvasive and hyperfilamentous phenotypes of *sfl1* loss of function. However, the defect of the *sfl1 flo11* double mutant was not as

-40-

severe as that of the *flo11* single mutant, suggesting that *FLO11* is not the only downstream target of Sfl1 involved in pseudohyphal development and haploid invasion.

It is reasonable to assume that many other genes that have been placed in
 5 signal transduction pathways, including the genes shown in Figure 10, will also be required for *FLO11* expression. Based on these results, and our recent identification of a number of additional genes that regulate invasion (and quite likely *FLO11* expression), we have constructed a wiring diagram for the genetic circuitry that regulates *FLO11* (Figure 10). These genes, listed in Table 1, all represent candidate
 10 targets for novel antifungal agents that act by blocking invasion and/or dimorphic growth.

To determine how much of this 5' region of *FLO11* was required for the regulated expression of *FLO11*, we examined the expression of plasmid-based *FLO11::lacZ* reporter constructs containing deletions in this non-coding region.
 15 Fourteen serial 200 bp deletions were constructed that span the region 2800 bases (bp -2800) upstream from the *FLO11* initiation codon. A *FLO11-lacZ* reporter plasmid was constructed by amplifying the 3 kb region 5' of the ATG by PCR using primers containing a *BglIII* site at the end and cloning into YEp355. (Sequences of primers used are 5'-CGCACACTATGCAAAGACCGAGATCTTCC-3' (SEQ ID NO: 7) and
 20 5'-GAAGATCTTCTCCACATACCAATCACTCG-3') (SEQ ID NO: 8). The 14 individual deletions in this reporter were constructed by primer overlap method using a KS+-Bluescript plasmid containing the 3 kb *FLO11*-promoter region (subcloned from YEp355-*FLO11::lacZ* as *EcoRI*/*HindIII* fragment). After mutagenesis the partially deleted *flo11-nn* promoter sequence was recloned into YEp355. The
 25 primers used for this purpose were:

-3'

#1F 5'-CAAGCATTTACGTTACTGCGAAAATCCATATACGCACACT-3'
 (SEQ ID NO: 9)

#1R 5'-AGTGTGCGTATATGGATTTTCGCAGTAACGTAAATGCTTG-3'

-41-

- (SEQ ID NO: 10)
- #2F 5'-TGATGAGGTAACCTTTACAACTCTCTTAGTTCAAGAAC-3'
- (SEQ ID NO: 11)
- #2R 5'-GTTCTTGAAGTAGAAGAGAGTTGTAAAGGTTACCTCATCA-3'
- 5 (SEQ ID NO: 12)
- #3F 5'-TTTCAATTCAATGGATTTGGAATGTCATAGAGTTACCAAT-3'
- (SEQ ID NO: 13)
- #3R 5'-ATTGGTAACTCTATGACATTCCAAATCCATTGAATTGAAA-3'
- (SEQ ID NO: 14)
- 10 #4F 5'-ATTTCTGCCTATACTCTTAAAGGTATTCGTTTGTTTACTA-3'
- (SEQ ID NO: 15)
- #4R 5'-TAGTAAACAAACGAATACCTTTAAGAGTATAGGCAGAAAT-3'
- (SEQ ID NO: 16)
- #5F 5'-TTGGGGCTAAGAATGGACACAGATCAGTCATTCATGTTGT-3'
- 15 (SEQ ID NO: 17)
- #5R 5'-ACAACATGAATGACTGATCTGTGTCCATTCTTAGCCCCAA-3'
- (SEQ ID NO: 18)
- #6F 5'-GGGTGTGCCTGGAAAGTTCATTCCCTTTTCTTTTCTTTG-3'
- (SEQ ID NO: 19)
- 20 #6R 5'-CAAAGAAAAAGAAAAGGGAATGAACTTTCCAGGCACACCC-3'
- (SEQ ID NO: 20)
- #7F 5'-CAAACTTTAGGAATACCGGAAATTAAGGTTTTTTTCTTC-3'
- (SEQ ID NO: 21)
- #7R 5'-GAAGAAAAAACCTTAATTTCCGGTATTCCTAAAGTTTTG-3'
- 25 (SEQ ID NO: 22)
- #8F 5'-CGAATGTGAATGCGCTAATCTTGTGTGCCTACGCCAGCCC-3'
- (SEQ ID NO: 23)
- #8R 5'-GGGCTGGCGTAGGCACACAAGATTAGCGCATTACATTCG-3'
- (SEQ ID NO: 24)

-42-

- #9F 5'-AGACAAAAAATAGGAAAAGTGGTATTTCCACCACATGAAA-3'
(SEQ ID NO: 25)
- #9R 5'-TTTCATGTGGTGGAAATACCACTTTTCCTATTTTTTGTCT-3'
(SEQ ID NO: 26)
- 5 #10F 5'-TTAGTGCGGAATACTTTCCTTTAATTAGTGATGGTTCTCA-3'
(SEQ ID NO: 27)
- #10R 5'-TGAGAACCATCACTAATTAAAGGAAAGTATTCCGCACTAA-3'
(SEQ ID NO: 28)
- 10 #11F 5'-CAGTGCTTTCAACACCTTTTATTCTCATCGAGAGCCGAGC-3'
(SEQ ID NO: 29)
- #11R 5'-GCTCGGCTCTCGATGAGAATAAAAGGTGTTGAAAGCACTG-3'
(SEQ ID NO: 30)
- #12F 5'-GTAGCTGAAAAGTCCATCTACATCTGTGTGCCATGTCAGA-3'
(SEQ ID NO: 31)
- 15 #12R 5'-TCTGACATGGCACACAGATGTAGATGGACTTTTCAGCTAC-3'
(SEQ ID NO: 32)
- #13F 5'-GAGATTATCTTGGGATCTATTCTGAATTATGAATGATACTA-3'
(SEQ ID NO: 33)
- #13R 5'-TAGTATCATTTCATAATTCGAATAGATCCCAAGATAATCTC-3'
(SEQ ID NO: 34)
- 20 #14F 5'-GTTTTGGCTCAATGGGACCGTTCACAAATTTACGGCTAAT-3'
(SEQ ID NO: 35)
- #14R 5'-ATTAGCCGTAAATTTGTGAACGGTCCCATTGAGCCAAAAC-3'
(SEQ ID NO: 36)

- 25 The resulting 14 plasmids for the deletion series were transformed into strain 10560-2B. At least three independent clones were tested using filter assays for equivalent expression of β -galactosidase. Diploid strains were created by mating of the respective 10560-2B *flo11-nn* transformant with strain 10560-5B by selection on

-43-

YNB containing only leucine as a supplement.

The 14 plasmids containing the 400 bp sequence elements were transformed into 10560-2B, L5795, L5816, L6149, L6150 and SR957. At least three independent clones were tested using filter assays for equivalent expression of

5 β -galactosidase. Filter assays were used to test the effect of α -factor (5 μ M).

The large number of *FLO11* promoter elements and multiple conditions that affect those elements required some economy in the experimental design. The measurement of β -galactosidase from our plasmid-based reporter containing each of these elements permitted the rapid construction of strains and reproducible

10 measurement of reporter activity. We confined the analysis to selective media so that the strains retained the plasmids. Our β -galactosidase assays show in general a higher activity for haploid strains than for diploid strains. For rich medium this result is in agreement with that found previously when *FLO11* expression was monitored by measurement of steady state mRNA-levels. When we measure *FLO11::lacZ* after

15 24-26h (post diauxic growth) or on SLAD medium, haploid cells show an induction of more than 10 fold and diploid cells, 5 fold induction. This large induction of *FLO11::lacZ* for haploid cells on SLAD was not observed in the experiments where *FLO11* mRNA was measured. This discrepancy could be due either to a difference in the stability of mRNA vs. protein or the differences in the times at which the cultures

20 were sampled. The expression of *FLO11* as measured by either method is extremely sensitive to growth conditions and growth phase.

Total RNA was prepared using hot acid phenol and northern blots were performed as described in Ausubel et al., (*supra*). Strains deleted for *ras1 ras2 pde2* were pre-grown in SC+1mM cAMP to OD600=1.0. The cells were washed twice

25 using SC and diluted to an OD600=0.3 into fresh SC medium or SC medium + 2 mM cAMP. The cells were grown to OD600=1.0 and harvested. 10-15 μ g of RNA were separated on a formaldehyde containing agarose gel. For hybridization to *FLO11* mRNA, a probe corresponding to bp 3502 - 4093 of the *FLO11* ORF was used.

Cells for β -galactosidase assays of *FG::TyA-lacZ* were incubated on

-44-

SLAD-plates for three days; cells for *FLO11::lacZ* expression studies were grown in the respective liquid media and quantitated according to Mosch et al. (*supra*).

Cells for quantitation of *FLO11::lacZ* expression in exponential growth phase were inoculated from confluent 20 h grown cultures 1:20 in fresh medium and grown for 4-6 h. Cells for quantitation of *FLO11::lacZ* expression after the post-diauxic shift were grown for 24-26 h. The same cultures were used to inoculate the exponentially growing cultures. Cells for quantitation of *FLO11::lacZ* expression in SLAD-medium were pre-grown for 20h in SC-medium, washed twice with 2% glucose, diluted 1:5 into SLAD-medium and grown for 4-6 hours. For detection of cAMP induced *FLO11* promoter segments strain SR957 harboring the individual plasmids was grown overnight in selective medium containing 1 mM cAMP, transferred to media containing no cAMP for 10 h and split into 2 cultures containing 2 mM cAMP or no cAMP and grown for 4 h before harvesting.

Expression of the deletions was assayed in haploid and diploid strains.

Since *FLO11* expression varies with growth phase of the cells, we analyzed exponentially growing cells on SC, cells grown on SC until the glucose had been depleted (post-diauxic), and cells on SLAD, a medium that is high in glucose and low in nitrogen.

Enzymatic assays on the individual *FLO11::lacZ* promoter deletions reveals an unusually long promoter with many sites. In subsequent sections, a site is tentatively assigned as an upstream repression site (URS) if its deletion leads to at least 3-fold enhanced expression of *lacZ*, and as an upstream activation site (UAS) if its deletion leads to at least 30% reduced expression.

Analysis of *cis*-acting elements by enzymatic assays of the individual *flo11-lacZ* promoter deletions reveals that the intact *FLO11* promoter is highly repressed. The deletions define at least nine URS elements whose activity depends on state of growth, nutrient conditions, and cell type. One of the URS elements is defined by *flo11-14* (bp -2600-2800), showing that *cis*-acting elements are present at least 2800 bases from the putative *FLO11* coding region. In general, haploid strains

-45-

show stronger repression than diploid strains.

A clear way to visualize the activity of the sites of repression is by comparison of the *lacZ* activity for each of the conditions with that of a haploid grown on SLAD. This comparison reveals URS elements within *flo11-4*, *-5*, *-7*, *-8*, *-12*, *-13*,
5 and *flo11-14*. A subset of these elements is key to repression on all media, but the strongest effect is in haploids grown on SLAD. Haploid-specific effects are found for deletions *flo11-4*, *-10*, *-11*, *-12*, and *flo11-13*. Clearly, there are sites in *flo11-4*, *flo11-12*, and *flo11-13* that function in the haploid-specific nitrogen repression of *FLO11*.

There are other differences between haploid and diploid strains, the most
10 notable of which being: 1) in diploids on SC (exponential growth), *flo11-4* has a 2-fold reduced expression level, whereas in haploids it has 33-fold elevated expression; 2) in diploids after the diauxic shift, *flo11-11* has a 3-fold reduced level whereas in haploids it has 12-fold elevated expression. In diploid cells, *flo11-4*, *flo11-10*, and *flo11-11* act as UAS elements. *flo11-5* is a strongly nitrogen-regulated site in both
15 haploids and diploids.

Deletion analysis also revealed sequence elements required for expression of *FLO11*. Under all conditions tested, *flo11-6* had a dramatic reduction in expression, suggesting that the sequence deleted in *flo11-6* (-1200 to -1000) contained a strong UAS. Furthermore, *flo11-1*, *flo11-2*, and *flo11-3* show consistently lower
20 activity, as compared to the wild-type *FLO11-lacZ* reporter construct, identifying these as UAS elements in the *FLO11* promoter. The reduced expression of *flo11-1* is likely to be a consequence of the deletion of the TATAA region in this construct.

We made two *flo11* promoter mutations in the chromosome at the *FLO11* locus. In one, *flo11-16*, we deleted virtually the entire promoter region (from -150 to
25 -2947). In the other, we replaced the entire wild-type promoter with *flo11-6*. Chromosomal deletion of the *FLO11* promoter was done by replacing base pairs -2947 to -150 with *URA3* (sequences of primers used:

5'-

ACCACAACATGACGAGGGATAATAACTGATGAATAGGGTGCTTTTATAC

-46-

TCTGTGCGGTATTTACACC-3' (SEQ ID NO: 37) and

5'-

TAAGGAGTCGTACCGCCAACTAAATCTGAATAACAATTTGGCTGCTAGAA
GCAGATTGTACTGAGAGTGC-3'; SEQ ID NO: 38), resulting in *flo11-16*

5 (SR1172)

To generate *flo11-6* in the chromosomal *FLO11* promoter region, the *URA3* gene was replaced by transformation with EcoRI/HindIII digested KS+*flo11-D6* and selection on 5-FOA to yield deletion of base pairs -1000 to -1200 (SR1174).

A strain carrying either *flo11-16* or *flo11-6* is completely defective in
10 haploid invasive growth and, as diploids (e.g., *flo11-6/flo11-6*), show severely reduced filamentation. The haploid invasion defect is as severe as that of a deletion of the *FLO11* coding region. The results with *flo11-6* support our conclusions based on the data from the *lacZ* plasmid constructs, which identified the segment deleted in the *flo11-6* construct as a critical UAS for *FLO11* expression.

15 In a second approach to identify UAS elements of the *FLO11* promoter, we designed 14 individual sequence elements of approximately 400 base pairs, to test activation of a *lacZ* reporter fused to a basal transcriptional unit (Figure 11). To determine UAS-sequence elements, 14 individual 400 bp elements, overlapping by 200 bp were amplified by PCR and cloned into pLG669Z. This vector contains one
20 codon of the *CYC1* gene fused to the *lacZ* gene, and the fused gene is preceded by 1100 nucleotides that lie upstream from *CYC1*. The promoter fragment has *XhoI* restriction sites at positions -683 and -249. The *XhoI* fragment has been excised and replaced with a fragment from the *FLO11* promoter. The fragments correspond to the following positions relative to the start codon of *FLO11*: -1 to -421 (*FLO11-2/1*), -
25 181 to -618 (*FLO11-3/2*), -380 to -819 (*FLO11-4/3*), -580 to -1017 (*FLO11-5/4*), -778 to -1219 (*FLO11-6/5*), -980 to -1420 (*FLO11-7/6*), -1181 to -1619 (*FLO11-8/7*), -1380 to -1819 (*FLO11-9/8*), -1572 to -2019 (*FLO11-10/9*), -1780 to -2219 (*FLO11-11/10*), -1980 to -2419 (*FLO11-12/11*), -2180 to -2619 (*FLO11-13/12*), -2380 to -2819 (*FLO11-14/13*), -2580 to -2983 (*FLO11-15/14*). For cloning purposes, a restriction

-47-

site (*XhoI*) was introduced at the 5' end of the PCR-primers. The primers used for this purpose were:

- | | | |
|----|------|--|
| | #1R | 5'-CCGCTCGAGAGTGTGCGTATATGGATTTT-3' (SEQ ID NO: 39) |
| | #2F | 5'-CCGCTCGAGTGATGAGGTAACCTTTACAA-3' (SEQ ID NO: 40) |
| 5 | #2R | 5'-CCGCTCGAGGTTCTTGAAGTAGAAGAGAG-3' (SEQ ID NO: 41) |
| | #3F | 5'-CCGCTCGAGTTTCAATTCAATGGATTTGG-3' (SEQ ID NO: 42) |
| | #3R | 5'-CCGCTCGAGATTGGTAACTCTATGACATT-3' (SEQ ID NO: 43) |
| | #4F | 5'-CCGCTCGAGATTTCTGCCTATACTCTTAA-3' (SEQ ID NO: 44) |
| | #4R | 5'-CCGCTCGAGTAGTAAACAAACGAATACCT-3' (SEQ ID NO: 45) |
| 10 | #5F | 5'-CCGCTCGAGTTGGGGCTAAGAATGGACTT-3' (SEQ ID NO: 46) |
| | #5R | 5'-CCGCTCGAGACAACATGAATGACTGATCT-3' (SEQ ID NO: 47) |
| | #6F | 5'-CCGCTCGAGGGGTGTGCCTGGAAAGTTCA-3' (SEQ ID NO: 48) |
| | #6R | 5'-CCGCTCGAGCAAAGAAAAAGAAAAGGGAA-3' (SEQ ID NO: 49) |
| | #7F | 5'-CCGCTCGAGCAAACTTTAGGAATACCGG-3' (SEQ ID NO: 50) |
| 15 | #7R | 5'-CCGCTCGAGGAAGAAAAAACCTTAATTT-3' (SEQ ID NO: 51) |
| | #8F | 5'-CCGCTCGAGCGAATGTGAATGCGCTAATC-3' (SEQ ID NO: 52) |
| | #8R | 5'-CCGCTCGAGGGGCTGGCGTAGGCACACAA-3' (SEQ ID NO: 53) |
| | #9F | 5'-CCGCTCGAGAGACAAAAAATAGGAAAAGT-3' (SEQ ID NO: 54) |
| | #9R | 5'-CCGCTCGAGGTAGCAGGTTTCATGTGGTG-3' (SEQ ID NO: 55) |
| 20 | #10F | 5'-CCGCTCGAGTTAGTGCGGAATACTTTCCT-3' (SEQ ID NO: 56) |
| | #10R | 5'-CCGCTCGAGTGAGAACCATCACTAATTAA-3' (SEQ ID NO: 57) |
| | #11F | 5'-CCGCTCGAGCAGTGCTTTCAACACCTTTT-3' (SEQ ID NO: 58) |
| | #11R | 5'-CCGCTCGAGGCTCGGCTCTCGATGAGAAT-3' (SEQ ID NO: 59) |
| | #12F | 5'-CCGCTCGAGGTAGCTGAAAAGTCCATCTA-3' (SEQ ID NO: 60) |
| 25 | #12R | 5'-CCGCTCGAGTCTGACATGGCACACAGATG-3' (SEQ ID NO: 61) |
| | #13F | 5'-CCGCTCGAGGAGATTATCTTGGGATCTAT-3' (SEQ ID NO: 62) |
| | #13R | 5'-CCGCTCGAGTAGTATCATTTCATAATTCGA-3' (SEQ ID NO: 63) |
| | #14F | 5'-CCGCTCGAGGTTTTGGCTCAATGGGACCG-3' (SEQ ID NO: 64) |

-48-

- #14R 5'-CCGCTCGAGATTAGCCGTAAATTTGTGAA-3' (SEQ ID NO: 65)
 #15F 5'-CCGCTCGAGCTCCACATACCAATCACTCG-3' (SEQ ID NO: 66)
 #15R 5'-CCGCTCGAGTAGTTAAACGTTTTATTAGC-3' (SEQ ID NO: 67)

This reporter construct series identified UAS elements in the segments
 5 *FLO11-2/1* and *FLO11-3/2* that overlap between bp -200 and -400, *FLO11-6/5* and
FLO11-7/6 that overlap between bp -1200 and -1000, as well as *FLO11-10/9* and
FLO11-11/10 that overlap between bp -2000 and -1800. These sequence elements
 show a more than 2-fold increase in β -galactosidase activity as compared to the
 reporter plasmid containing the basal transcriptional unit but without any insert. The
 10 activity of *FLO11-2/1*, *FLO11-3/2* and *FLO11-11/10* are induced in post-diauxic
 cells, leading to an induction of up to 200-fold. These results suggested that elements
FLO11-2, *FLO11-3*, and *FLO11-11* are required for *FLO11* expression in later stages
 of growth. Taken together with the deletion analysis, these data suggested that there
 were at least four UAS elements in the *FLO11* promoter. The *FLO11* promoter has
 15 extensive homologies to the promoter regions of the *MUC1*, *STA1*, *STA2*, and *STA3*
 genes from *S. cerevisiae* var. *diastaticus*.

The types of promoter analyses described above, in combination with the
 series of mutant strains identified which have defects in diploid filamentous growth or
 haploid invasion, allows for the identification of trans-acting elements and the regions
 20 of the *FLO11* promoter that are targeted by them. In one example, we transformed
 the 14 individual 400 bp sequence elements into strains deleted for *FLO8*, *STE12*,
TEC1, or for both *STE12* and *TEC1*.

Deletion of *FLO8* led to a severe reduction in the expression of *FLO11-6/5*
 and *FLO11-7/6* in both exponential (8-fold and 4-fold reduction, respectively) and
 25 post-diauxic growth (5-fold for both elements). These elements are also induced by
 high cAMP levels. *FLO8* function is also required for maximum expression of
FLO11-3/2 and *FLO11-8/7* in post-diauxic growth phase, but not in exponential
 growth, a result suggesting that Flo8 may function differently depending upon

-49-

nutrient conditions.

Deletion of *STE12* had a stronger effect in exponentially-growing cells than in post-diauxic cells. In exponentially-growing cells lacking *Ste12*, the *FLO11-6/5*, *FLO11-10/9*, and *FLO11-11/10* segments showed at least a 3-fold reduction in expression. In post-diauxic cells, only *FLO11-10/9* showed reduced expression in an *STE12* deletion strain.

Deletion of *TEC1* had significant effects on expression of the *FLO11* insertion reporter series, but the reduction could be observed only in exponentially-growing cells and was less severe than that observed for strains deleted for *STE12* or *FLO8*. This observation agrees with the northern analysis of the intact *FLO11* promoter, where *FLO11* mRNA levels showed less of a reduction in a strain deleted for *TEC1* (L6149) than it did in strains deleted for *STE12* (L5795) or *FLO8* (L5816). *FLO11-6/5*, *FLO11-10/9*, and *FLO11-12/11* were dependent upon *TEC1* in exponentially-growing cells. Deletion of *TEC1* in a *ste12* strain showed a modest reduction in the expression of *FLO11-10/9* as compared to the single mutant strains. However, since the deletion of *STE12* led to a >10-fold stronger effect than deletion of *TEC1*, this result may indicate a *Tec1*-independent role for *Ste12* at this site.

Our results suggest that *Flo8* and *Ste12/Tec1* act via multiple sites in the *FLO11* promoter that are largely non-overlapping. The strongest effect of *Flo8* and *Ste12*, both in exponential and post-diauxic cells, was observed with two distinct sequence elements of the *FLO11* promoter. *Flo8* acted on the sequence element defined by *flo11-6* (bp -1200 to -1000), whereas *Ste12* acted on *FLO11-10/9* (bp -1800 to -1600). *FLO11-12/11* and *FLO11-10/9* were targeted both by *Tec1* and *Ste12*. The existence of spatially distinct sites for different transcription factors provides strong evidence in support for the combinatorial control over *FLO11* transcription.

In a second example, we measured the expression of *lacZ* from fragments of the *FLO11* promoter in strains mutant for *AFL1*. The diploids of this mutant strain do not form filaments or invade under conditions where wild-type yeast do. We discovered that one element, *FLO11-11/10*, was completely dependent upon *AFL1* for

-50-

expression. We also found that expression from *FLO11* promoter fragment 11/10 was induced more than 15-fold as yeast cells change from log phase growth to stationary phase growth. Furthermore, this stationary phase induction of transcription from *FLO11-11/10* was completely dependent on *AFL1*.

5 As shown above, *FLO11* expression is dependent upon numerous genes involved in pseudohyphal growth and haploid invasion. Thus, by combining the analysis of the *FLO11* promoter with the variety of mutant strains, we will be able to map the trans-acting elements which regulate *FLO11*, as well as the important promoter elements which serve as targets. As many of the *S. cerevisiae* genes have
10 homologs in other fungi, this analysis will allow for identification of putative targets for compounds which prevent fungal invasion or which promote production of secondary metabolites.

 In another example of using *FLO11* promoter fragments and deletions in combination with mutant strains, the sites within the promoter where the cAMP signal
15 activates *FLO11* transcription were determined. We transformed the 400 bp reporter series into a *ras1 ras2 pde2* mutant strain (SR957), a strain where internal cAMP levels can be manipulated by adding cAMP to the media. Addition of 2 mM cAMP to SR957 led to a 3-fold induction of *FLO11-6/5* and a 2-fold induction of *FLO11-7/6*, *FLO11-8/7* and *FLO11-10/9*, as compared to SR957 grown without cAMP. These
20 results suggest that trans-acting elements upregulate *FLO11* expression through a cAMP-mediated signal via more than one *cis*-acting element. The segment most strongly induced by cAMP is defined by the overlapping elements *FLO11-6/5* and *FLO11-7/6* (bp -1200 to -1000), the same element targeted by Flo8. As shown earlier, this element is also required for induction of invasive and filamentous growth.

25 As described above, *FLO11* transcripts were not detectable in a strain (L5816, *flo8-2*) that contains a deletion of the *FLO8* gene. Furthermore, *FLO11* induction by cAMP is blocked in a *ras1 ras2 pde2* strain (SR1081) carrying a deletion of *FLO8*. The *ste12 ras1 ras2 pde2* strain (SR1088), like the *flo8 ras1 ras2 pde2* strain (SR1081), has dramatically reduced expression of *FLO11*. However, *FLO11*

-51-

transcription can be induced by cAMP in the *ste12 ras1 ras2 pde2* strain. The induction of *FLO11* by cAMP in the *ste12* mutant and not in the *flo8* mutant is consistent with the phenotypes of the corresponding strains: a *flo8 ras1 ras2 pde2* strain is unable to form filaments on SLAD plates or to invade the agar on YPD plates, even in the presence of cAMP, whereas *ste12 ras1 ras2 pde2* is both invasive and able to form filaments on YPD or SLAD plates containing 2 mM cAMP. Thus, high cAMP levels can bypass the requirement for the MAPK cascade transcription factor Ste12, but not the requirement for Flo8 in the activation of *FLO11* transcription. These experiments support a model in which several signal transduction cascades converge on the promoter of *FLO11*.

The suppression patterns of *ste12* and *flo8* mutants by overexpression of *FLO8* and *STE12*, respectively, supports a model of their joint control over *FLO11*. Overexpression of *FLO8* in a *ste12* strain (SR1021) and overexpression of *STE12* in a *flo8* strain (SR1134) suppressed the pseudohyphal and invasion defects of the mutants. The morphologies of the pseudohyphae in the "suppressed" strains were not identical to that of wild-type. In *flo8* strains overexpressing *STE12*, the cells of each pseudohyphal strand appear more elongate than the cells of wild-type pseudohyphae. In *ste12* strains overexpressing *FLO8*, the cells are not longer than wild type. However, they have a denser network of filaments. This colony morphology is similar to that of strains that are induced to form filaments by cAMP (SR959).

The patterns of suppression by overexpression were reflected in the *FLO11* expression pattern. Overexpression of *FLO8* enhanced the expression of *FLO11* 10-fold in a *ste12* mutant (SR1021). The reciprocal experiment in which *STE12* was overexpressed is more difficult because high levels of Ste12 are toxic. To control the levels of *STE12*, we used a *GAL::STE12* construct which could be regulated by galactose. In a *flo8* strain (SR1134) containing this *GAL::STE12* construct on a plasmid, the *FLO11* transcript levels were increased 3-fold on SC-glucose medium as compared to the strain transformed with the control plasmid (SR1097). This increase probably represented incomplete repression of the GAL

-52-

promoter. If *STE12* was induced by incubation for four hours in SC-galactose medium, *FLO11* expression was increased 10-fold.

To determine whether a high level of internal cAMP stimulated *FLO11* transcription, we deleted *IRA1* in an otherwise wild-type strain. Ira1 is a Ras-GAP
5 that inactivates Ras-GTP by converting it to Ras-GDP. Loss of Ira1 function leads to a higher proportion of activated Ras and thus to elevated cAMP levels in the cell (Tanaka et al., 1989). In the *ira1* mutant strain (SR599), *FLO11* transcripts were strongly induced. This *FLO11* induction was reflected in the hyperinvasive phenotype of strains devoid of *IRA1* function. A *ste12 ira1* mutant (SR1133) was still
10 hyperinvasive, illustrating that at least some of the cAMP signal was independent of the MAPK pathway. However, *flo11 ira1* (SR1079) or *flo8 ira1* (SR1132) strains failed to invade. These results are consistent with the interpretation that Flo8 is required for the induction of *FLO11* by high internal and external cAMP levels. A strain (SR1132) lacking both *FLO8* and *IRA1* had dramatically reduced levels of
15 *FLO11* transcripts, whereas deletion of *STE12* in an *ira1* background (SR1133) still showed *FLO11* transcript levels comparable to wild type. These results are consistent with the hyper-invasive phenotype of the *ira1 ste12* strain and the non-invasive phenotype of the *ira1 flo8* strain.

Analysis of the regulation of the *FLO11* promoter in *S. cerevisiae* has
20 provided, and is likely to continue to provide, valuable information regarding the regulation of invasion and secondary metabolite production in diverse fungal species. Promoters of other genes involved in invasion or secondary metabolite production from *S. cerevisiae* or other fungal species are similarly likely to provide further valuable information about the regulation of invasion and secondary metabolite
25 production. An example of such a promoter is the *ECE1* gene promoter from *Candida albicans*. Expression of the *Candida albicans ECE1* gene is highly induced during the conversion from noninvasive yeast growth to invasive hyphal growth. In order to clone *Candida* regulators of invasive growth, a fusion between the *ECE1* promoter and the *E. coli lacZ* gene was constructed. Specifically, PCR primers were

-53-

designed to generate a DNA fragment consisting of 706 bases upstream of the *ECE1* start codon and the first 10 codons of the *ECE1* gene. That fragment was cloned to create an in-frame translational fusion with *lacZ* carried on a yeast 2μ /*LEU2* shuttle vector. The fusion plasmid was used to transform a diploid *Saccharomyces cerevisiae* strain that was homozygous *leu2/leu2* and *ura3/ura3*. The strain was subsequently transformed with a library of *Candida albicans* genomic DNA fragments cloned in a yeast 2μ /*URA3* vector. Resulting double transformants were recovered on selective medium lacking supplemental amino acids, pooled, and then replated at low density (200-300 colonies/plate) on minimal medium that contained 50 mM phosphate buffer (pH 7) and .003% w/v XGAL. The plates were incubated for one week and dark blue colonies were picked with the idea that cloned *Candida* regulators of invasion would activate transcription of *lacZ* via the *ECE1* promoter. The 2μ /*URA3* plasmids were isolated from the blue transformants, retested and then the cloned DNA was sequenced. One of the genes identified was *Candida AFL1*. Expression of the *Candida AFL1* gene in *S. cerevisiae* imparted enhanced invasive behavior on diploids under rich medium conditions where it normally does not invade the substrate. Standard database searching for homologs of the *Candida AFL1* gene revealed an *S. cerevisiae* homolog. An *S. cerevisiae* strain containing a complete deletion of *AFL1* did not form filaments or invade under conditions where wild-type yeast did.

AFL1 regulates the expression of both *S. cerevisiae FLO11* (described above) and *Candida ECE1*. It is likely that homologs of other *S. cerevisiae* genes which regulate *FLO11* will regulate the promoters of genes which themselves regulate hyphal growth or invasion in other fungi. The downstream genes can be determined through a number of techniques known to those skilled in the art. One example is to use microarray analysis, as described in DeRisi et al. Science 1997, 278:680.

The use of *Saccharomyces* to clone a *Candida* gene by screening for its function as an inducer of *Candida ECE1* gene transcription exemplifies another approach to isolate important fungal genes involved in invasion or production of secondary metabolites. The success of this experiment in cloning an important

-54-

Candida regulator of invasion proves the concept that it is possible to clone regulators of transcription from potentially diverse species by using *Saccharomyces* as a heterologous host in which to screen. This technique gives the advantages of the sophisticated molecular genetic tools available for *Saccharomyces*, but not for other organisms. This has implications not only for fungi like *Candida*, but potentially for very disparate species such as mammalian species. This method may also be useful in performing more detailed analysis of the function of regulators of transcription from non-*Saccharomyces* species. The use of *Saccharomyces* as a heterologous host can be combined with selection-based screens to rapidly screen cDNA or genomic libraries to isolate regulators of transcription of *Candida*, or any other organism.

Screening Assays for Genes and Compounds

As discussed above, we have identified a number of fungal invasion-promoting and invasion-inhibiting factors that are involved in pathogenicity and that may therefore be used to screen for compounds that reduce the virulence of pathogenic fungi, as well as other microbial pathogens or, alternatively, increase the production of secondary metabolites. Any number of methods are available for carrying out such screening assays. According to one approach, candidate compounds are added at varying concentrations to the culture medium of pathogenic fungal cells expressing one of the nucleic acid sequences described herein. Gene expression is then measured, for example, by standard northern blot analysis (Ausubel et al., *supra*), using any appropriate fragment prepared from the nucleic acid molecule as a hybridization probe. The level of gene expression in the presence of the candidate compound is compared to the level measured in a control culture medium lacking the candidate molecule. A compound which promotes a decrease in the expression of the invasion-promoting factor is considered useful in the invention; such a molecule may be used, for example, as a therapeutic to combat the pathogenicity of an infectious organism. A compound which promotes an increase in the expression of the invasion-promoting factor is considered useful in the invention; such a molecule may

-55-

be used, for example, as a potentiator, increasing production of commercially important secondary metabolites.

If desired, the effect of candidate compounds or genes may, in the alternative, be measured by assaying the protein polypeptide level. There are numerous preferred protein assays, including standard immunological techniques, such as western blotting or immunoprecipitation with an antibody specific for an invasin polypeptide. For example, immunoassays may be used to detect or monitor the expression of at least one of the polypeptides of the invention in a pathogenic organism. Polyclonal or monoclonal antibodies (produced as described in Harlow and Lane, *Antibodies, a laboratory manual* 1988, Cold Spring Harbor Press) which are capable of binding to such a polypeptide may be used in any standard immunoassay format (e.g., ELISA, western blot, or RIA assay) to measure the level of the pathogenicity polypeptide. In another example, polypeptide levels may be determined using enzymatic activity in standard assays. Standard kits are available (for example the Galacto-Plus and GUS light systems, available from Tropix, Inc., Bedford Mass.) which allow for measurement of enzymatic activity of, for example, Chloramphenicol acetyl transferase (CAT) and β -galactosidase (encoded by the *lacZ* gene). Protein levels can also be determined using techniques such as fluorescence-activated cell sorting (FACS), spectrophotometry, or luminescence. A compound which promotes a decrease in the expression of the invasion-promoting polypeptide is considered useful. Again, such a molecule may be used, for example, as a therapeutic to combat the pathogenicity of an infectious organism. A compound or which promotes an increase in the expression of the invasion-promoting polypeptide is also considered useful. Again, such a molecule may be used, for example, as a potentiator, increasing production of commercially important secondary metabolites.

Alternatively, or in addition, candidate compounds may be screened for those which specifically bind to and inhibit an invasin polypeptide of the invention. The efficacy of such a candidate compound is dependent upon its ability to interact with the invasin polypeptide. Such an interaction can be readily assayed using any

-56-

number of standard binding techniques and functional assays (e.g., those described in Ausubel et al., *supra*). For example, a candidate compound may be tested *in vitro* for interaction and binding with a polypeptide of the invention and its ability to modulate pathogenicity may be assayed by any standard assays (e.g., those described herein).

5 In one particular example, a candidate compound that binds to an invasin polypeptide may be identified using a chromatography-based technique. For example, a recombinant polypeptide of the invention may be purified by standard techniques from cells engineered to express the polypeptide (e.g., those described above) and may be immobilized on a column. A solution of candidate compounds is
10 then passed through the column, and a compound specific for the invasin polypeptide is identified on the basis of its ability to bind to the invasin polypeptide and be immobilized on the column. To isolate the compound, the column is washed to remove non-specifically bound molecules, and the compound of interest is then released from the column and collected. Compounds isolated by this method (or any
15 other appropriate method) may, if desired, be further purified (e.g., by high performance liquid chromatography). In addition, these candidate compounds may be tested for their ability to render a pathogen less virulent (e.g., as described herein). Compounds isolated by this approach may also be used, for example, as therapeutics to treat or prevent the onset of a pathogenic infection, disease, or both. Compounds
20 which are identified as binding to pathogenicity polypeptides with an affinity constant less than or equal to 10 mM are considered particularly useful in the invention.

 In yet another approach, candidate genes and compounds are screened for the ability to inhibit the virulence of a fungal cell by monitoring expression from a promoter element known to be positively or negatively regulated during filamentous
25 invasion, hyphal growth, pseudohyphal growth or haploid digging. These same selection-based systems may be configured to screen for genes or compounds which lead to increased expression from the *FLO11* promoter (P_{FLO11}). In one example, P_{FLO11} is fused to a gene that confers a growth advantage when their expression is increased. For example, a P_{FLO11} -*HIS3* fusion that allows growth on SC-HIS when

-57-

present in a *his3* mutant has been generated. This fusion has the added advantage that expression levels can be titrated by the compound 3-aminotriazole (3-AT). 3-AT is a competitive inhibitor of His3 that, when present in sufficient amounts, will inhibit the His3 expressed from P_{FLO11} and prevent this strain from growing on SC-HIS.

- 5 Therefore, growth of a strain containing P_{FLO11} -*HIS3* only occurs on SC-HIS+3-AT plated when P_{FLO11} -*HIS3* expression is increased to overcome the competitive inhibition of His3 by 3-AT. Increased expression of the transcription factor Tec1 confers increased resistance to 3-AT in such a strain. By varying the amount of 3-AT used, the extent of increased P_{FLO11} -*HIS3* necessary for growth can be modulated.
- 10 Numerous markers could be used for such positive selection systems, including, but not limited to, *URA3*, *TRP1*, *ADE2*, *LEU2*. Those skilled in the art will recognize that other positive selection systems will also work in this system.

- In another example, gene fusions that link P_{FLO11} to a gene product that confers a growth disadvantage (in its most extreme case--death) can be used to select
- 15 for genes and compounds which down-regulate *FLO11* expression. In this case, any condition that decreases and/or eliminates *FLO11* expression will alleviate the growth disadvantage and allow strains to grow. For example, a fusion of P_{FLO11} to the *URA3* open reading frame that allows for growth on SC-URA in a P_{FLO11} -dependent manner has been created. Since expression of *URA3* is toxic in the presence of 5-fluoro-orotic acid (5-FOA), selection against *FLO11* expression can be accomplished by screening
- 20 for growth on SC+5-FOA of a strain carrying a P_{FLO11} -*URA3* fusion. Those skilled in the art will recognize that other negative selection systems will also work in this system.

- While the systems described above allow for the selection for or against
- 25 *FLO11* expression, similar technologies can be used to screen for changes in *FLO11* expression. Other examples of useful P_{FLO11} reporter gene fusions that can be quantified include, but are not limited to, enzymatic or fluorescent reporters such as *lacZ* and green fluorescent protein (GFP).

The selection and screening systems described here have a number of

-58-

potential applications beyond those stated above. For example, they can be used to identify, by selection methods, functional homologs for many of the genes that regulate *FLO11*. For example, mutation of a gene that eliminates *FLO11* expression in a strain deleted for *his3* and carrying a *P_{FLO11}HIS3* fusion will cause this strain to be a histidine auxotroph (unable to grow in media lacking histidine). However, cDNA or genomic DNA clones from other organisms that restore *FLO11* expression in such strains (either by complementation or suppression of the mutant allele) can be directly selected for by selecting for growth on media lacking histidine. Similarly, novel regulators of *FLO11* expression from *S. cerevisiae* and heterologous organisms can be identified using the same selection schemes.

In another application of using promoters known to be regulated during hyphal or pseudohyphal growth, deletion constructs can be generated in order to map the cis elements of the promoter required for each signal transduction pathway. As an example, the *FLO11* promoter screening and selection assays, in which nested deletions of 200 bp steps from the 3kb region upstream of the *FLO11* ORF have been generated, are being analyzed for effects on *lacZ* expression in various wild-type and mutant background strains. In another example, overlapping 400 bp fragments of the *FLO11* promoter have been cloned into the *CYC1* transcriptional unit (Figure 11). Together, these examples will demonstrate which DNA regions are required for expression (and to what extent each of these regions is required). Furthermore, reporter gene fusions with subcloned pieces of promoters regulated during hyphal growth or pseudohyphal growth, such as the *FLO11* promoter, can be assessed for expression in various mutants that block (or activate) distinct pathways. A person skilled in the art will recognize that regulatory elements from other invasins, including those described herein, can be isolated as described using the methods described herein, in conjunction with standard techniques described in Ausubel et al. (*supra*). These methods include fusion of a DNA segment from a putative regulatory or promoter region to a reporter gene, as well as deletion analysis. Moreover, the pathway specificity of any invasin promoter can be determined through the use of

wild-type and mutant host strains. If a given DNA segment confers reporter expression in a wild-type strain, but shows either no or increased expression in specific mutants, then this sequence can be inferred to mediate invasin expression by whatever pathway that mutant defines. Using this approach, a set of gene fusions that report distinct pathways that regulate *FLO11* can be generated. A variety of basal or inducible promoter elements are applicable for this technique, including, but not limited to, *CYC1*, *PGK1*, *ADH1*, *GAL1-10*, *tet-R*, *MET25*, and *CUP1*. Using the above system, a mode of action can be assigned for any given treatment on *FLO11* expression. Assessment of the effect of a chemical or genetic treatment on pathway-specific reporters will make it possible to determine which pathway is altered by this treatment. For example, consider two different reporter fusions, one (Reporter 1) that reports STE pathway-mediated expression of *FLO11*, and the other (Reporter 2) that reports INV pathway-mediated expression of *FLO11*. If compound *X*, which was identified by its ability to eliminate expression of the full-length *P_{FLO11}*, is shown to affect Reporter 1 but not Reporter 2, then it is inferred that compound *X* blocks *FLO11* expression by affecting STE pathway activity. Similarly, where the compound affects a given pathway will also be refined using pathway-specific *P_{FLO11}* reporter constructs and activated alleles of certain signaling components. For example, the mutant *STE11-4* and overexpression of *STE12* are both predicted to increase *FLO11* expression. If compound *X* blocks the increased expression of *FLO11* mediated by *STE11-4*, but not *STE12* overexpression, then compound *X* can be inferred to antagonize the STE pathway before *STE12*, but at or below *STE11*. Assessing reporter expression in various deletion mutants will enable similar approaches to assess the effect of compounds that activate expression of *FLO11*.

25 The reporters used in these experiments can be utilized in the same way as those described for the full-length *FLO11* promoter to allow for positive and negative selections and a variety of screening methods. This will make it possible to identify pathway-specific modulators (heterologous genes, compounds, peptides etc.) of *FLO11* expression. Such a system is also useful in identifying modulators of

-60-

important homologs of these regulatory genes from other organisms. For example, the small G-protein Ras is activated in many kinds of human tumors, and it is of interest to identify inhibitors of *RAS* as candidate antitumor agents. Having a *FLO11* promoter fragment fusion that reports the activity of human *RAS* in yeast (e.g., in a yeast strain deleted for the two yeast *RAS* genes and expressing human *RAS*) would allow one to select and/or screen for modulators of human Ras in yeast.

Another example of a screen is based on the observation that yeast from haploid *S. cerevisiae* invade agar when grown on rich (YPD) medium without forming pseudohyphae. This nonfilamentous invasion behavior has been termed “digging,” and the assay used to detect this behavior has been termed the “dig assay.” Roberts and Fink, *supra*. Mutations that block digging of haploid *S. cerevisiae* on rich media also inhibit pseudohyphal growth and agar invasion of diploid *S. cerevisiae* under low nitrogen conditions. Mutant strains defective for digging are referred to as “dig minus,” or “dig-.” The correlation of pseudohyphal invasion and behavior in the dig assay is an essential aspect of this screen. The dig assay is comparatively easy to perform relative to pseudohyphal invasion assays, and, as it occurs in haploid cells, is more amenable to genetic approaches that rely upon recessive mutations.

We have discovered that pathogenic fungi can display similar digging behavior, characterized by increased invasion into or adherence to a defined substrate. For example, *C. albicans* displays a nonfilamentous invasion of substrate in a variety of suitable conditions (e.g., YPD, and SPIDER). This behavior is similar to the reported digging behavior of *S. cerevisiae*. As is true for *S. cerevisiae*, non-hyphal agar invasion by any given *C. albicans* mutant strain correlates with the ability of that strain to form filaments under filament-inducing conditions (e.g., agar + serum). Thus, screening for compounds that block the digging phenotype in fungi will allow for identification of compounds that block filament formation and, as a result, pathogenesis. These compounds are considered useful as fungicides or fungistats. Similarly, screening for compounds that increase substrate invasion will allow for

-61-

identification of compounds which may also increase production or yield of secondary metabolites.

An example of the dig assay is given below. To test whether a chemical compound would affect the nonfilamentous agar invasion behavior of nonmutant *S. cerevisiae* or *C. albicans* at concentrations much lower than the lowest growth inhibitory concentration, these fungi were spotted onto agar plates containing rich medium (YPD) and a gradient of the antifungal fluconazole. The plates were then incubated for two days at optimum growth temperatures and washed with water. Both fungi exhibited inhibition of agar invasion at significantly lower concentrations of fluconazole than those necessary to inhibit growth (Figure 12). This assay can be performed on other dimorphic fungi, such as *U. maydis*, as well as on other fungi. In all cases, the invasion assay can be used to isolate compounds which inhibit invasion, or those which promote invasion. Each type of compound would have valued uses as described herein.

Optionally, invasion-inhibiting compounds identified in any of the above-described assays may be confirmed as useful in conferring protection against the development of a pathogenic infection in any standard animal model. One example is described herein. Candidate compounds, if successful, may be used for anti-pathogen therapeutics. Invasion-promoting compounds may be confirmed by assessing production of secondary metabolites. Candidate compounds, if successful, may be used as potentiators to increase production or yield of these or other secondary metabolites.

Test Compounds and Extracts

In general, compounds are identified from large libraries of both natural product and synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any

-62-

number of chemical extracts or compounds can be screened using the methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their anti-pathogenic activity should be employed whenever possible.

When a crude extract is found to have an invasion-promoting or invasion-inhibiting activity, or a binding activity, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having the desired activity. Methods of fractionation and purification of such heterogenous extracts are known in the art. If desired, compounds shown to be useful

-63-

agents for the treatment of pathogenicity or increased production of secondary metabolites are chemically modified according to methods known in the art.

Pharmaceutical Therapeutics and Plant Protectants

- The invention provides a simple means for identifying compounds
- 5 (including peptides, small molecule inhibitors, and mimetics) capable of inhibiting the pathogenicity or virulence of a pathogen. Accordingly, chemical entities discovered to have medicinal or agricultural value using the methods described herein are useful as either drugs, plant protectants, or as information for structural modification of existing anti-pathogenic compounds, e.g., by rational drug design.
- 10 Such methods are useful for screening compounds having an effect on a variety of pathogens including, but not limited to, bacteria, viruses, fungi, annelids, nematodes, Platyhelminthes, and protozoans. Examples of pathogenic fungi include, without limitation, *Candida albicans*, *Aspergillus sp.*, *Mucor sp.*, *Rhizopus sp.*, *Fusarium sp.*, *Penicillium marneffei*, *Microsporium sp.*, *Cryptococcus neoformans*, *Pneumocystis*
- 15 *carinii*, and *Trichophyton sp.*

- For therapeutic uses, the compositions or agents identified using the methods disclosed herein may be administered systemically, for example, formulated in a pharmaceutically-acceptable buffer such as physiological saline. Treatment may be accomplished directly, e.g., by treating the animal with antagonists which disrupt,
- 20 suppress, attenuate, or neutralize the biological events associated with a pathogenicity polypeptide. Preferable routes of administration include, for example, inhalation or subcutaneous, intravenous, interperitoneally, intramuscular, or intradermal injections which provide continuous, sustained levels of the drug in the patient. Treatment of human patients or other animals will be carried out using a therapeutically effective
- 25 amount of an anti-pathogenic agent in a physiologically-acceptable carrier. Suitable carriers and their formulation are described, for example, in Remington's *Pharmaceutical Sciences* by E.W. Martin. The amount of the anti-pathogenic agent to be administered varies depending upon the manner of administration, the age and

-64-

body weight of the patient, and with the type of disease and extensiveness of the disease. Generally, amounts will be in the range of those used for other agents used in the treatment of other microbial diseases, although in certain instances lower amounts will be needed because of the increased specificity of the compound. A compound is
5 administered at a dosage that inhibits microbial proliferation. For example, for systemic administration a compound is administered typically in the range of 0.1 ng - 10 g/kg body weight.

For agricultural uses, the compositions or agents identified using the methods disclosed herein may be used as chemicals applied as sprays or dusts on the
10 foliage of plants, or in irrigation systems. Typically, such agents are to be administered on the surface of the plant in advance of the pathogen in order to prevent infection. Seeds, bulbs, roots, tubers, and corms are also treated to prevent pathogenic attack after planting by controlling pathogens carried on them or existing in the soil at the planting site. Soil to be planted with vegetables, ornamentals, shrubs, or trees can
15 also be treated with chemical fumigants for control of a variety of microbial pathogens. Treatment is preferably done several days or weeks before planting. The chemicals can be applied by either a mechanized route, e.g., a tractor or with hand applications. In addition, chemicals identified using the methods of the assay can be used as disinfectants.

20 In addition, the antipathogenic agent may be added to materials used to make catheters, including but not limited to intravenous, urinary, intraperitoneal, ventricular, spinal and surgical drainage catheters, in order to prevent colonization and systemic seeding by potential pathogens. Similarly, the antipathogenic agent may be added to the materials that constitute various surgical prostheses and to dentures to
25 prevent colonization by pathogens and thereby prevent more serious invasive infection or systemic seeding by pathogens.

Enhancement of Secondary Metabolite Production

The invention provides a simple means for identifying compounds

-65-

(including peptides, small molecules and mimetics) that are capable of activating secondary metabolite production in fungi. Accordingly, a chemical entity discovered to have such characteristics using the methods described herein is useful as a means to increase the yields of currently marketed pharmaceuticals whose production, in whole or in part, is dependent upon a fungal fermentation. Examples of marketed secondary metabolites whose yields during fermentation could be increased by such compounds include, without limitation, cyclosporin, penicillin, cephalosporin, ergot alkaloids, lovastatin, mevastatin, and the biosynthetic intermediates thereof. In addition, such chemical entities can also be used to increase the likelihood of identifying new secondary metabolites with medicinal or agricultural value by increasing the concentration of such metabolites (and hence, the likelihood of detection by chemical or bioassay) in a fermentation broth. In both instances, increased yield of metabolite can be accomplished by contacting fungi with the entity and/or transforming a fungus with a gene expression construct or constructs that would result in the production of said entity within the fungus.

The invention also provides a simple means for identifying candidate genes that both positively and negatively regulate secondary metabolite production in fungi. In addition, methods to identify activated and dominant negative versions of these genes are described. Accordingly, such genes and their derivatives are likely candidates to enable the genetic engineering of fungi to increase production of secondary metabolites both through the introduction of altered forms of these genes into production fungi by standard transformation methods and also by elimination of relevant gene function through the construction of knockouts. Examples of marketed secondary metabolites whose yields during fermentation could be increased by genetic engineering methods such as these include, without limitation, cyclosporin, penicillin, cephalosporin, ergot alkaloids, lovastatin, mevastatin, and the biosynthetic intermediates thereof.

-66-

Production and Detection Methods for Fungal Secondary Metabolites

Methods for fermentation and production of beta-lactam antibiotics, statins, ergot alkaloids, cyclosporin, and other fungal metabolites are described in Masurekar (Biotechnology 1992, 21: 241-301), and references therein. The detection
5 of secondary metabolites is specific for each metabolite and well-known to those practiced in the art. General methods to assess production and integrity of compounds in fermentation broths include, but are not limited to, bioassays for antimicrobial activity, high-performance liquid chromatography (HPLC) analysis, nuclear magnetic resonance, thin-layer chromatography, and absorbance spectrometry. Purification of
10 metabolites from a fermentation broth can include removal of fungal cells or hyphae by centrifugation or filtration, adjustment of pH and/or salt concentrations after fermentation (to enhance solubility and/or subsequent extraction efficiency), and extraction of broths with appropriate organic solvents.

Other Embodiments

15 In general, the invention includes any nucleic acid sequence which may be isolated as described herein or which is readily isolated by homology screening or PCR amplification using the nucleic acid sequences of the invention. Also included in the invention are polypeptides which are modified in ways which do not abolish their pathogenic activity (assayed, for example as described herein). Such changes
20 may include certain mutations, deletions, insertions, or post-translational modifications, or may involve the inclusion of any of the polypeptides of the invention as one component of a larger fusion protein.

Thus, in other embodiments, the invention includes any protein which is substantially identical to a polypeptide of the invention. Such homologs include other
25 substantially pure naturally-occurring polypeptides as well as allelic variants; natural mutants; induced mutants; proteins encoded by DNA that hybridizes to any one of the nucleic acid sequences of the invention under high stringency conditions or, less preferably, under low stringency conditions (e.g., washing at 2X SSC at 40°C with a

-67-

probe length of at least 40 nucleotides); and proteins specifically bound by antisera of the invention.

The invention further includes analogs of any naturally-occurring polypeptide of the invention. Analogs can differ from the naturally-occurring polypeptide of the invention by amino acid sequence differences, by post-translational modifications, or by both. Analogs of the invention will generally exhibit at least 85%, more preferably 90%, and most preferably 95% or even 99% identity with all or part of a naturally-occurring amino acid sequence of the invention. The length of sequence comparison is at least 15 amino acid residues, preferably at least 25 amino acid residues, and more preferably more than 35 amino acid residues. Again, in an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e^{-3} and e^{-100} indicating a closely related sequence. Modifications include *in vivo* and *in vitro* chemical derivatization of polypeptides, e.g., acetylation, carboxylation, phosphorylation, or glycosylation; such modifications may occur during polypeptide synthesis or processing or following treatment with isolated modifying enzymes. Analogs can also differ from the naturally-occurring polypeptides of the invention by alterations in primary sequence. These include genetic variants, both natural and induced (for example, resulting from random mutagenesis by irradiation or exposure to ethanemethylsulfate or by site-specific mutagenesis as described in Sambrook, Fritsch and Maniatis, *Molecular Cloning: A Laboratory Manual* (2d ed.), CSH Press, 1989, or Ausubel et al., *supra*). Also included are cyclized peptides, molecules, and analogs which contain residues other than L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., β or γ amino acids.

In addition to full-length polypeptides, the invention also includes fragments of any one of the polypeptides of the invention. As used herein, the term "fragment," means at least five, preferably at least 20 contiguous amino acids, preferably at least 30 contiguous amino acids, more preferably at least 50 contiguous amino acids, and most preferably at least 60 to 80 or more contiguous amino acids.

-68-

Fragments of the invention can be generated by methods known to those skilled in the art or may result from normal protein processing (e.g., removal of amino acids from the nascent polypeptide that are not required for biological activity or removal of amino acids by alternative mRNA splicing or alternative protein processing events).

5 The invention further provides compositions (e.g., nucleotide sequence probes) and methods for the diagnosis of a pathogenic condition.

 All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by
10 reference.

 Other embodiments are within the scope of the claims.

 What is claimed is:

-69-

Claims

1. A method for determining whether a candidate compound decreases the expression of a gene operably linked to a fungal invasin gene promoter, said method comprising
- 5 (a) providing a fungus expressing said gene operably linked to a fungal invasin gene promoter;
- (b) contacting said fungus with said candidate compound; and
- (c) detecting or measuring expression of said gene following contact of the fungus with said candidate compound.
- 10 2. The method of claim 1, wherein said fungus is a wild-type strain.
3. The method of claim 2, wherein said wild-type strain is *Saccharomyces cerevisiae*, *Candida albicans*, or *Aspergillus nidulans*.
4. The method of claim 1, wherein said fungus is a mutant strain.
5. The method of claim 1, wherein said fungus is a transgenic fungus
- 15 6. The method of claim 1, wherein said gene comprises a fungal invasin gene.
7. The method of claim 6, wherein said fungal invasin gene is *FLO11* or *MUC1*.
8. The method of claim 1, wherein said fungal invasin gene is *AFL1*,
20 *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*,
INV15, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*,

-70-

RIM15, SFL1, SRB11, SSD1, STE21, STP22, SWI4, TPK2, TPK3, RIM1, or YPR1

9. The method of claim 1, wherein said gene comprises a reporter gene.

10. The method of claim 9, wherein said reporter gene is *lacZ*, *URA3*, or *HIS3*.

5 11. The method of claim 1, wherein said fungal invasin gene promoter is the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

12. The method of claim 1, wherein said fungal invasin gene promoter is the *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *RIM1*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*,
10 *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene promoter.

13. The method of claim 1, wherein said fungal invasin gene promoter is a fragment or deletion of a fungal invasin gene promoter.

14. The method of claim 13, wherein said fragment is fused to a basal
15 promoter.

15. The method of claim 14, wherein said basal promoter comprises *PGK1*, *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1* or *CUP1*.

16. The method of claim 1, wherein said gene expression is measured by assaying the protein level of the expressed gene.

20 17. The method of claim 1, wherein said gene expression is measured by

-71-

assaying the RNA level of the expressed gene.

18. The method of claim 6, wherein a decrease in the expression of said fungal invasin gene inhibits fungal invasion.

19. The method of claim 6, wherein a decrease in the expression of said
5 fungal invasin gene inhibits the switch from yeast form to pseudohyphal growth.

20. The method of claim 1, wherein said candidate compound inhibits or decreases the pathogenicity of a fungus.

21. A method for determining whether a candidate compound increases the expression of a gene operably linked to a fungal invasin gene promoter, said
10 method comprising

(a) providing a fungus expressing said gene operably linked to a fungal invasin gene promoter;

(b) contacting said fungus with said candidate compound; and

(c) detecting or measuring expression of said gene following contact of the
15 fungus with said candidate compound.

22. The method of claim 21, wherein said fungus is a wild-type strain.

23. The method of claim 22, wherein said wild-type strain is
Saccharomyces cerevisiae, *Aspergillus nidulans*, *Penicillium chrysogenum*, or
Acremonium chrysogenum.

20

24. The method of claim 21, wherein said fungus is a mutant strain.

25. The method of claim 21, wherein said fungus is a transgenic fungus

-72-

26. The method of claim 21, wherein said gene comprises a fungal invasin gene.

27. The method of claim 26, wherein said fungal invasin gene is *FLO11* or *MUC1*.

5 28. The method of claim 26, wherein said fungal invasin gene is *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *RIM1*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1*

10 29. The method of claim 21, wherein said gene comprises a reporter gene.

30. The method of claim 29, wherein said reporter gene is *lacZ*, *URA3*, or *HIS3*.

31. The method of claim 21, wherein said fungal invasin gene promoter is the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

15 32. The method of claim 21, wherein said fungal invasin gene promoter is the *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *RIM1*, *TPK3*, or *YPR1* gene promoter.

20 33. The method of claim 21, wherein said fungal invasin gene promoter is a fragment or deletion of a fungal invasin gene promoter.

-73-

34. The method of claim 33, wherein said fragment is fused to a basal promoter.

35. The method of claim 34, wherein said basal promoter is *PGK1*, *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1* or *CUP1*.

5 36. The method of claim 21, wherein said gene expression is measured by assaying the protein level of the expressed gene.

37. The method of claim 21, wherein said gene expression is measured by assaying the RNA level of the expressed gene.

10 38. The method of claim 21, further comprising determining whether said candidate compound increases the production of a secondary metabolite in a fungus.

39. A method for determining whether a candidate compound inhibits fungal invasion, said method comprising

(a) contacting a fungus with a candidate compound under conditions suitable for invasion; and

15 (b) measuring or detecting invasion by said fungus following contact with said candidate compound.

40. The method of claim 39, wherein said fungus is *Candida albicans*.

41. The method of claim 39, wherein said fungus is *Saccharomyces cerevisiae*.

20 42. A method for determining whether a candidate compound promotes fungal invasion, said method comprising

-74-

(a) contacting a fungus with a candidate compound under conditions suitable for invasion; and

(b) measuring or detecting invasion by said fungus following contact with said candidate compound.

5 43. The method of claim 42, wherein said fungus is *Candida albicans*.

44. The method of claim 42 wherein said fungus is *Saccharomyces cerevisiae*.

45. The method of claim 42, wherein said fungus is *Aspergillus nidulans*.

10 46. A method for identifying a fungal invasion-promoting gene, said method comprising

(a) expressing in a fungus (i) a first gene operably linked to a fungal invasin gene promoter and (ii) a second candidate gene or a fragment thereof; and

(b) monitoring the expression of said first gene,
wherein an increase in said expression identifies said candidate gene as a fungal
15 invasion-promoting gene.

47. The method of claim 46, wherein said fungus is a wild-type strain.

48. The method of claim 47, wherein said wild-type strain is *Saccharomyces cerevisiae*.

49. The method of claim 46, wherein said fungus is a mutant strain.

20 50. The method of claim 46, wherein said fungus is a transgenic fungus

-75-

51. The method of claim 46, wherein said first gene comprises a fungal invasin gene.

52. The method of claim 51, wherein said fungal invasin gene is *FLO11* or *MUC1*.

5 53. The method of claim 51, wherein said fungal invasin gene is *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *RIM1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1*

10 54. The method of claim 46, wherein said first gene comprises a reporter gene.

55. The method of claim 54, wherein said reporter gene is *lacZ*, *URA3*, or *HIS3*.

56. The method of claim 46, wherein said fungal invasin gene promoter is the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

15 57. The method of claim 46, wherein said fungal invasin gene promoter is the *AFL1*, *DHH1*, *INV1*, *RIM1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene promoter.

20 58. The method of claim 46, wherein said fungal invasin gene promoter is a fragment or deletion of the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

-76-

59. The method of claim 58, wherein said fragment is fused to a basal promoter.

60. The method of claim 59, wherein said basal promoter is *PGK1*, *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1* or *CUP1*.

5 61. The method of claim 46, wherein said gene expression is measured by assaying the protein level of the expressed first gene.

62. The method of claim 46, wherein said gene expression is measured by assaying the RNA level of the expressed first gene.

63. The method of claim 46, wherein said fungal invasion-promoting
10 gene comprises a member of an invasin pathway.

64. A method for identifying a fungal invasion-inhibiting gene, comprising

(a) expressing in a fungus (i) a first gene operably linked to a fungal invasin gene promoter and (ii) a second candidate gene or fragment thereof; and

15 (b) monitoring the expression of said first gene,
wherein a decrease in said expression identifies said candidate gene as a fungal invasion-inhibiting gene.

65. The method of claim 64, wherein said fungus is a wild-type strain.

66. The method of claim 65, wherein said wild-type strain is
20 *Saccharomyces cerevisiae*.

67. The method of claim 64, wherein said fungus is a mutant strain.

-77-

68. The method of claim 64, wherein said fungus is a transgenic fungus

69. The method of claim 64, wherein said first gene comprises a fungal invasin gene.

70. The method of claim 69, wherein said fungal invasin gene is *FLO11* or *MUC1*.

71. The method of claim 69, wherein said fungal invasin gene is *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *RIM1*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1*

72. The method of claim 64, wherein said first gene comprises a reporter gene.

73. The method of claim 72, wherein said reporter gene is *lacZ*, *URA3*, or *HIS3*.

74. The method of claim 64, wherein said fungal invasin gene promoter is the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

75. The method of claim 64, wherein said fungal invasin gene promoter is the *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1* gene promoter.

76. The method of claim 64, wherein said fungal invasin gene promoter

-78-

is a fragment or deletion of the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

77. The method of claim 76, wherein said fragment is fused to a basal promoter.

78. The method of claim 77, wherein said basal promoter is *PGK1*,
5 *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1* or *CUP1*.

79. The method of claim 64, wherein said gene expression is measured by assaying the protein level of the expressed first gene.

80. The method of claim 64, wherein said gene expression is measured by assaying the RNA level of the expressed first gene.

10 81. The method of claim 64, wherein said fungal invasion-inhibiting gene comprises a member of an invasin pathway.

82. A method for increasing production of a secondary metabolite in a fungal cell, said method comprising the step of contacting said fungal cell with a fungal invasion-promoting compound.

15 83. A method for increasing production of a secondary metabolite in a fungal cell, said method comprising the step of decreasing the expression of a fungal invasion-inhibiting gene.

84. The method of claim 83, wherein said decreased expression of said fungal invasion-inhibiting gene results from an inactivation of said fungal invasion-
20 inhibiting gene.

-79-

85. The method of claim 83, wherein said fungal invasion-inhibiting gene is mutated.

86. The method of claim 83, wherein said fungal invasion-inhibiting gene comprises *HOG1*, *BEM2*, *RIM15*, *SFL1*, *IRA1*, *SSD1*, *SRB11*, *SWI4*, or *TPK3*.

5 87. A method for increasing production of a fungal secondary metabolite, said method comprising the step of increasing the expression of a fungal invasion-promoting gene.

88. The method of claim 87, wherein said fungal invasion-promoting gene is *AFL1*, *DHH1*, *INV7*, *INV8*, *STE21*, *PET9*, *MEP2*, *INV1*, *INV5*, *INV6*, *INV9*,
10 *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *CDC25*, *MCM1*, *MGA1*, *PHD2*, *PHO23*, *PTC1*, *RIM1*, *STP22*, *TPK2*, or *YPR1*.

89. The method of claim 87, wherein said fungal invasion-promoting gene is constitutively expressed or overexpressed.

90. The method of claim 87, wherein said fungal invasion-promoting
15 gene is mutated.

91. A method for increasing production of a fungal secondary metabolite, said method comprising the step of expressing a gene, or fragment thereof, that encodes an activated form of a invasion-promoting polypeptide.

92. The method of claim 91, wherein said activated form of said
20 invasion-promoting polypeptide comprises a fusion between the invasion-promoting polypeptide and a second polypeptide that further enhances the activity of said invasion-promoting polypeptide.

-80-

93. The method of claim 91, wherein said gene has a mutation.

94. A method for increasing production of a secondary metabolite in a fungal cell, said method comprising the step of decreasing the activity of a fungal invasion-inhibiting polypeptide.

5 95. The method of claim 94, wherein said fungal invasion-inhibiting polypeptide has a mutation.

96. The method of claim 95, wherein said mutation encodes a dominant-inactive polypeptide.

97. The method of claim 94, wherein said fungal invasion-inhibiting
10 polypeptide comprises Hog1, Bem2, Rim15, Ira1, Sfl1, Ssd1, Srb11, Swi4, or Tpk3.

98. A method for increasing production of a fungal secondary metabolite, said method comprising the step of increasing the activity of a fungal invasion-promoting polypeptide.

99. The method of claim 98, wherein said fungal invasion-promoting
15 polypeptide has a mutation.

100. The method of claim 99, wherein said mutation encodes a dominant-active polypeptide.

101. The method of claim 98, wherein said fungal invasion-promoting polypeptide is Afl1, Dhh1, Inv1, Inv5, Inv6, Inv9, Inv10, Inv11, Inv12, Inv13, Inv14,
20 Rim1, Inv15, Cdc25, Inv7, Mcm1, Mga1, Phd2, Pho23, Ptc1, Inv8, Ste2, Pet9, Mep2, Stp22, Tpk2, or Ypr1.

-81-

102. A method of isolating a fungal invasin gene, said method comprising

(a) providing a fungus expressing a gene operably linked to a fungal invasin gene promoter;

5 (b) mutagenizing said fungus;

(c) measuring expression of the gene, wherein an increase or decrease in the expression of said gene identifies a mutation in said invasin gene; and

(d) using said mutation as a marker for isolating said invasin gene.

103. The method of claim 102, wherein said fungus is a wild-type strain.

10 104. The method of claim 103, wherein said wild-type strain is *Saccharomyces cerevisiae*.

105. The method of claim 102, wherein said fungus is a mutant strain.

106. The method of claim 102, wherein said gene comprises a fungal invasin gene.

15 107. The method of claim 106, wherein said fungal invasin gene is *FLO11* or *MUC1*.

108. The method of claim 106, wherein said fungal invasin gene is *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *RIM1*,
20 *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*, *TPK2*, *TPK3*, or *YPR1*

109. The method of claim 102, wherein said gene comprises a reporter

-82-

gene.

110. The method of claim 109, wherein said reporter gene is *lacZ*, *URA3*, or *HIS3*.

5 111. The method of claim 102, wherein said fungal invasin gene promoter is the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

112. The method of claim 102, wherein said fungal invasin gene promoter is the *AFL1*, *DHH1*, *INV1*, *INV5*, *INV6*, *INV7*, *INV8*, *INV9*, *INV10*, *INV11*, *INV12*, *INV13*, *INV14*, *INV15*, *BEM2*, *CDC25*, *RIM1*, *HOG1*, *IRA1*, *MCM1*, *MGA1*, *PET9*, *PHD2*, *PHO23*, *PTC1*, *RIM15*, *SFL1*, *SRB11*, *SSD1*, *STE21*, *STP22*, *SWI4*,
10 *TPK2*, *TPK3*, or *YPR1* gene promoter.

113. The method of claim 102, wherein said fungal invasin gene promoter is a fragment or deletion of the *FLO11*, *MUC1*, *STA1*, *STA2*, or *STA3* gene promoter.

15 114. The method of claim 113, wherein said fragment is fused to a basal promoter.

115. The method of claim 114, wherein said basal promoter is *PGK1*, *ADH1*, *GAL1-10*, *tet-R*, *MET25*, *CYC1* or *CUP1*.

116. The method of claim 102, wherein said gene expression is measured by assaying the protein level of the expressed gene.

20 117. The method of claim 102, wherein said gene expression is measured by assaying the RNA level of the expressed gene.

-83-

118. A method of using a heterologous cell for identifying a gene which regulates the expression from a *Candida albicans* gene promoter, said method comprising

- (a) providing a heterologous cell expressing a reporter gene operably
5 linked to a *Candida albicans* gene promoter;
- (b) expressing a candidate gene in said heterologous cell; and
- (c) detecting or measuring said expression of said reporter gene.

119. The method of claim 118, wherein said heterologous cell is *Saccharomyces cerevisiae*.

- 10 120. A method for preparing a transgenic fungal cell having increased secondary metabolite production, said method comprising
- (a) introducing a transgene into a fungal cell; and
 - (b) selecting a cell that expresses the transgene to produce a protein,
- wherein said transgene is *AFL1*, *DHH1*, *INV7*, *INV8*, *STE21*, *PET9*, *MEP2*, *INV1*,
15 *INV5*, *INV6*, *INV9*, *INV10*, *INV11*, *RIM1*, *INV12*, *INV13*, *INV14*, *INV15*, *CDC25*,
MCM1, *MGAI*, *PHD2*, *PHO23*, *PTC1*, *STP22*, *TPK2*, *YPR1*, *HOG1*, *BEM2*, *RIM15*,
SFL1, *IRA1*, *SSD1*, *SRB11*, *SWI4*, *TPK3*, or a fragment thereof.

121. The method of claim 120, wherein said transgene has a mutation.

122. The method of claim 121, wherein said mutation is a dominant-
20 active mutation.

123. The method of claim 121, wherein said mutation is a dominant-inactive mutation.

124. A method for increasing a secondary metabolite in a fungus, said

-84-

method comprising

(a) culturing said fungus in culture with conditions allowing for secondary metabolite production;

(b) adding to said culture a fungal invasion-promoting compound; and

5 (c) isolating said metabolite from said culture.

125. The method of claim 124, wherein said fungus has a mutation.

126. The method of claim 124, wherein said fungus is a wild-type strain.

127. A transgenic filamentous fungus comprising a mutation in its *HOG1* gene, said mutation inhibits the activity of a functional Hog1 protein.

10 128. The transgenic filamentous fungus of claim 127, wherein said fungus has increased secondary metabolite production.

129. A transgenic filamentous fungus comprising a mutation in its *SWI4* gene, said mutation inhibits the activity of a functional Swi4 protein.

15 130. The transgenic filamentous fungus of claim 129, wherein said fungus has increased secondary metabolite production.

131. A transgenic filamentous fungus comprising a mutation in its *BEM2* gene, said mutation inhibits the activity of a functional Bem2 protein.

132. The transgenic filamentous fungus of claim 131, wherein said fungus has increased secondary metabolite production.

20 133. A transgenic filamentous fungus comprising a mutation in its *SRB11*

-85-

gene, said mutation inhibits the expression of a functional *Srb11* protein.

134. The transgenic filamentous fungus of claim 133, wherein said fungus has increased secondary metabolite production.

135. A transgenic filamentous fungus comprising a mutation in its *SSD1*
5 gene, said mutation inhibits the expression of a functional *Ssd1* protein.

136. The transgenic filamentous fungus of claim 135, wherein said fungus has increased secondary metabolite production.

137. A transgenic filamentous fungus comprising a mutation in its *TPK3* gene, said mutation inhibits the expression of a functional *Tpk3* protein.

10 138. The transgenic filamentous fungus of claim 137, wherein said fungus has increased secondary metabolite production.

139. A transgenic filamentous fungus comprising a mutation in its *SFL1* gene, said mutation inhibits the expression of a functional *Sfl1* protein.

15 140. The transgenic filamentous fungus of claim 139, wherein said fungus has increased secondary metabolite production.

141. A transgenic filamentous fungus comprising a mutation in its *IRA1* gene, said mutation inhibits the expression of a functional *Ira1* protein.

142. The transgenic filamentous fungus of claim 141, wherein said fungus has increased secondary metabolite production.

1/27

Eleven *INV* genes are required for
regulated *Inv8p* proteolysis




Fig. 1

SUBSTITUTE SHEET (RULE 26)

2/27




Fig. 2A




Fig. 2B

3/27




Fig. 3

4/27




Fig. 4A




Fig. 4B

Fig. 5A-1

6/27

Vsp I
|
CTTCATCTTTTACTTCGTCCCAATCACCTCACATTAATGCTATGGGTAACAGTCCCCCATTCCTCATTCACCTCTCAATCT
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 560
GAAGTAGAAAAATGAAGCAGGGTAGTGGAGTGTAATTACGATACCCATTGTCAGGGGTAAAGGAGTAAGTGAGAGATTAGA
P P S S F T S S Q S P H I N A M G N S P H S S F T S Q S
-----Ca RIM1

PstI		Xcm I	
	GCAGCCAAATCTCCTATCACTGATGCCAAACAACATTTGGTTAAACCAACCAACCAAGCCAGCAGCTTTTGCTCCTAG		640
	CGTCGGTTAAGAGGATAGTGACTACGGTTTGTGTTAAACCAATTGGTTGGTGGTTCGGTCGTAACCAACGAGGATC		
	A A N S P I T D A K Q H L Y K P T T K P A A F A P S		
		Ca RIM1	

Fig. 5A-2

Esp31

960

GAATCAAC CAGCTCCACAACA AAAATCCAGTCAAGCCATTCAAAAAGACATACAAGAAAATCAGAGACGAA GATTGAAAG
CTTAGTTGGTCGAGGTGTTGTTTAGGTCAGTTCGGTAAGTTTCTGTATGTTCTTTAGTCTCTGCTCTCTAAACTTC

N Q P A P Q Q N P V K P F K K T Y K K I R D E D L K

Ca RIM1

Fig. 5A-3

8/27

Bpm I Bcg I
 GTCC TTTCAAAGTGT TGTGGAGCAACTGTAGCATTA TTTTCGAGACTCCAGAAATTTTGTACGATCATTTGTGTGACGAC
 CAGGAAAGTTCACAAACACCTCGTTGACATCGTAATAAAAGCTCTGAGGTCTTTAAAAACATGCTAGTAAACACACTGCTG
 G P F K C L W S N C S I I F E T P E I L Y D H L C D D
 Ca RIM1

1040

Xmn I Bbs I Csp45 I
 CATGTTGGTAGAAAGTCTTCGAAACAATTGTGTCATTGACTTGTCTTTGGGAAAATTTGTGGCACAACACTACAGTTAAGAGAGA
 GTACAACCATCTTTCAGAGAGCTTGTTAAACAGTAACAGTAACAGAAACCCCTTTTAACACCCGTTGTGATGTCAATTCCTCTCT
 H V G R K S S N N L S L T C L W E N C G T T T V K R D
 Ca RIM1

1120

Xmn I Psh I Bsa I Eco31 I
 TCACATTACTTCTCACTTGAGAGTCCCATGTCCCATTTGAAGCCTTTCCATTGTGACTTGTGTCCTCCAAATCGTTCAAGAGAC
 AGTGTAATGAAGAGTGAAGTCTCAGGTACAGGGTAACTTCGGAAAGGTAAACACTGAACACACAGGGTTTAGCAAGTTCTCTG
 H I T S H L R V H V P L K P F H C D L C P K S F K R
 Ca RIM1

1200

Fig. 5A-4

9/27

Bbs I Eco57 I
 CTCAAGATTGAAGAAACATTCCAAAGACTCAGCTGAAGACCATCCAAAGAGTTAAAGGACACAAAGAGAGTTGATG
 1280
 GAGTCTAAACTTCTTTGTAAGGTTCTGAGTGGGACTTCTGAGTGGTTCCTCAATTTTTCCTCGTGTCTCTCAACTAC
 P Q D L K K H S K T H A E D H P K K L K K A Q R E L M
 Ca RIM1

Bal I MluN I Msc I BsaM I
 AAACAACAACAAAAGAGGCCAAGCAACAACAGAAATTGGCCCAACAGAGAGCAAACTCGATGAATGCAACTACCGCATC
 1360
 TTTGTTGTTGTTTCTCCGGTTCGTTGTTGTTCTTAACCGGTTGTTCTCTCGTTTGAGCTACTTACGTTGATGGCGTAG
 K Q Q Q K E A K Q Q Q K L A N K R A N S M N A T T A S
 Ca RIM1

Mfe I Mun I BstE II
 CGATTGCAATTGAACACTATTCTGGTAACCCCTGCTGATGGATTGAACTACGACGACACCTCCAAAAAGAGATACG
 1440
 GCTAAACGTTAACTTGATGATAAGACCAATTGGGACGACTACCTAACTTGATGCTGCTGGAGGTTTCTTCTATGC
 D L Q Q L N Y Y S G N P A D G L N Y D D T S K K R R Y
 Ca RIM1

Fig. 5A-5

10/27

BspLU11 I Xmn I Van91 I
 AAAACAATTCTCAACACACATGTATGTGGTTAATAGTATTTTGAACGATTTCAACTTCCAACAATGGCTCAAGCTCCA
 TTTTGTAAAGAGTTGTGTGTACATACACCAATTATCATATAAACTTGCTAAAGTTGAAGTTGTTTACCGAGTTCGAGGT
 E N N S Q H N M Y V N S I L N D F N F Q Q M A Q A P
 Ca RIM1

BspM I Alwn I NgoA IV
 CAGCAACCAGGCGTTGTTGGAAACCGCAGGTTCTGCTGAGTTCACCACCAAGAGGATGAAAGCCGGCAGTGAAGTATAACAT
 GTCGTTGGTCCGCAACAACCTTGGCGTCCCAAGACGACTCAAGTGGTGTCTCTCTACTTTCGGCCGTGACTCATATTGTA
 Q Q P G V Y G T A G S A E F T T K R M K A G T E Y N I
 Ca RIM1

TGATGTGTTTAAACAAGTTGAATCATTTGGACGACCACCTTGACACCACCCCTCAACAGCAACACCCACAACAAT
 ACTACACAAATTGTTCAACTAGTAAACCTGCTGGTGAACGTGGTGGTGGGAGTTGTCGTTGTTGGTGTGTTGTTA
 D V F N K L N H L D D H L H H H P Q Q Q H P Q Q Q
 Ca RIM1

Fig. 5A-6

SUBSTITUTE SHEET (RULE 26)

11/27

ECOR I BspLU11 I
 ATGGCGGTAAACATCTATGAAGCTGAAATAATCTTCAACTCCTTATCGAATTCCTATCGACATCGCAATATCAAAACATGTCA
 TACCGCCATTGTAGATACTTCGACTTTTAAAGAAGTTGAGGAATAGCTTAAGGTAGCTGTSCGTTATAGTTTGTACAGT
 Y G G N I Y E A E K F F N S L S N S I Q M Q Y Q N M S
 Ca RIM1

Bal I
 MluN I
 Msc I
 Mfe I
 Mun I
 ACCCAATATCAACAACATGCTGGTTCTACTTTTGCTCAACAGAAACCAACTCAACAAGCAAGTGGCCAAATTGTATCC
 TGGGTTATAGTTGTTGTACGACCAAGATGAAACGAGTTGTCTTTGGTTGAGTTGTTCTCGTTCACCGGTTAACATAGG
 T Q Y Q Q Q H A G S T F A Q Q K P T Q Q A S G Q L Y P
 Ca RIM1

Van91 I BsrD I
 TTCTTTACCAACCATTTGGCAATGGCTCATACACCAGTGGATCATCACAAAGAAGGTTGGTTAATAACCATACGGAT
 AAGAAATGGTTGGTAACCGTTACCGAGTATGTGGTCACCTAGTAGTGTCTTCTCCCAACCAATTATTGGTATTGCCTA
 S L P T I G N G S Y T S G S S H K E G L Y N N H N G
 Ca RIM1

Fig. 5A-7

12/27

Dra III

ACTTGCCATCTTATCCTCAATCAACCGTTCTTTTGCCATATTCTTCTGGTGGCACAAACCAACCAAGTGCAATTAGAG 2000
 TGAACGGTAGAATAGGAGTTTAGTTGGCAAGAAACGGTATAAGAAGACCAACCGTGTGTGGTGGTTCACGTAATCTC
 Y L P S Y P Q I N R S L P Y S S Y A Q P P S A L E
 Ca RIM1

TTTGGCGGTGTTTCAACCTACCAGAAATCTGCACAATCATATGAAGAAGACAGCAGCGACAGTTCAGAGGAAGACGATTA 2080
 AAACCGCCACAAAGTTGGATGGTCTTTAGACGTTAGTACTTCTTCTGTCGCTGTCAGTCAAGTCTCCTTCTGCTAAT
 F G G Y S T Y Q K S A Q S Y E E D S S E E D D Y
 Ca RIM1

CAGCACTTCTTCAGAAGACGAGCTTGACACCTTGTTGATAAATTAAACATCGATGACAAATAAAGTTGAAGAAGTGACGA 2160
 CTCGTGAAGAAGTCTTCTGCTCGAACTGTGGAACAACATAATTGTTAGTACTGTTATTTCAACTTCTTCACTGCT
 S T S S E D E L D T L F Q K L N I D D N K V E E Y T
 Ca RIM1

Fig. 5A-8

SUBSTITUTE SHEET (RULE 26)

[illegible]

F
Ca RIM1 **STOP**

Fig. 5A-9

AATTCCCTCATGTTTGGATTTTAGTGTGTTTATTGTATATTACGTATAAGTTTATTTATTATTAGTACAAAGTTTGTGAAAGTAG
 2480
 TAAAGGAGTACAAAACATAAAATCACACAAAATAACATATAAATGCATATTCAAATAAAATAATCATGTTCAAAAACCTTTCATC
 Vsp I BsrG I
 TGTTACCGTTCTCTATTACATGGTTCCTATTAAATCATTCACCTCCCAATACTTGATTCCCTTTGTACAAACACACCAGCT
 2560
 ACAATGGCAAGAGATAAATGTACCAGATAATTAGTAAGGTGGAGGGTTATGAACTAAGGGAAACATGTTGTGTGGTCCGA
 Kas I
 Nar I
 BsrS I
 Ehe I
 Ebe I
 Hpa I Eco57 I
 TGACCTGGCGCCAAAGCACGAACCTGGGGTTTCTAATTCGACGGTTAACCTATCTTGCAGCTCAATAATTCCTTGTAACAGG
 2640
 ACTGGACCGCGGTTTCGTGCTTGACCCCAAGATTAAAGCTGCCCAATTGGATAGAACGTCGAGTTATTAAAGAACATTGTCTC
 BsrD I BsrD I Bsu36 I
 GATTGACTTCAGCAATGAATGATACTGAAATTGCAATGATTGGAGACAAAACACCTTTTCCTTAGGGGTGAACCATTTCTA
 CTAACCTGAAGTCGTTACTTACTATGACTTAAACGTTACTAACCTCTGTTTGTGGAAAAGGAATCCACATTGGTGAAGAT
 2720

Fig. 5A-10

15/27

ACTGCGTCAATTCCACAGTTTGTTTGAACAACTTGGGGTTATCGTGAACCTTTAACTATGATGATTTGATTTTCTCATAA 2800
 TGACGCAGTTAAGGTGTCAAAACAACTTGTGAAACCCCAATAGCACTGGAAATGATACTACTAAACTAAAGAGTATT
 Sph I Eco57 I
 TTCTTATCGCTGACAAACCAATGCCCTTGGTATTGTGGATCTGCTTGGGCATGCACACTGAAGATTCTTGGCCTATCGT
 AAGAAATAGCGACTGTGTGGTTACGGAAACCATACACCTAGACGAAACGCCGTACGTGTGACTTCTAAAGACCGGATAGCA 2880
 Sph I BsrS I
 AGCATGCCATAGCCCCCTTGTGTGACCCCAACCTTACCATCTTCAGTGATTATGTCACTGGGTTTCTTGGGATATAAT 2960
 TCGTACGGTATCGGGGAACACAACTGGGGTTTGGAAATGGTAGAAGTCACTAATACAGTGGACCCCAAGACCCCTATATTA
 Dra I
 CATTAAAACTCTCGGAAGTTTGACTGCTGCGGATTAAACAAAGCATAGCCCTTGGGAGTCGGGTTTGTGTGTGTGT 3040
 GTAAATTTTGAGAGCCTTCAAACTGACGACGCCCTAATTGTTTCGTATCGGGAACCCCTCAGCCCAACAAACGACACACA
 Bal I
 Dra I MluN I Msc I
 AATTAACTGGTCAATGTCCTCAATTCCTCGAATCTGTGGTTTGATATAGTGCCCAATGGGTAATAAGATTTTCGATAACGA 3120
 TTAATTTGACCACTACACGGTTAAGGGCTTAGACACCAAACTATATCACCAGTTACCCATTATTCTAAAGCTATTGCT

SUBSTITUTE SHEET (RULE 26)

Fig. 5A-11

16/27




Fig. 5A-12

SUBSTITUTE SHEET (RULE 26)

17/27

Candida *RIM1*

Complementation
in *Saccharomyces*

<i>inv8</i> -	<i>inv8</i> - <i>inv14</i> -
+	-
-	-
+	+

zn finger
DNA
binding




Fig. 5B

18/27

(SEQ ID NO:3)

CCCAGTTTCT	CATAACCCGT	CATTTGAGCG	ATTGCTAGTT	GAAACTATAT
ACAGCTAGTT	AGTAAGATTT	TAAAAGACGA	AAAGAACGGA	AAGTAGGACA
ACTACCAAAA	AAAAAGATGG	AAGGTTTCTT	TGGTTAGTTA	GCAGTATCCG
CGTAATGCCT	TAGACGTTTT	TGATCAGAAA	AAAATAAAAC	TTGATTTTCG
CCAGGATCGA	ACTGGGGACG	TTCTGCGTGT	TAAGCAGATG	CCATAACCGA
CTAGACCACG	AAACCAGTTT	TTTGATGTTT	CGTTTAGGAC	AAGAGTCCTA
TGAGAGTCCA	CTAAAATTCT	AAAAATAATT	GTATCAACAA	CCGTCATGCA
GCTGTTGTAT	CAAGAATCGA	CCACCATCTA	TAGACTATTG	TTCATAGCTG
TATTACAATA	TCATATAAGA	TGTAAGGATA	GAACGTGAAG	ATCGAGAAAC
AGTCAGCAGA	TTTAATGGAA	GCTGAAATGC	ACGGATTGAT	AATGTAATAG
AATAAGTGAC	AACATAAGAA	ATGAAAGAAA	AAAAATAACA	TTAATATAAT
TTAGAAATGT	TAGTTTCCTT	CTATGAAGTC	TCGTATCCCT	GGGGAGGACT
TTCAATATAT	TCAGTATACC	TACCGTTCAA	ATGATACTCT	AAAATATCAT
CTATTAAGTG	GTATTCAGGT	TTTTCCCACG	CAAGATTGAG	TGCGTCAGGC
AAAGCCACGA	TCGCAGATTA	CTCTCCTAAC	AATATTAAAG	TCGTCAAGAA
CATCCGGTTT	TACTCAAGCG	CTTAATACAA	CACGTCGGCT	TTCGCTCAAC
TGCAGTATAT	TGTGTCTGTA	ACCTCTCCCG	TCAAGTTTGC	GCCACGGGCC
CAATAACCAA	CTTCTGCGCC	ATTGTTACGG	AAAAGTGGCC	ATCTTTGCTA
TGCTCGTAAG	GCTAGCGCTC	TCTAAGTACG	CCAGCCCAAA	AACTCCGTAT
CGCTCTTCAT	CGGAATTGCT	ATATCTACAG	CCGGACGGGC	ACTCTATGTA
TACTCATATC	ACAGCCACTG	TTGCACTACA	TTATTTCGCAG	GGACTCCGAG
ATCGCTGAGC	ATGTTGCTAA	GCAACTTACC	AAGGTTGGAA	TGCATTATAT
AGTCCGATAT	AGACCCCGCT	CGGACTATAT	TATATAAATT	CAAATAGCAC
TTTCAACGAG	TGTCTTAATC	CGTCCTAGTT	CCTGCTCTCG	CTCCACGTTG
TCATCCCACC	CATTCGCACG	GGTCTTCTGT	GCGAATGAGC	CACAACGGGG
CCGAGTTCAG	GCCGTGTCCG	CCTACAACGT	CCGCCAACTA	GTGGCAATTG
CTACGTACGC	CGACCACGCT	GACACGCACC	GTTCTACTCG	CTCTATGCTG
CGGTGTGACG	TGTGAACGCG	CGATCGTTTCG	CAATCGTATC	GTTTGCCAAG
AAAAAAAGCC	AATCGGAGAA	TCTGAAAATC	GCTATTTCGGC	TTGCAGGTCG
CACGCACTCA	GAGTACGAAA	TGCCAAGTAC	CGGAATTTCC	TTGGCCTTTT
TTAAGTTTCT	TCTCTTCTAT	TCTTTTTTCCC	CTTTCCTTCT	TCCTTTGCTA
TCTGTCTGGT	TTAAATAAAC	ATAGTATTTT	TTTGTGTCTA	AGCCTCTTCC
TCTTCTCTCG	TACTTGCTCT	ACTACCACTT	TACTTAATCG	CCTTTCTTTG
TTTTCTTTCT	TCGTTATTTG	TTCTTGGAAC	TTTTCCGCTC	CAATCCCAAC
GATTGGCTTC	AAAACACGTT	CTACTGTCTA	GCAATTTCTG	CAGGTGCCAT
TTTTCTTAGG	CTTATACCCT	TTCTTTTTC	CCTTACATTT	GATTTCTTCT
TCAAAGTTCC	TTATAGTATT	ATTGTCTAAG	CTCTATTGAG	TCAAAGGTAA
CAATCTAGAC	GAAGGAAAAA	AAAAAAATAG	AAAATAGACA	TCCCCGAATA
CGCATCATCT	CACGCACGTA	CAAGATTTTA	ACGTAAAGC	CAAAGTACGC
TAGTATAGTA	TCATCAGCAT	CACCCTCACT	ATCGGTAGCA	TTGACCAAAC
ATGTCGTTAC	TGAGACTGTG	GAACAAAGAA	TCAAGGGCAC	CATCAAAAAT

Fig. 6A-1

SUBSTITUTE SHEET (RULE 26)

19/27

AAAGAGTCAT	GGTATTGTTG	GCAGTTACGG	CAACAGCATG	CTGGCCCATA
ACAACGTGAA	GCAATTTTCGT	ATAGACATAG	ACGAACCGCA	TAGAGTATGG
AAACCGAATG	AAAGCATAAC	CGGAGAAGCG	GTCATTGACA	TAAAGAGAGA
CATAACTAAC	GTAGCGATCA	AATTATCGCT	AGTATGTGAG	GTTCGCGTGA
AAACGGGGAA	CAGTCCAACC	TCCAAGAATA	AGAGAATTGA	GAAAACCTTA
GAGAAGTCGA	CGTTTCTTTA	TGGACAGGAC	TACGTAAAGA	CAGCTTTTTTC
GGCTAAGGAA	AAGAAACCGC	ATGTTGACAA	AACCACCATT	CTCAATGGTT
TAAGCAAGGG	GGAACACAGG	TTTCCCTTTA	GGATACGAAT	ACCACGAGGC
AGAGGAATGT	TGAGCTCTAT	AAAGTTCGAA	AGGGGCTCGA	TAACATACTT
CCTCTCTTGC	ACTTTAGAAT	CCCTCAACAA	CATCAACGGA	TTAAAAAAAC
CGGAAGCAAG	ATGCGAACGT	GAGTTTGCAG	TCATAGTTCC	GCTGGACGTC
TCGAGGCTGC	CCAAGCCGAA	AACTAAGACA	GTGGTTTTTAC	AATCAGCATC
TATGGTCCAA	AACAAAAAGA	ACAAATCTAC	AGAGGACGAA	TCCTCATCGT
ATACACAATT	AACTCAAAAG	TCTACTACTT	CTAATTCTTC	TAGCAGTTCA
GTAAACTCCA	AGACGTCCCC	CTTACCAAAT	AAAACGGTGA	CTATATCCGT
AGACATACCG	CAGGCTGGAT	TCATGATTGG	TGAAATTATC	CCTATAGACG
TTAAGATTGA	CCACTATAAG	CCTTTCTATG	CCCCTGCGGG	TCTCACCACC
ACTTTGGTGA	GGATATGTAG	GGTGGGCGGT	GCAGGCAAAG	ATGATCCTAT
GGAGACTTTC	AGAAAAGATA	TATGTCAGAG	TATCTCTCCT	ATATATATTA
ACCCTGAAAC	GTTGCAGTTT	CAATCTAGAG	TTTATCTGAA	AGTGCCCCCTT
GATGCATTTT	CGACCCTTAC	TACTGTGGGA	AAATTTTTTCT	CCTTCCAATA
CTATATCGAG	GTTATGGTTA	ACTTATCAAA	AAAAAACGTG	GTTTACACAG
AATCTAATAG	AATAATAGGA	ACTCCTATTG	GAGAACAAAA	TGGCTTGGGC
GTAGAGAATA	ATATCAACCG	TATCCAAAGG	AAAATGCTAC	GTATGGTCAA
TCCAGAAACG	TTGGAGAACG	ATTCTGAGGG	TTATGAATCC	AGTATATTTT
TCAAAGATAT	GGTAAATGTG	GAAAAGCTAA	AGAGACTGAG	GAATGTAAct
GGTATGTCCA	TAGAAACCGT	CATAGGAACG	ACGAGATCCG	AACAGCAGCA
ATCTGATGCA	AGCATCCCAT	CCCAATCCTC	AATCACGGCT	CCTCAAAATT
CTCCATCGAA	TTTAAGAGAT	TGGTTGGCCC	CATTAAATGC	ATATGATAGT
GACGATGTTT	CAGTTCCAAA	GTATTTCGCA	AATGATAAAG	TCAGTGTACC
GTCGGAAGAC	AAACAAGAAC	TTGAACAAAA	AAGACTACAA	CAGTTAGAAA
GCGATCCTCC	CCCTTGTGAT	GACTATTAAA	AAGTGCAGGT	AACAAGTCAT
ATACTCGCAG	CTTGCGCCGT	GTTGGAACATA	GGCGCCTTAA	TCATGTTTGC
ATATTTCCAC	TATCCCAGCC	ACGTAATGAT	CCATGACATT	AACATAGAAA
AAAAAAATCG	AAGCATGCAC	AAACCTGAGA	TTTATATATG	TTCATGTGTA
CTTAATATAC	GTTTAATGAT	TAAAACTATA	GCCGTCCTCA	GGCAAACTGA
GATAAGAAAC	GAAAAAATAG	CAGTAACGTA	AACGTTATTC	TATATTTATA
AAGACGTCAA	AAAAAAAAGT	GATTGTGATA	TTGAGATGTA	AGCTATATAC
CGAACTTTGA	GCTCCCTCAC	GTGGAAAATA	TGATAGATTG	TTGCCTCATC
ATTGCGGAAC	CGCATTTTTT	TTTTGTATTT	TTGCCTCCCT	AGTTTCAAAA
TGCACCAAAT	TCTCCCCTTA	ATGCTTTTTT	TTTTAAGTCC	CAAATAGCCA
TCCTTTCATC	ATCGGGCAAG	ATAGAAATTT	GACTGTCATT	CAGTTGTAAC
ACCTGTTTCA	GTAGTTCTTT	CTGTTTGTTA	AGCACAGCTG	GATCCACCAC

Fig. 6A-2

SUBSTITUTE SHEET (RULE 26)

20/27

CTCGTTCACG	CTATTGTTAT	TCGTAGCCGA	TGCCTCTTCT	TGCGGCCTGG
AAGCTAACGG	GATCAAATCA	TCCACTTTAC	ATATCCCATT	CGTTAGCAAT
AATTCAGCCG	TAACAAAAC	CAACTGTGGA	CACAGCTCTA	ATAGCGAAAC
AGCATCTTCA	GGATGCGCTC	TTGTCCATTC	TTGGAATTTT	TGTAAAAATT
TCAACTGCAC	CTCTTTCGGT	TTTTTAGCTA	GTTCGCTCGA	TATCATCATA
GCAGGGGTGG	TCATGTTTAT	GTTAACGTCG	ATACCAGAGG	GCAATTCTGG
AACTTTTGA	CTTAGAAAAT	TGGCATTTC	GCTGTTTTGA	AAGTCCGGCC
CATTACTATT	ATTATTATTA	TTTCCATTGT	TGTTATTGTT	CCCATTAATG
TTGTTGTACT	GTTGTTGTTG	CTGTTGTGAA	ACTCCCGATA	TATCACTATT
GCTGGAGTAA	CCGCATTTC	AAAACCTAGA	GCCTAATTGG	TATCCATTCA
AATTACGTAC	TGCGCTGGCA	CTGGACTCTA	AATCTCTAAA	TTCAATAAAC
GCGTACCCTT	TCGACCTACC	AGTTTGGGGG	TCGAACATCA	TT

Fig. 6A-3

21/27

(SEQ ID NO:4)

MSLLRLWNKESRAPSKI KSHGIVGSYGNSMLAHNNVKQFRIDIDEPHRVW
KPNESITGEAVIDIKRDITNVAIKLSLVCEVRVKTGNSPTS SKNKRIEKT
EKSTFLYGQDYVKTA FSAKEKKPHVDKTTILNGLSKGEHRFPFRIRIPRG
RGMLSSIKFERGSITYFLSCTLESLN NINGLKKPEARCEREF AVIVPLDV
SRLPKPKTKTVVLQSAS MVQNKKNKSTEDESSSYTQLTQKSTTSNSSSSS
VNSKTSPLPNKTVTISVDIPQAGFMIGEIIPI DVKIDHYKPFYAPAGLTT
TLVRICRVGGAGKDDPMETFRKD ICQSISPIYINPETLQFQSRVYLKVPL
DAFSTLTTVGKFFSFQYYIEVMVNLSKKNV VYTESNRIIGTPIGEQNGLG
VENNINRIQRKMLRMVNPETLENDSEGYESSIFFKDMVNVEK LKRLRNVT
GMSIETVIGTTRSEQQQSDASIPSQSSITAPQNSPSNLRDWLAPLNAYDS
DDVPVPKYSPNDKVSVPSEDKQE LEQKRLQQLES DPPPCDDY


Fig. 6B

22/27


C. albicans rim1/rim1 mutant does
not form hyphae in response to serum

YNB

Agar+S



WT



rim1




Fig. 7

23/27




Fig. 8

24/27




Fig. 9

WIRING DIAGRAM FOR REGULATION OF INVASION




Fig. 10

26/27

Flo11 Promoter Fragment Reporters




Fig. 11

27/27

THE AGAR INVASION ASSAY IS MORE SENSITIVE THAN A
GROWTH INHIBITION ASSAY IN DETECTING FLUCONAZOLE ACTIVITY




Fig. 12

SEQUENCE LISTING

<110> Microbia, Inc.

<120> REGULATION OF FUNGAL GENE EXPRESSION

<130> 50078/003WO2

<140> PCT/US98/XXXXX

<141> 1998-11-18

<150> 60/066,129

<151> 1997-11-19

<150> 60/066,308

<151> 1997-11-21

<150> 60/066,462

<151> 1997-11-24

<150> 60/078,610

<151> 1998-03-19

<150> 60/094,523

<151> 1998-07-29

<150> 09/XXX,XXX

<151> 1998-11-10

<160> 67

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Candida albicans
sequence

<400> 1

gaattaaccc tcactaaagg gaaarmgnga ycayathac

39

<210> 2

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Candida albicans
sequence

<400> 2
gtaatacgcac tcactatagg gtgyttyttn arrtcygt

38

<210> 3
<211> 3463
<212> DNA
<213> Candida albicans

<400> 3
ttaaaaagtt tttgattggt gaacttttaa attttttctt ggcaatccat tcccagacaa 60
agtaataact acgaatagat cattcattgg tttattatgt ttgcatggaa atatttgaat 120
ttccattttt tttttttata gtggttggtt aagcttcgca gttttttttt ttctagggag 180
aaattattat acattatata tatattatca actttttctc gttacaaaag tcacaccttt 240
tttttttcta cttgttcttc tttcaacaac taactaattt tatactatcc acgaactata 300
gatattacat ataagttttt aacctagaca aacgagattt ttagacaatg aattacaaca 360
ttcatcccggt aacatactta aatgctgata gcaataccgg tgcaagtgg agtactgcaa 420
gtcaccatgg ttccaagaaa tcaccttctt cagatattga ttagataaat gctwcgtcac 480
cttcattctt tacttgcgtc caatcacctc acattaatgc tatgggtaac agtccccatt 540
cctcattcac ttctcaatct gcagccaatt ctctatcac tgatgccaaa caacatttgg 600
ttaaaccaac caccaccaag ccagcagctt ttgctcctag tgctaataca tctaaccacca 660
cagctccgca atcttatacc caaccagcac aacaattacc aactcagtta cacccaagtc 720
ttaaccaagc ctacaacaac caaccatctt attatttaca ccaaccaact tatggctacc 780
aacaacaaca acaacaaca caacaccaag agtttaacca accatcacag caataccacg 840
accatcacgg atactactca aacaacaaca ttttgaatca gaatcaacca gctccacaac 900
aaaatccagt caagccattc aaaaagacat acaagaaaat cagagacgaa gatttgaaag 960
gtcctttcaa gtgtttgtgg agcaactgta gcattatgtt cgagactcca gaaattttgt 1020
acgatcattt gtgtgacgac catgttggtt gaaagtcttc gaacaatttg tcattgactt 1080
gtctttggga aaattgtggc acaactacag ttaagagaga tcacattact tctcacttga 1140
gagtcattgt cccattgaag cctttccatt gtgacttggt tcccaaatcg ttcaagagac 1200
ctcaagattt gaagaaacat tccaagactc acgctgaaga ccatccaaag aagttaaaaa 1260
aggcacaag agagttgatg aaacaacaac aaaaagaggc caagcaacaa cagaaatttg 1320
ccaacaagag agcaactcg atgaatgcaa ctaccgcac cgatttgcaa ttgaactact 1380
attctggtta cctgctgatg ggattgaact acgacgacac ctccaaaaaa agaagatacg 1440
aaaacaattc tcaacacaac atgtatgtgg ttaatagtat tttgaacgat ttcaacttcc 1500
aacaatggc tgaagctcca cagcaaccag gcgttgattg aaccgcaggt tctgctgagt 1560
tcaccacca caagatgaaa gccggcactg agtataacat tgatgtgttt aacaagtga 1620
atcatttgga cgaccacttg caccaccacc accctcaaca gcaacacca caacaacaat 1680
atggcggtta catctatgaa gctgaaaaat tcttcaactc cttatcgaat tccatcgaca 1740
tgcaatatca aaacatgtca acccaatata aacaacaaca tgctggttct acttttgctc 1800
aacagaaacc aactcaacaa gcaagtggcc aattgtatcc ttctttacca accattggca 1860
atggctcata caccagtggg tcatcacaca aagaagggtt ggtaataaac cataacggat 1920
acttgccatc ttatctcaa atcaaccgtt ctttgccata ttcttctggt gtggcacaac 1980
aaccaccaag tgcattagag tttggcggtg tttcaacctt ccagaaatct gcacaatcat 2040
atgaagaaga cagcagcgac agttcagagg aagacgatta cagcacttct tcagaagacg 2100
agcttgacac cttgtttgat aaattaaaca tcgatgacaa taaagttgaa gaagtgcga 2160
ttgatgggtt caatttgaag gatgttgcca agcacagaga aatgatccat gctgttcttg 2220
gctatttgag aaaccaaact gaacaacaag aaaaggaaaa gagcaaaagaa caaaaggagg 2280
ttgacgttaa tgaaactaaa ttatatccaa ctataactgc tttctaagca attatatcga 2340
ttttactttt ttatttattt ttattttttt gtttaggggtg gttttcaatt tttttttttt 2400
atttcctcat gtttgatttt agtgtgtttt attgtatatt acgtataagt ttattttatt 2460
agtacaagtt ttgaaagtag tgttaccgtt ctctattttac atgggttctat taatcattcc 2520
acctcccaat acttgattcc ctttgtaaca cacaccagct tgacctggcg ccaaagcacg 2580
aactgggggt tctaattcga cggttaacct atcttgacgc tcaataattc ttgtaacagg 2640
gattgacttc agcaatgaat gatactgaaa ttgcaatgat tggagacaaa acaccttttc 2700
cttaggggtg aaccattcta actgcgtcaa ttccacagtt tgtttgaaca acttgggggtt 2760

```

atcgtgacct ttaactatga tgatttgatt tttctcataa ttcttatcgc tgacaaacca 2820
aatgccttgg tatttggtgat ctgcttgagg catgcacact gaagatttct ggcctatcgt 2880
agcatgccat agccccttgt gttgacccca aaccttacca tcttcagtga ttatgtcacc 2940
tggtgtttct gggatataat cttttaaaaa ctctcggaag tttgactgct gcggattaac 3000
aaagcatagc ccttgggagt cgggttttgt tgctgtgtgt aattttaaact ggtcatgtgc 3060
caattccga atctgtggtt tgatatagtg gccaatgggt aataagattt tcgataacga 3120
agattgtggg atcgacgaaa gatagtaact ttggtctttc cgttgactca aacctcgcaa 3180
taaatggtag tctccagttt cgttgtgttt catgattcgg gcgtaatgac cagtactaa 3240
ccaccaatct ttgctgtgc catcgtattt cttatgcaag taatcaatca acttcccaaa 3300
tttgacaaat ttgttgaccc caatgtcagg gttcggcggt agtccctttt cgtatttctc 3360
tatcattggc ataaacacat cctgccaata ttcgtgttca aagttaactc tctcacaact 3420
ggaaatacct agatcgacct cgaggggggg cccggtacca gtt 3463

```

<210> 4

<211> 659

<212> PRT

<213> Candida albicans

<400> 4

```

Met Asn Tyr Asn Ile His Pro Val Thr Tyr Leu Asn Ala Asp Ser Asn
1      5      10      15
Thr Gly Ala Ser Glu Ser Thr Ala Ser His His Gly Ser Lys Lys Ser
20     25     30
Pro Ser Ser Asp Ile Asp Val Asp Asn Ala Xaa Ser Pro Ser Ser Phe
35     40     45
Thr Ser Ser Gln Ser Pro His Ile Asn Ala Met Gly Asn Ser Pro His
50     55     60
Ser Ser Phe Thr Ser Gln Ser Ala Ala Asn Ser Pro Ile Thr Asp Ala
65     70     75     80
Lys Gln His Leu Val Lys Pro Thr Thr Thr Lys Pro Ala Ala Phe Ala
85     90     95
Pro Ser Ala Asn Gln Ser Asn Thr Thr Ala Pro Gln Ser Tyr Thr Gln
100    105    110
Pro Ala Gln Gln Leu Pro Thr Gln Leu His Pro Ser Leu Asn Gln Ala
115    120    125
Tyr Asn Asn Gln Pro Ser Tyr Tyr Leu His Gln Pro Thr Tyr Gly Tyr
130    135    140
Gln Gln Gln Gln Gln Gln Gln His Gln Glu Phe Asn Gln Pro Ser
145    150    155    160
Gln Gln Tyr His Asp His His Gly Tyr Tyr Ser Asn Asn Asn Ile Leu
165    170    175
Asn Gln Asn Gln Pro Ala Pro Gln Gln Asn Pro Val Lys Pro Phe Lys
180    185    190
Lys Thr Tyr Lys Lys Ile Arg Asp Glu Asp Leu Lys Gly Pro Phe Lys
195    200    205
Cys Leu Trp Ser Asn Cys Ser Ile Ile Phe Glu Thr Pro Glu Ile Leu
210    215    220
Tyr Asp His Leu Cys Asp Asp His Val Gly Arg Lys Ser Ser Asn Asn
225    230    235    240
Leu Ser Leu Thr Cys Leu Trp Glu Asn Cys Gly Thr Thr Thr Val Lys
245    250    255
Arg Asp His Ile Thr Ser His Leu Arg Val His Val Pro Leu Lys Pro
260    265    270
Phe His Cys Asp Leu Cys Pro Lys Ser Phe Lys Arg Pro Gln Asp Leu
275    280    285

```

Lys Lys His Ser Lys Thr His Ala Glu Asp His Pro Lys Lys Leu Lys
 290 295 300
 Lys Ala Gln Arg Glu Leu Met Lys Gln Gln Gln Lys Glu Ala Lys Gln
 305 310 315 320
 Gln Gln Lys Leu Ala Asn Lys Arg Ala Asn Ser Met Asn Ala Thr Thr
 325 330 335
 Ala Ser Asp Leu Gln Leu Asn Tyr Tyr Ser Gly Asn Pro Ala Asp Gly
 340 345 350
 Leu Asn Tyr Asp Asp Thr Ser Lys Lys Arg Arg Tyr Glu Asn Asn Ser
 355 360 365
 Gln His Asn Met Tyr Val Val Asn Ser Ile Leu Asn Asp Phe Asn Phe
 370 375 380
 Gln Gln Met Ala Gln Ala Pro Gln Gln Pro Gly Val Val Gly Thr Ala
 385 390 395 400
 Gly Ser Ala Glu Phe Thr Thr Lys Arg Met Lys Ala Gly Thr Glu Tyr
 405 410 415
 Asn Ile Asp Val Phe Asn Lys Leu Asn His Leu Asp Asp His Leu His
 420 425 430
 His His His Pro Gln Gln Gln His Pro Gln Gln Gln Tyr Gly Gly Asn
 435 440 445
 Ile Tyr Glu Ala Glu Lys Phe Phe Asn Ser Leu Ser Asn Ser Ile Asp
 450 455 460
 Met Gln Tyr Gln Asn Met Ser Thr Gln Tyr Gln Gln Gln His Ala Gly
 465 470 475 480
 Ser Thr Phe Ala Gln Lys Pro Thr Gln Gln Ala Ser Gly Gln Leu
 485 490 495
 Tyr Pro Ser Leu Pro Thr Ile Gly Asn Gly Ser Tyr Thr Ser Gly Ser
 500 505 510
 Ser His Lys Glu Gly Leu Val Asn Asn His Asn Gly Tyr Leu Pro Ser
 515 520 525
 Tyr Pro Gln Ile Asn Arg Ser Leu Pro Tyr Ser Ser Gly Val Ala Gln
 530 535 540
 Gln Pro Pro Ser Ala Leu Glu Phe Gly Gly Val Ser Thr Tyr Gln Lys
 545 550 555 560
 Ser Ala Gln Ser Tyr Glu Glu Asp Ser Ser Asp Ser Ser Glu Glu Asp
 565 570 575
 Asp Tyr Ser Thr Ser Ser Glu Asp Glu Leu Asp Thr Leu Phe Asp Lys
 580 585 590
 Leu Asn Ile Asp Asp Asn Lys Val Glu Glu Val Thr Ile Asp Gly Phe
 595 600 605
 Asn Leu Lys Asp Val Ala Lys His Arg Glu Met Ile His Ala Val Leu
 610 615 620
 Gly Tyr Leu Arg Asn Gln Ile Glu Gln Gln Glu Lys Glu Lys Ser Lys
 625 630 635 640
 Glu Gln Lys Glu Val Asp Val Asn Glu Thr Lys Leu Tyr Pro Thr Ile
 645 650 655
 Thr Ala Phe

<210> 5

<211> 4792

<212> DNA

<213> *Saccharomyces cerevisiae*

<400> 5

cccagtttct	cataaccggt	catttgagcg	attgctagtt	gaaactatat	acagctagtt	60
agtaagattt	taaaagacga	aaagaacgga	aagtaggaca	actaccaaaa	aaaaagatgg	120
aaggtttctt	tggtagttaa	gcagtatccg	cgtaatgcct	tagacgtttt	tgatcagaaa	180
aaaaataaac	ttgatttcgc	ccaggatcga	actggggacg	ttctgcgtgt	taagcagatg	240
ccataaccga	ctagaccacg	aaaccagttt	tttgatgttt	cgtttaggac	aagagtccta	300
tgagagtcca	ctaaaattct	aaaaataatt	gtatcaacaa	ccgtcatgca	gctgttgat	360
caagaatcga	ccaccatcta	tagactattg	ttcatagctg	tattacaata	tcatataaga	420
tgtaaggata	gaacgtgaag	atcgagaaac	agtcagcaga	tttaattggaa	gctgaaatgc	480
acggattgat	aatgtaatag	aataagtac	aacataagaa	atgaaagaaa	aaaaataaca	540
ttaatataat	ttagaaatgt	tagtttcctt	ctatgaactc	tcgtatccct	ggggaggact	600
ttcaatata	tcagtatacc	taccgttcaa	atgatactct	aaaatatcat	ctattaagtg	660
gtattcaggt	ttttcccacg	caagattgag	tgcgtcaggc	aaagccacga	tcgcagatta	720
ctctcctaac	aatattaaga	tcgtcaagaa	catccggttt	tactcaagcg	cttaatacaa	780
cacgtcggct	ttcgtccaac	tgcagtatat	tgtgtctgta	acctctcccg	tcaagtttgc	840
gccacggggc	caataaccaa	cttctgcgcc	attgttacgg	aaaagtggcc	atctttgcta	900
tgctcgtaag	gctagcgctc	tctaagtacg	ccagcccaaa	aactccgtat	cgctcttcat	960
cggaattgct	atatctacag	ccggacgggc	actctatgta	tactcatatc	acagccactg	1020
ttgcactaca	ttattcgcag	ggactccgag	atcgctgagc	atgttgctaa	gcaacttacc	1080
aaggttggaa	tgcatatat	agtccgatat	agaccccgct	cggaactatat	tatataaatt	1140
caaatagcac	tttcaacgag	tgtcttaate	cgtcctagtt	cctgctctcg	ctccagttg	1200
tcattcccac	cattcgcacg	ggtcttctgt	gcgaatgagc	caacaacggg	ccgacttcag	1260
gccgtgtccg	cctacaacgt	ccgccaacta	gtggcaattg	ctacgtacgc	cgaccacgct	1320
gacacgcacc	gttctactcg	ctctatgctg	cgggtgtgacg	tgtgaacgcg	cgatcgttcg	1380
caatcgatc	gtttgccaa	aaaaaaagcc	aatcggagaa	tctgaaaatc	gctattcggc	1440
ttgcaggtcg	cacgcactca	gagtagcaaa	tgccaagtac	cggaatttcc	ttggcctttt	1500
ttaaagttct	tctcttctat	tctttttccc	ctttctttct	tcctttgcta	tctgtctggt	1560
ttaaataaac	atagtatttt	tttgtgtcta	agcctcttcc	tcttctctcg	tacttgcctt	1620
actaccactt	tacttaatcg	cctttctttg	ttttctttct	tcgttatttg	ttcttggaac	1680
ttttccgctc	caatcccaac	gattggcttc	aaaacacggt	ctactgtcta	gcaatttctg	1740
caggtgccat	ttttcttagg	cttataccct	ttccttttcc	ccttacattt	gatttcttct	1800
tcaaagttcc	ttatagtatt	attgtctaag	ctctattgag	tcaaaagtaa	caatctagac	1860
gaaggaaaaa	aaaaaaatag	aaaatagaca	tccccgaata	cgcatcatct	cacgcacgta	1920
caagatttta	acgttaaagc	caaagtacgc	tagtatagta	tcatcagcat	caccctcact	1980
atcggtagca	ttgaccaaac	atgtcgttac	tgagactgtg	gaacaaagaa	tcaagggcac	2040
catcaaaaat	aaagagtcac	ggtattgttg	gcagttacgg	caacagcatg	ctggcccata	2100
acaacgtgaa	gcaatttcgt	atagacatag	acgaaccgca	tagagtatgg	aaaccgaatg	2160
aaagcataac	cggagaagcg	gtcattgaca	taaagagaga	cataactaac	gtagcgatca	2220
aattatcgct	agtatgtgag	gttcgcgtga	aaacggggaa	cagtccaacc	tccaagaata	2280
agagaattga	gaaaacctta	gagaagtcca	cgtttcttta	tggacaggac	tacgtaaaaga	2340
cagctttttc	ggctaaggaa	aagaaaccgc	atgttgacaa	aaccaccatt	ctcaatgggt	2400
taagcaaggg	ggaacacagg	tttcccttta	ggatagcaat	accacgaggg	agaggaatgt	2460
tgagctctat	aaagttcgaa	aggggctcga	taacatactt	cctctcttgc	actttagaat	2520
ccctcaacaa	catcaacgga	ttaaaaaac	cggaagcaag	atgcgaacgt	gagtttgacg	2580
tcatagttcc	gctggacgtc	tcgaggctgc	ccaagccgaa	aactaagaca	gtggttttac	2640
aatcagcatc	tatggtccaa	aacaaaaaga	acaaatctac	agaggacgaa	tcctcatcgt	2700
atacacaatt	aactcaaaag	tctactactt	ctaattcttc	tagcagttca	gtaaactcca	2760
agacgtcccc	cttaccaaat	aaaacggtga	ctatatccgt	agacataccg	caggctggat	2820
tcatgattgg	tgaaattatc	cctatagacg	ttaaagattga	ccactataag	cctttctatg	2880
cccctgcggg	tctcaccacc	actttgggtga	ggatatgtag	gggtggcggt	gcaggcaaa	2940
atgatcctat	ggagactttc	agaaaagata	tatgtcagag	tatctctcct	atatatatta	3000
accctgaaac	gttgcagttt	caatctagag	tttatctgaa	agtgcocctt	gatgcatttt	3060
cgacccttac	tactgtggga	aaatttttct	ccttccaata	ctatatcgag	gttatggtta	3120
acttatcaaa	aaaaaacgtg	gtttacacag	aatctaata	aataatagga	actcctattg	3180
gagaacaaaa	tggtctgggc	gtagagaata	atatcaaccg	tatccaaagg	aaaatgctac	3240
gtatggtcaa	tccagaaaacg	ttggagaacg	attctgaggg	ttatgaatcc	agtatatttt	3300

```

tcaaagatat ggtaaatgtg gaaaagctaa agagactgag gaatgtaact ggtatgtcca 3360
tagaaaccgt cataggaacg acgagatccg aacagcagca atctgatgca agcatcccat 3420
cccaatcctc aatcacggct cctcaaaatt ctccatcgaa ttttaagagat tggttggccc 3480
cattaaatgc atatgatagt gacgatgttc cagttccaaa gtattcgcca aatgataaaag 3540
tcagtgtacc gtcggaagac aaacaagaac ttgaacaaaa aagactacaa cagttagaaa 3600
gcgatcctcc cccttgtgat gactattaaa aagtgcaggt aacaagtcac atactcgag 3660
cttgcccggt gttggaacta ggcgccttaa tcatgtttgc atatttccac tatcccagcc 3720
acgtaatgat ccatgacatt aacatagaaa aaaaaaatcg aagcatgcac aaacctgaga 3780
tttatatatg ttcattgtga cttaatatat gtttaatgat taaaactata gccgtcctca 3840
ggcaaactga gataagaaac gaaaaaatag cagtaacgta aacgttattc tatatttata 3900
aagacgtcaa aaaaaaaagt gattgtgata ttgagatgta agctatatac cgaactttga 3960
gtccctcac gtggaaaata tgatagattg ttgcctcatc attgcggaac cgcatttttt 4020
ttttgtattt ttgcctccct agtttcaaaa tgcaccaaatt tctcccctta atgctttttg 4080
ttttaagtcc caaatagcca tcctttcatc atcgggcaag atagaaattt gactgtcatt 4140
cagttgtaac acctgtttca gtagttcttt ctgtttgtta agcacagctg gatccaccac 4200
ctcgttcacg ctattgttat tcgtagccga tgcctcttct tgcggcctgg aagctaacgg 4260
gatcaaatac tccactttac atatcccatt cgtttagcaat aattcagccg taacaaaact 4320
caactgtgga cacagctcta atagcgaaac agcatcttca ggatgcgctc ttgtccattc 4380
ttggaatttt tgtaaaaatt tcaactgcac ctctttcggg ttttttagcta gttcgctcga 4440
tatcatcata gcaggggtgg tcatgtttat gttaacgtcg ataccagagg gcaattctgg 4500
aaacttttga cttagaaaat tggcatttcc gctgttttga aagtccggcc cattactatt 4560
attattatta tttccattgt tgttattgtt cccattaatg ttgttgact gttgttggtg 4620
ctgttgtaa actcccata tatcactatt gctggagtaa ccgcatttca aaaacctaga 4680
gcctaattgg tatccattca aattacgtac tgcgtggca ctggactcta aatctctaaa 4740
ttcaataaac gcgtaccctt tcgacctacc agtttggggg tcgaacatca tt 4792

```

<210> 6

<211> 542

<212> PRT

<213> *Saccharomyces cerevisiae*

<400> 6

```

Met Ser Leu Leu Arg Leu Trp Asn Lys Glu Ser Arg Ala Pro Ser Lys
 1          5          10          15
Ile Lys Ser His Gly Ile Val Gly Ser Tyr Gly Asn Ser Met Leu Ala
          20          25          30
His Asn Asn Val Lys Gln Phe Arg Ile Asp Ile Asp Glu Pro His Arg
          35          40          45
Val Trp Lys Pro Asn Glu Ser Ile Thr Gly Glu Ala Val Ile Asp Ile
          50          55          60
Lys Arg Asp Ile Thr Asn Val Ala Ile Lys Leu Ser Leu Val Cys Glu
65          70          75          80
Val Arg Val Lys Thr Gly Asn Ser Pro Thr Ser Lys Asn Lys Arg Ile
          85          90          95
Glu Lys Thr Leu Glu Lys Ser Thr Phe Leu Tyr Gly Gln Asp Tyr Val
          100          105          110
Lys Thr Ala Phe Ser Ala Lys Glu Lys Lys Pro His Val Asp Lys Thr
          115          120          125
Thr Ile Leu Asn Gly Leu Ser Lys Gly Glu His Arg Phe Pro Phe Arg
          130          135          140
Ile Arg Ile Pro Arg Gly Arg Gly Met Leu Ser Ser Ile Lys Phe Glu
145          150          155          160
Arg Gly Ser Ile Thr Tyr Phe Leu Ser Cys Thr Leu Glu Ser Leu Asn
          165          170          175
Asn Ile Asn Gly Leu Lys Lys Pro Glu Ala Arg Cys Glu Arg Glu Phe

```


Ala	Val	Ile	Val	Pro	Leu	Asp	Val	Ser	Arg	Leu	Pro	Lys	Pro	Lys	Thr
180															
195															
Lys	Thr	Val	Val	Leu	Gln	Ser	Ala	Ser	Met	Val	Gln	Asn	Lys	Lys	Asn
210															
Lys	Ser	Thr	Glu	Asp	Glu	Ser	Ser	Ser	Tyr	Thr	Gln	Leu	Thr	Gln	Lys
225															
230															
235															
240															
Ser	Thr	Thr	Ser	Asn	Ser	Ser	Ser	Ser	Ser	Val	Asn	Ser	Lys	Thr	Ser
245															
250															
255															
Pro	Leu	Pro	Asn	Lys	Thr	Val	Thr	Ile	Ser	Val	Asp	Ile	Pro	Gln	Ala
260															
265															
270															
Gly	Phe	Met	Ile	Gly	Glu	Ile	Ile	Pro	Ile	Asp	Val	Lys	Ile	Asp	His
275															
280															
285															
Tyr	Lys	Pro	Phe	Tyr	Ala	Pro	Ala	Gly	Leu	Thr	Thr	Thr	Leu	Val	Arg
290															
295															
300															
Ile	Cys	Arg	Val	Gly	Gly	Ala	Gly	Lys	Asp	Asp	Pro	Met	Glu	Thr	Phe
305															
310															
315															
320															
Arg	Lys	Asp	Ile	Cys	Gln	Ser	Ile	Ser	Pro	Ile	Tyr	Ile	Asn	Pro	Glu
325															
330															
335															
Thr	Leu	Gln	Phe	Gln	Ser	Arg	Val	Tyr	Leu	Lys	Val	Pro	Leu	Asp	Ala
340															
345															
350															
Phe	Ser	Thr	Leu	Thr	Thr	Val	Gly	Lys	Phe	Phe	Ser	Phe	Gln	Tyr	Tyr
355															
360															
365															
Ile	Glu	Val	Met	Val	Asn	Leu	Ser	Lys	Lys	Asn	Val	Val	Tyr	Thr	Glu
370															
375															
380															
Ser	Asn	Arg	Ile	Ile	Gly	Thr	Pro	Ile	Gly	Glu	Gln	Asn	Gly	Leu	Gly
385															
390															
395															
400															
Val	Glu	Asn	Asn	Ile	Asn	Arg	Ile	Gln	Arg	Lys	Met	Leu	Arg	Met	Val
405															
410															
415															
Asn	Pro	Glu	Thr	Leu	Glu	Asn	Asp	Ser	Glu	Gly	Tyr	Glu	Ser	Ser	Ile
420															
425															
430															
Phe	Phe	Lys	Asp	Met	Val	Asn	Val	Glu	Lys	Leu	Lys	Arg	Leu	Arg	Asn
435															
440															
445															
Val	Thr	Gly	Met	Ser	Ile	Glu	Thr	Val	Ile	Gly	Thr	Thr	Arg	Ser	Glu
450															
455															
460															
Gln	Gln	Gln	Ser	Asp	Ala	Ser	Ile	Pro	Ser	Gln	Ser	Ser	Ile	Thr	Ala
465															
470															
475															
480															
Pro	Gln	Asn	Ser	Pro	Ser	Asn	Leu	Arg	Asp	Trp	Leu	Ala	Pro	Leu	Asn
485															
490															
495															
Ala	Tyr	Asp	Ser	Asp	Val	Pro	Val	Pro	Lys	Tyr	Ser	Pro	Asn	Asp	
500															
505															
510															
Lys	Val	Ser	Val	Pro	Ser	Glu	Asp	Lys	Gln	Glu	Leu	Glu	Gln	Lys	Arg
515															
520															
525															
Leu	Gln	Gln	Leu	Glu	Ser	Asp	Pro	Pro	Pro	Cys	Asp	Asp	Tyr		
530															
535															
540															

<210> 7

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on *Saccharomyces cerevisiae* sequence

<400> 7
cgcacactat gcaaagaccg agatcttcc 29

<210> 8
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 8
gaagatcttc tccacatacc aatcactcg 29

<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 9
caagcattta cgttactgcg aaaatccata tacgcacact 40

<210> 10
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 10
agtgtgcgta tatggatttt cgcagtaacg taaatgcttg 40

<210> 11
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 11
tgatgaggta acctttacaa ctctcttcta gttcaagaac 40

<210> 12
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 12

gttcttgaac tagaagagag ttgtaaaggt tacctcatca

40

<210> 13

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 13

tttcaattca atggatttgg aatgtcatag agttaccaat

40

<210> 14

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 14

attggttaact ctatgacatt ccaaattccat tgaattgaaa

40

<210> 15

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 15

atttctgcct atactcttaa aggtattcgt ttgtttacta

40

<210> 16

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 16

tagtaaaciaa acgaatacct ttaagagtat aggcagaaat

40

<210> 17
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic primer based on Saccharomyces cerevisaie
 sequence

 <400> 17
 ttggggctaa gaatggacac agatcagtca ttcattgtgt 40

 <210> 18
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic primer based on Saccharomyces cerevisaie
 sequence

 <400> 18
 acaacatgaa tgactgatct gtgtccattc ttagcccca 40

 <210> 19
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic primer based on Saccharomyces cerevisaie
 sequence

 <400> 19
 ggggtgtgcct ggaaagttca ttcccttttc tttttctttg 40

 <210> 20
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic primer based on Saccharomyces cerevisaie
 sequence

 <400> 20
 caaagaaaaa gaaaaggga tgaactttcc aggcacaccc 40

 <210> 21
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic primer based on Saccharomyces cerevisaie

sequence

<400> 21
caaaacttta ggaataccgg aaattaagggt ttttttcttc 40

<210> 22
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 22
gaagaaaaaa accttaattt ccggtattcc taaagttttg 40

<210> 23
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 23
cgaatgtgaa tgcgctaatac ttgtgtgcct acgccagccc 40

<210> 24
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 24
gggctggcgt aggcacacaa gattagcgca ttcacattcg 40

<210> 25
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 25
agacaaaaaa taggaaaagt ggtatttcca ccacatgaaa 40

<210> 26
<211> 40

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 26
tttcatgtgg tggaaatacc acttttccta ttttttgtct 40

<210> 27
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 27
ttagtgcgga atactttcct ttaattagtg atggttctca 40

<210> 28
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 28
tgagaacccat cactaattaa aggaaagtat tccgcactaa 40

<210> 29
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 29
cagtgcctttc aacacctttt attctcatcg agagccgagc 40

<210> 30
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 30
gctcggctct cgatgagaat aaaagggtgtt gaaagcactg 40

<210> 31
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 31
gtagctgaaa agtccatcta catctgtgtg ccatgtcaga 40

<210> 32
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 32
tctgacatgg cacacagatg tagatggact tttcagctac 40

<210> 33
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 33
gagattatct tgggatctat tcgaattatg aatgatacta 40

<210> 34
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 34
tagtatcatt cataattcga atagatccca agataatctc 40

<210> 35
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 35

gttttggtc aatgggaccg ttcacaaatt tacggcta

40

<210> 36

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 36

attagcgta aatttgtgaa cgggtccatt gagccaaaac

40

<210> 37

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 37

accacaacat gacgagggat aataactgat gaataggggtg ctttttatac tctgtgcggt
atttcacacc

60

70

<210> 38

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 38

taaggagtcg taccgccaac taaatctgaa taacaatttg gctgctagaa gcagattgta
ctgagagtgc

60

70

<210> 39

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 39

ccgctcgaga gtgtgcgtat atggatttt

29

<210> 40

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 40

ccgctcgagt gatgaggtaa cctttacaa

29

<210> 41

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 41

ccgctcgagg ttcttgaact agaagagag

29

<210> 42

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 42

ccgctcgagt ttcaattcaa tggatttgg

29

<210> 43

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 43

ccgctcgaga ttggttaactc tatgacatt

29

<210> 44

<211> 29

<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 44
ccgctcgaga tttctgccta tactcttaa 29

<210> 45
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 45
ccgctcgagt agtaaacaaa cgaatacct 29

<210> 46
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 46
ccgctcgagt tggggctaag aatggactt 29

<210> 47
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 47
ccgctcgaga caacatgaat gactgatct 29

<210> 48
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 48
ccgctcgagg ggtgtgctg gaaagttca 29

<210> 49
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 49
ccgctcgagc aaagaaaaag aaaagggaa 29

<210> 50
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 50
ccgctcgagc aaaacttttag gaataccgg 29

<210> 51
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 51
ccgctcgagg aagaaaaaaa ccttaattt 29

<210> 52
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 52
ccgctcgagc gaatgtgaat gcgctaadc 29

<210> 53
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie

sequence

<400> 53
ccgctcgagg ggctggcgta ggcacacaa 29

<210> 54
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 54
ccgctcgaga gacaaaaaat aggaaaagt 29

<210> 55
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 55
ccgctcgagg tagcaggttt catgtggtg 29

<210> 56
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 56
ccgctcgagt tagtgcggaa tactttcct 29

<210> 57
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 57
ccgctcgagt gagaaccatc actaattaa 29

<210> 58
<211> 29

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisiae sequence

<400> 58
ccgctcgagc agtgctttca acacctttt 29

<210> 59
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisiae sequence

<400> 59
ccgctcgagg ctgggctctc gatgagaat 29

<210> 60
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisiae sequence

<400> 60
ccgctcgagg tagctgaaaa gtccatcta 29

<210> 61
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisiae sequence

<400> 61
ccgctcgagt ctgacatggc acacagatg 29

<210> 62
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisiae sequence

<400> 62
ccgctcgagg agattatctt gggatctat 29

<210> 63
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 63
ccgctcgagt agtatcattc ataattcga 29

<210> 64
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 64
ccgctcgagg ttttggctca atgggaccg 29

<210> 65
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 65
ccgctcgaga ttagccgtaa atttgtgaa 29

<210> 66
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer based on Saccharomyces cerevisaie
sequence

<400> 66
ccgctcgagc tccacatacc aatcactcg 29

<210> 67
<211> 29
<212> DNA
<213> Artificial Sequence

<220>

<223> Synthetic primer based on Saccharomyces cerevisiae
sequence

<400> 67

ccgctcgagt agttaaactgt tttattagc

29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/24646

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/02, 1/14, 1/18, 1/68

US CL : 435/6, 29, 32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 29, 32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,665,543 A (FOULKES et al) 09 September 1997, see entire document, especially columns 4 and 21-28.	1-38
Y	US 5,024,941 A (MAINE et al) 18 June 1991, see entire document, especially column 4.	1-5, 8-13, 16-17, 20-26, 28-33, 36-38
Y	OREJAS et al. Activation of the Aspergillus PacC transcription factor in response to alkaline ambient pH requires proteolysis of the carboxy-terminal moiety. Genes & Development. 01 July 1995, Vol. 9, No. 13, pages 1622-1632, see entire document.	1-5, 8-10, 12-13, 16-17, 20-26, 28-30, 32-33, 36-37

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 MARCH 1999

Date of mailing of the international search report

24 MAR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

TERRY A. MCKELVEY

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/24646

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LO et al. FLO11, a Yeast Gene Related to the STA Genes, Encodes a Novel Cell Surface Flocculin. Journal of Bacteriology. December 1996, Vol. 178, No. 24, pages 7144-7151, see entire document, especially page 7144.	1-7, 9-11, 13, 16-27, 29-31, 33, 36-37
Y	LAMBRECHTS et al. Muc1, a mucin-like protein that is regulated by Mss10, is critical for pseudohyphal differentiation in yeast. Proceedings of the National Academy of Sciences (USA). August 1996, Vol. 93, pages 8419-8424, see entire document.	1-7, 9-11, 13, 16-27, 29-31, 33, 36-37
Y	GIMENO et al. Induction of Pseudohyphal Growth by Overexpression of PHD1, a Saccharomyces cerevisiae Gene Related to Transcriptional Regulators of Fungal Development. Molecular and Cellular Biology. March 1994, Vol. 14, No. 3, pages 2100-2112, see entire document.	1, 6, 18-19
Y	WO 94/26885 A1 (IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.) 24 November 1994, see entire document.	1, 6, 18-19
Y	PEREZ-ESTEBAN et al. Molecular characterization of a fungal secondary metabolism promoter: transcription of the Aspergillus nidulans isopenicillin N synthetase gene is modulated by upstream negative elements. Molecular Microbiology. August 1993, Vol. 9, No. 4, pages 881-895, see entire document.	21, 38
Y	5,633,146 A (FLEER et al) 27 May 1997, see entire document, especially column 3.	1, 13-15, 21, 33-35

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/24646

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-38

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/24646

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG (biotech OneSearch databases, MEDLINE, European Patents Fulltext)
search terms: invasin?, fungi, fungus, yeast, saccharomyces, cerevisiae, invasion, promoter?, regulatory, region?, screen?, test?, assay?, secondary metabolite?, candida, albicans, aspergillus, nidulans, filamentous growth, pseudohyphal growth, digging, invasive growth, flo11, muc1, afl1, dhh1, inv1, inv(5-15), bem2, cdc25, hog1, ira1, mcm1, mgal, pet9, phd2, pho23, ptcl, rim15, sfl1, srb11, ssd1, ste21, stp22, swi4, tpk2, tpk3, rim1, ypr1, pathogen?, detect?, pgk1, adh1, gal(1-10), tet-R, met25, cycl, cup1, basal promoter?, hybrid, chimera?, fusion, lacZ, ura3, his3

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

- Group I, claims 1-38, drawn to method for determining whether a compound affects expression of a gene operably linked to a fungal invasin gene promoter.
- Group II, claims 39-45, drawn to method for determining whether a candidate compound inhibits fungal invasion.
- Group III, claims 46-81 and 118-119, drawn to method for identifying a fungal invasin promoting gene and method of identifying a gene which regulates a *C. albicans* gene promoter.
- Group IV, claims 82-101 and 120-126, drawn to method for increasing or decreasing production of a secondary metabolite.
- Group V, claims 102-117, drawn to method for isolating a fungal invasin gene by random mutagenesis.
- Group VI, claims 127-142, drawn to transgenic fungus comprising a specific mutation.
- Group VII, claims 143-148, drawn to Inv9 polypeptide preparation.
- Group VIII, claims 149-153, drawn to DNA encoding Inv9 polypeptide.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions of Groups I-V are methods each of which have a special technical feature which is one or more steps that are not present in the methods of the other groups: providing a fungus expressing a gene operably linked to a fungal invasin gene promoter and detecting expression of said gene following the contact of the fungus with a candidate compound (Group I), contacting a fungus with a candidate compound and detecting invasion by said fungus following said contact (Group II), co-expressing a first gene operably linked to a fungal invasin gene promoter and a second candidate gene and monitoring expression of the first gene to identify said second gene as a fungal invasion-promoting gene (Group III), increasing production of a secondary metabolite by contacting a fungal cell with a fungal invasion-promoting compound (Group IV), and mutagenizing a fungus, measuring expression of a gene operably linked to a fungal invasin gene promoter, and isolating gene using the mutation as a marker (Group V).

The inventions of Groups VI-VIII are products each of constitute a special technical feature which is not present or used in the methods of Groups I-V or is present in the other products of Groups VI-VIII: transgenic fungus comprising a specific mutation such as a HOG1 mutation, SWI4 mutation, etc (Group VI), an Inv9 polypeptide preparation (Group VII) and DNA, vector, cell encoding and expressing Inv9 polypeptide (Group VIII).

